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Chapter 1 
1. Introduction 
Parts of this chapter were adapted from Daniel M. Borràs1 and Bart Janssen1 - “The use of 
transcriptomics in clinical applications.” (under revision). 
1GenomeScan B.V., Pleasmanlaan 1d, Leiden 
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1.1. Renal disorders in the health care system 
Renal diseases have a great impact in the health care economy of any modern society. Among 
these renal diseases, Chronic Kidney Disease (CKD) has a global prevalence which was 
estimated from literature searches to be up to 13% (Table 1) (Hill et al., 2016). The lack of an 
early diagnosis of CKD and the asymptomatic nature of CKD in early stages, hampers the 
accurate calculation of the real prevalence, which may be even higher than the estimated 13% 
(Hill et al., 2016). In addition to the high economical cost associated to CKD, in all of its 
different stages, CKD is an independent risk factor for cardiovascular disease (CVD) which is 
a primary cause of morbidity and mortality (Go et al., 2004; Hill et al., 2016). Advanced 
CKD stages, namely stages 4 and 5, are associated with low kidney function that result in 
severe clinical manifestations. Advanced CKD stages can progress to end stage renal disease 
(ESRD) in which there is a complete loss of kidney function, and is associated with even 
higher healthcare costs of maintaining a dialysis program or renal replacement therapy (RRT) 
(Wetmore and Collins, 2016).  
Table 1: Prevalence of CKD for stages from 1 to 5 in USA, Canada and Europe represented as mean prevalence 
and confidence interval extracted from 100 CKD studies from year 2000 (Hill et al., 2016). 
 
 CKD stages 1 to 5 CKD stages 3 to 5 
 Prevalence (%) Prevalence (%) 
USA, Canada 15.45 (11.71, 19.20) 14.44 (8.52, 20.36) 
Europe 18.38 (11.57, 25.20) 11.86 (9.93, 13.79) 
*Adapted from Hill et al, 2016. 
Table 2: Most common causes of ESRD, USA (www.usrds.org). 
 
Cause ESRD patients (%) 
Diabetes mellitus 45 
Hypertension 27 
Glomerulonephritis 8 
Polycystic kidney disease 2 
Other/Unkown 18 
*Adapted from Hall and Guyton, 2011. 
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Figure 1: Incidence rates of ESRD, by country, from 2000 to 2012. 
*Adapted from Wetmore and Collins, 2016. 
 
Since most renal disorders evolve into ESRD in their final stages, a global measure of the 
impact of renal diseases in the healthcare costs could be abstracted as the number of cases of 
ESRD per year. Using these measurements, we can observe that there have been 
advancements in the overall health outcomes related to kidney diseases over the past decade 
(Figure 1). The incidence rates of ESRD seem to be stabilized for some countries in recent 
years despite an overall increasing trend in ESRD cases (Figure 1) (Wetmore and Collins, 
2016). However, these trends do not represent the health care costs of each country which can 
vary case by case depending on patient accessibility to dialysis and Renal Replacement 
Therapy (RRT) among other factors (Wetmore and Collins, 2016). The increased survival of 
20% observed for dialysis patients in USA from 2003 to 2012 may explains the growth in the 
prevalent population of dialysis patients despite the opposite trend observed in incidence rates 
of ESRD in developed countries (Figure 1) (Wetmore and Collins, 2016). Among the most 
common cause of ESRD there are glomerulonephritis and polycystic kidney disease, as well 
as diabetes mellitus and hypertension (Table 2) (Hall and Guyton, 2011). Therefore, it is 
important to stress the relevance of any research performed in the context of renal diseases, 
which will have a great impact in terms of improvement of the healthcare costs associated to 
renal disorders, and most important the quality of life as well as life expectancy of patients 
suffering from kidney diseases. 
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1.2. Understanding the renal system, anatomy and physiology 
The kidneys are two bean-shaped organs, located in the abdominal cavity, which have the 
important function of eliminating toxic and waste products from the blood stream. Waste 
products include direct or side products of metabolic processes that are no longer needed, as 
well as some exogenous chemicals, drugs. The most important waste products are urea 
resulting from amino-acid metabolic processes, creatinine from muscle fiber metabolism, uric 
acid from metabolic processes involving nucleic acids, hemoglobin degradation products 
such as bilirubin, and side metabolites produced by hormone processing metabolism. Other 
kidney functions of major importance include maintenance of fluid and electrolyte 
homeostasis as well as blood pressure, and excretion/metabolism of hormones amongst other 
metabolic functions such as acid-base balance and gluconeogenesis. Most of these functions 
performed by the kidney occur in the outer cortex or the inner medulla (Figure 2). Each 
human kidney contains large numbers of nephrons (≥200,000 up to ≤2 million) (Denic et al., 
2017), that are the functional unit of the kidneys. The nephron, can be divided into two main 
units, a: the corpuscle, including the glomerulus and Bowman’s capsule where large amounts 
of plasma are filtered (Figure 2); and b: the tubule, which concentrates and processes the 
excreted fluids to be converted into urine (Figure 2). 
One of the primary aspects of excretion is the regulation of water and electrolyte balances, 
directly adjusted by their excretion levels. These, combined with the secretion of vasoactive 
substances such as renin, takes also part in the kidney’s function to regulate arterial pressure. 
The difference in hydrostatic pressure and osmotic pressure between the glomerular vessels 
 
 
 
 
 
 
 
 
Figure 2: Summarized scheme of the structure of the 
kidney (A) and the nephron (B), that are of most relevance 
for this thesis. 
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and the Bowman’s space will determine the fluid movement across the capillary walls and 
thereby the production of ultrafiltrate plasma (primary urine). In the course of 24 hours, 
around 180 liters of plasma is normally filtered by the glomeruli. Under physiological 
conditions, the glomerular filtration barrier should retain cellular elements, and most of 
proteins from the ultrafiltrate. Substances that pass this filtration are further reabsorbed by the 
tubular system recovering the majority of wanted substances such as water, small proteins 
and electrolytes. The remaining substances will then form part of the excreted urine (final 
urine) with the water that was not reabsorbed. The efficiency of filtration performed by the 
kidney is also known as glomerular filtration rate (GFR) which can be measured by the 
creatinine levels observed in blood and the urine. Creatinine is a side product of muscle 
metabolism that is freely filtered by the glomerular barrier, but not re-absorbed by the 
nephron. Accordingly, excreted creatinine per minute represent a direct measure of the 
creatinine that has been filtered and provides the means to measure the GFR (ml/min).  
Monitoring GFR in the clinic can indicate disease states which often affect the filtration 
surface area decreasing the ultrafiltrate. GFR may change because of different factors 
associated with renal diseases such as reduction of functional glomeruli, constriction of 
glomerular arterioles, decreased renal perfusion either by increased afferent or decreased 
efferent arteriole resistance, reduced glomerular oncotic pressure of proteins, and increased 
Bowman’s space hydrostatic pressure by obstruction. In addition, there are many hormones 
that can influence the GFR such as angiotensin, and prostaglandins (Table 3). 
Table 3: Hormones that regulate the Glomerular Filtration Rate. 
 
  GFR 
Vasoconstrictors 
Angiotensin II ↘ 
Endothelin ↘ 
Sympathetic nerves ↘ 
Vasodilators 
Prostaglandins → or ↗ 
Nitric oxide ↗ 
Bradykinin ↗ 
Natriuretic peptides ↗ 
*Adapted from Koeppen and Stanton, 2013. 
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Overall, the renal system is a crucial part of the human body. Renal diseases that impede the 
proper functioning of the kidneys can have a greater impact than the localized damage 
because of its main roles on the excretion of waste products, chemicals, drugs and hormone 
metabolites, the regulation of water and electrolytes, the regulation of blood pressure, the 
buffering of blood acid-base balance, and the regulation of erythrocyte and vitamin D 
production among other indirect functions. Therefore, the understanding of kidney-damaging 
mechanisms and the recovery of kidney function are key for the protection of patients from 
further advancing into more severe stages. 
1.3. Renal disorders 
Severe kidney diseases may be grouped into to two main categories depending on the period 
that they occur, (1.) acute renal failure, also known as acute kidney injury (AKI) which 
involves an abrupt stop of the normal functions of the kidney; and (2.) chronic renal failure, 
also known as CKD, which differs from AKI by its gradual and permanent loss of renal 
functions. We believe important to clarify at this point that this thesis is based on integrative 
omics approaches. This includes technical and methodological approaches such as NGS, data 
analysis, as well as systems biology, and renal systems medicine methodologies. Renal 
disorders are very diverse with many etiologies that converge into a common outcome, ESRD 
(Figure 3). Hence, we focused the background information provided in this introduction 
 
Figure 3: Scheme of common tools and research approaches used for biomarker and clinical research applied to 
renal disorders with a common endpoint, ESRD. Highlighted (bold) are key diseases, concepts and terms that 
are addressed in this thesis. 
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chapter to 3 selected renal diseases that are further studied in this thesis such as ADPKD, 
Glomerulosclerosis, and AKI. 
1.3.1. Chronic Kidney Disease 
 Chronic renal failure, also known as CKD, is mainly defined by an irreversible loss of 
kidney function that has its origin in the decrease of functional or healthy nephrons. 
Nephrogenesis is generally assumed to be completed few weeks before birth, when the full 
set of nephrons should be complete and will gradually reduce in number along the years (Hoy 
et al., 2010; Denic et al., 2017). The renal system, despite its important role for the proper 
functioning of the human body, cannot regenerate new nephrons. The permanent loss of renal 
functional units could be estimated relative to the number of functional glomeruli in the 
kidney, and showed a direct relationship of functional units with the decrease of GFR (Denic 
et al., 2017). It is well established that any injuries that the kidneys suffer, such as damage 
produced by aging, physical injuries, or disease-associated injuries, would accumulate during 
the years and have a strong impact on the proper functioning of the kidneys. This cumulative 
effect would lead to a vicious cycle of continuous deterioration and progression of loss of 
kidney function that would evolve into CKD and ESRD in the more severe cases (Hall and 
Guyton, 2011). The majority of CKD cases passes unnoticed until the number of functional 
nephrons is drastically reduced. Normal kidney function can usually be maintained until the 
number of functional nephrons drop below 20 or 25% of normal amounts when severe 
clinical symptoms will appear (Table 4). The main causes of nephron loss that progress to 
CKD may include a wide variety of disorders including metabolic disorders (diabetes, 
obesity), hypertension, immunologic disorders (glomerulonephritis, lupus), vascular disorders 
(atherosclerosis), infections (tuberculosis), primary tubular disorders (nephrotoxins), and 
urinary obstructions (renal calculi) among others (Table 5). 
Table 4: Values of excretion of the overall nephrons and per nephron in renal failure. 
 
  Normal kidneys 75% Nephron-loss kidneys  
 Number of nephrons 2 0.5 Millions 
All nephrons 
GFR 125 40 
ml/min 
Volume excreted  1.5 1.5 
Single nephron 
GFR 62.5 80 
nl/min 
Volume excreted 0.75 3 
*Adapted from Hall and Guyton, 2011. 
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1.3.1.1. Autosomal Dominant Polycystic Kidney Disease (ADPKD) 
ADPKD is a common inherited kidney disease that accounts for 5% to 10% of ESRD cases 
(Spithoven et al., 2014). Most causing mutations of ADPKD occur in PKD1 and PKD2 genes 
with a reported prevalence of 75-85% and 15-25%, respectively (Barua et al., 2009; Harris 
and Rossetti, 2010). This renal disease phenotype is characterized by a phenotype of enlarged 
kidneys because of the presence of numerous renal cysts. Since ADPKD is a multisystem 
disorder, cysts are not solely limited to the renal tissue but may appear in other organs as well 
such as the liver, seminal vesicles or the pancreas among others. On average, at the age of 58-
60, 50-70% of the ADPKD patients progress to ESRD (Harris and Torres, 1993; Gansevoort 
et al., 2016).  
Mutations in PKD1 and PKD2, may disrupt the functions of these genes and are the main 
cause of ADPKD. PKD1 (Polycystin 1) and PKD2 (Polycystin 2) are two transmembrane 
proteins expressed in the primary cilia that are involved in the reabsorption of Ca2+. 
Activation of PKD2 by PKD1 allows the flow of Ca2+ increasing the intracellular Ca2+, which 
in return also activates K+ channels to secrete K+ into the tubular fluid. Disruptions in the 
amino-acid sequence of PKD1, in the form of DNA variants, not only affects the Ca2+ uptake 
because of its interaction with PKD2, but will also alter PKD1’s signaling pathways, 
Table 5: Some of the main causes of CKD 
 
Metabolic Disorders 
Diabetes mellitus 
Obesity 
Amyloidosis 
Hypertension  
Renal vascular disorders 
Atherosclerosis 
Nephrosclerosis-hypertension 
Immunologic disorders 
Glomerulonephritis 
Polyarteritis nodosa 
Lupus erythernotosus 
Infections 
Pyelonephritis 
Tuberculosis 
Primary tubular disorders Nephrotoxins (analgesics, heavy metals) 
Urinary tract obstructions 
Renal calculi 
Hypertrophy of prostate 
Urethral constriction 
Congenital disorders 
Polycystic disease 
Renal hypoplasia 
*Adapted from Hall and Guyton, 2011. 
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including kidney cell proliferation, cell adhesion, cell migration, cell differentiation, and 
apoptosis (Koeppen and Stanton, 2013; Castelli et al., 2015). Because of the close interaction 
between PKD1 and PKD2, mutations in any of these genes will play a role in the cysts 
formation and the development of ADPKD, particularly with truncating mutations in PKD1 
(Gainullin et al., 2015; Gansevoort et al., 2016).  
The current treatment strategy for ADPKD include the use of vasopressin V2 receptor 
antagonist (Tolvaptan) to slow the advance of ADPKD patients with CKD in stages from 1 to 
3 that show clear signals of rapid progression (Yu et al., 2015; Gansevoort et al., 2016). 
However, due to the side effects of this drug, and its cost, a clear selection of patients is 
needed to identify patients that could benefit the most from this treatment. Promising results 
were obtained with mTOR inhibitors such as rapamycin using animal models, but the same 
efficacy could not be observed on human clinical trials (Yu et al., 2015). Other research on 
therapeutic compounds for ADPKD have showed that STAT3 inhibitors such as 
pyrimethamine, S3I-201, or the broad spectrum diferulomethane (curcumin) have great 
potential to become a new generation of drugs for the treatment of ADPKD (Leonhard et al., 
2011; Harris and Torres, 2014). 
The diagnosis of ADPKD by screening of PKD1 is still challenging due to its high homology 
with six other PKD1 pseudogenes (Rossetti et al., 2007). There have been several attempts to 
use next generation sequencing (NGS)-based diagnostic approaches to improve PKD1 
resolution for diagnostic applications (Tan et al., 2014; Trujillano et al., 2014; Eisenberger et 
al., 2015; Mallawaarachchi et al., 2016). These approaches rely on the high-quality sequence 
information that can be obtained from Illumina sequencing platforms at relatively low cost 
(Su et al., 2011; Mardis, 2013; Oliver et al., 2015). However, short-read NGS sequencing 
approaches such as whole genome (WGS) and whole exome sequencing (WES), often fail at 
reliably characterizing complex regions of the human genome (Lee and Schatz, 2012; 
Chaisson et al., 2015). These regions are quite often associated with high GC-content, 
segmental duplications (SDs), low complexity sequences and gaps still present in the 
reference sequence of the human genome (Lee and Schatz, 2012; Steinberg et al., 2014; 
Chaisson et al., 2015). Some of these complex regions could be resolved using single-
molecule long-read sequencing, which can improve our understanding of genetic variations in 
complex but clinically relevant genomic regions (Guo et al., 2013; Loomis et al., 2013; Laver 
et al., 2016; Qiao et al., 2016). Therefore, we used single-molecule long-read sequencing as a 
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tool with added value to characterize genetic variants from complex genomic regions such as 
PKD1, which serves as an excellent example of a challenging and complex locus. 
1.3.1.2. Glomerulosclerosis 
Different types of sclerosis can lead to ischemia and damage the kidney tissue including 
atherosclerosis, nephrosclerosis and glomerulosclerosis. Naturally occurring sclerosis occurs 
and accumulates with age (Denic et al., 2017). Typically, after a small lesion in the vessel, 
fibrinoid deposits accumulate in response to small plasma leakage. This cause the vessel 
walls to become thicker, eventually ending in a permanent occlusion. If this occur within the 
glomeruli, the injury is named glomerulosclerosis. The loss of functional glomeruli decreases 
with age while the number of sclerotic glomeruli increases, with an estimated 50% loss of 
total nephrons from the age of 18-20 to 70-75 years (Denic et al., 2017). There is a trend of 
increased loss of nephrons with nephrosclerosis and glomerulosclerosis, as well as 
hypertension (Denic et al., 2017). Other causes of glomerulosclerosis include the most 
common form of glomerular disease that leads to ESRD, focal segmental glomerulosclerosis 
(FSGS) (Kiffel et al., 2011). Up to 80% of FSGS patients were identified within the group of 
idiopathic nephrotic syndrome patients that not respond to steroid therapies (Han and Kim, 
2016). There seems not to be a clear alternative treatment for FSGS patients that are 
corticosteroid resistant, and the many of these progress to ESRD (Han and Kim, 2016). Some 
second line alternatives provided mixed results due to effectiveness, nephrotoxicity, or other 
adverse reactions depending on each individual case such as cycloshosphoamide, 
cyclosporine, rituximab, abatacept, adalimumab, or fresolimumab (Kiffel et al., 2011; Han 
and Kim, 2016). Regardless of the source cause of FSGS, renal fibrosis and loss of kidney 
function will progress in patients that are resistant to therapies. Further studies to understand 
the underlying mechanisms of fibrosis may aid the development of alternative therapies to 
diminish the progression of nephrosclerosis and glomerulosclerosis. 
1.3.2. Acute kidney injury 
Main causes of AKI are included in three categories defined as prerenal, intrarenal, and 
postrenal AKI. Prerenal causes include abnormalities that originate outside the kidneys such 
as heart failure or haemorrhages that produce low blood pressure, and volume (Table 6). The 
intrarenal AKI results from internal abnormalities from the kidney that may affect the blood 
vessels from the kidney, the glomeruli or the tubules, and postrenal AKI is caused by 
abnormalities in the lower urinary tract, usually blocking the urine flow (Table 6). There exist 
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no specific therapies that can attenuate AKI and improve the recovery of the kidney function 
after an AKI insult (Bellomo et al., 2012). Therefore, current treatments are mostly 
supportive or preventive, including dialysis, with the intention of reducing the loss of kidney 
function and prevent the progression into CKD, or even ESRD (Bellomo et al., 2012; Harty, 
2014). AKI episodes are more frequent in hospitalized patients under surgery or critically ill 
as well as patients following high risk drug treatments such as chemotherapies (Bellomo et 
al., 2012). AKI episodes pose a substantial risk to these patients, including increased 
morbidity, progression to severe CKD stages, or death. 
Exposure to some chemicals or drugs such as antibiotics, immunosuppressants, cancer 
chemotherapy, non-steroidal anti-inflammatory drugs among others, have an undesired 
nephrotoxic effect that is considered among the most common causes of AKI observed in 
humans, alongside ischemia, and urinary obstructions (Yang et al., 2010). A common and 
accepted model of nephrotoxicity is folic acid nephropathy which was also previously 
reported to occur in humans (Metz-Kurschel et al., 1990). This causes reversible increase in 
serum creatinine and urea, tubular cell death, compensatory tubular cell proliferation, 
activation of an inflammatory response, and eventual progression to mild fibrosis (Fang et al., 
2005; Doi et al., 2006; Ortega et al., 2006). Previous studies performed using mouse models 
showed that Gdf15 gene may have a protective effect against tubular and interstitial damage 
(Mazagova et al., 2013). The role of Gdf15 and the mechanisms of recovery of the kidney 
function are still poorly understood (Breit et al., 2012; Mazagova et al., 2013; Vallon, 2016). 
Table 6: List of some of the causes of AKI. 
Prerenal 
Intravascular volume 
depletion 
Hemorrhage, Diarrhea, vomiting. 
Cardiac failure Myocardial infarction, valvular damage. 
Peripheral vasodilation and 
resultant hypotension 
Anaphylactic shock, anesthesia, sepsis and severe infections, 
primary renal hemodynamic abnormalities, renal artery 
stenosis, and embolism or thrombosis of renal artery or veins. 
Intrarenal 
Small vessel and glomerular 
injury 
Vasculitis (polyarteritis nodosa), cholesterol emboli, malignant 
hypertension, acute glomerulonephritis. 
Tubular epithelial injury 
(tubular necrosis) 
Acute tubular necrosis due to ischemia, acute necrosis due to 
toxins (heavy metals, ethylene glycol, insecticides, poison 
mushrooms, carbon tetrachloride). 
Renal interstitial injury Acute pyelonephritis, acute allergic interstitial nephritis. 
Postrenal  
Bilateral obstruction of ureters (large stones or blood clots), 
bladder obstruction, urethra obstruction. 
*Adapted from Hall and Guyton, 2011. 
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Therefore, within this thesis we used an unbiased RNA sequencing approach to unravel the 
genetic drivers of renal tissue protection and recovery led by Gdf15 expression. 
1.4. Sequencing approaches in clinical applications 
The currently available, and rapid advancement of sequencing technologies allows for the use 
of nucleic-acid material for clinical use with single base precision. Screening for multiple 
disease determinants, obtaining information on disease causes or determining a potential 
response to a particular treatment is now possible in a single run or test. Despite this, 
sequencing-based screening approaches are still not preferred over PCR tests mainly because 
of price. However, in complex diseases where multiple genes are implicated, such as acute 
myeloid leukemia, breast cancer, cardiovascular diseases, and some renal diseases, we can 
find good examples of the added diagnostic value of sequencing-based methods compared to 
traditional approaches. As discussed above, we focused our research efforts to study kidney 
diseases that could benefit from new advancements in NGS technologies and data analysis 
approaches such as ADPKD, AKI, or glomerulosclerosis.  
The associations between genes and diseases have already been the subject of study for many 
decades. The clearest cases of associations showed that a particular change in a single gene 
can be the potential cause for a particular disease. There are over 1500 defined genes that 
were classified as monogenic disorders with an associated phenotype (Brinkman et al., 2006), 
but these do not cover most of the human diseases which are mainly multi-factorial. In their 
expert opinion Stylianos Antonarakis and Jacques Beckmann state that monogenic disorders 
are an unfortunate casualty in the race to find the determinants of complex diseases 
(Antonarakis and Beckmann, 2006; Brinkman et al., 2006; O’Connor and Crystal, 2006). Not 
all genetic mutations are detected or diagnosed using the same type of material. Isolated 
DNA is the most common type of patient material used for diagnostics applied to nucleotides. 
However, the analysis of other nucleic acids such as messenger RNAs (mRNAs) has also 
great potential to elucidate many genetic disorders. In particular, RNA can be used to 
diagnose complex diseases where multiple genes are implicated such as cardiovascular 
disease, breast cancer, and type 2 diabetes mellitus (Ross et al., 2008; Herder et al., 2011).  
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Figure 4: Visualization examples of a combined diagnostic test using RNA-seq to identify different types of nucleic 
factors in AML patients. (A) Gene coverage for RNA-Seq data. First gene track (blue line) shows the gene structure of 
MECOM by RefSeq gene annotation. Thick lines show exon locations and arrowed lines intronic locations. Second 
and third track show the coverage of MECOM for samples 1 and 2, respectively. In grey, the depth of coverage of 
sample 1 indicates that there is expression where the peaks are located. The extent of the expression is proportional to 
the height of the peaks, and the amplitude represents how much of the gene sequence is expressed, usually coinciding 
with exon boundaries. (B) Visual representation of splicing detected for two sequenced patients with RNA-Seq. 
Bottom blue track represents gene structure of IRF1 gene. Thick lines show exons bases and arrowed line intronic 
bases. Green track shows the coverage of sample 3 (green blocks) as well as the number of reads that span the distance 
to the next splice acceptor region (green line). Red tracks show coverage of sample 5 (red blocks) and number of reads 
that span the distance to the next splice acceptor region (red line) connecting two exons. Last red track show an 
alternative splicing event with 221 reads that are connecting exons 3 and 5 but skipping exon 4. This shows that exon 
4 is partially skipped by some transcripts in sample 5. (C) Visualization of a SNV detected by RNA-Seq. The 4bp 
insertion (TCTG) is represented as a purple line on the Alignment track for the NPM1 gene. The gene track (blue) 
shows the codons present in this particular location (blue and dim blue) as well as the amino acid it encodes for 
(letters). The sequence of this particular location is shown and the black arrow gives information about the strand of 
the shown nucleotides (forward). Third track shows the coverage for each of the represented bases. Finally, the 
alignment is shown where horizontal grey lines represent a match with the reference sequence and a colored horizontal 
line represents a mismatch, which is colored with the same colors as the sequence nucleotides, being T red, A green, C 
blue, and G orange, black represents a deletion. 
*(Primary data was kindly provided by Prof. Veelken, H., Head of Department of Hematology, Leiden University 
Medical Center) 
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Over the years many diagnostic tests have been developed that took advantage of the latest 
advances in technology for biomarker discovery. The ultimate goal of molecular diagnostics 
is to accurately predict the presence or absence of a particular genetic disorder, infectious 
disease, or even response to a particular drug treatment. Towards this end, the latest advances 
in high throughput technologies opened up new opportunities for nucleic acid-based 
diagnostics allowing the development of new and more sensitive disease diagnostic tools. 
This goal is achieved by applying advanced statistical methods that reveal hidden patterns 
within the data that can characterize multi-factorial diseases. This was accomplished to some 
extent with the appearance of high throughput technologies such as micro-arrays and  
sequencing technologies, both able to analyze thousands of measurements in the DNA or the 
RNA in a single run. The global analysis of the DNA mutations or mRNAs expression can be 
quite rewarding and informative, providing information on many variations with base pair 
accuracy in the case of some diagnostic tools. The analysis of not only the DNA variants but 
also the analysis of transcription products in diagnostics allowed to detect many diseases 
caused by genomic alterations as well as specific transcript modifications such as single 
nucleotide polymorphisms (SNP), small variants (SV), translocations, inversions, chimeric 
genes, breakpoints, post-transcriptional modifications, alternative splicing and gene 
expression (Dominissini et al., 2011; Su et al., 2011; Sánchez-Pla et al., 2012; Shyr and Liu, 
2013; Mimura et al., 2014; Chaussabel, 2015). Many different methodologies commonly 
used for diagnosis of complex diseases are nowadays possible to combine in a single NGS 
test (Griffionen et al., 2016), such as the detection of gene expression, splicing variants, and 
SVs (Figure 4) in acute myeloid leukemia identified in MECOM, IRF1, and NPM1, 
respectively. Furthermore, global sequencing approaches can be used towards clinical 
diagnostics on autoimmune disorders, cancer, and infectious diseases (Chaussabel, 2015) as 
well as provide an alternative non-invasive procedure that could detect transplant rejection in 
early stages (Chen et al., 2013).  
1.4.1. Prior to sequencing, sample material and preparation 
 In order to perform a diagnostic test on DNA, mRNA or any other source of nucleic acid 
material, the DNA or RNA first needs to be accurately extracted. There are many extraction 
methods available, and their applicability mainly depends on the sample source and type of 
material. Each method can provide specific advantages depending on the variety of accessible 
biological sample types and the downstream analysis to be performed. Some of these 
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advantages can be evaluated in several ways but yield and integrity are generally accepted as 
criteria of successful extraction. The material obtained from the sample extraction, regardless 
of the method used and the success of the extraction, is generally in the form of DNA or total 
RNA (Devonshire et al., 2013). In this state, the DNA isolated is usually quite pure and ready 
to be used for sequencing. However, the RNA extracted material from human samples 
contains mainly ribosomal RNA (rRNA) transcripts (approximately 80%), and tRNA 
transcripts (approximately 15%). The presence of these two RNA types greatly reduces the 
relative abundance of the other transcript species which are of diagnostic interest such as 
mRNAs. Therefore, an additional enrichment step of the preferred RNA species, such as 
mRNA, is needed after the extraction of total RNA. This enrichment of mRNA will further 
enhance the reliability and sensitivity of the diagnostic test.  
The isolation of DNA or RNA from the biological samples can be currently achieved by 
several methods including magnetic bead-based extraction, silica columns and acid 
phenol/chloroform. This is usually achieved by several steps, which may include degradation 
steps of non-desired nucleic acids, amplification of DNA as well as hybridization and ligation 
amongst others. The degradation of the non-desired DNA carry over from an RNA sample 
can be performed by DNase treatments. The degradation of non-desired RNAs from a DNA 
sample can be performed by RNase degradation. Such RNA degradation is, for instance, 
performed after the reverse transcription amplification of enriched mRNAs by using poly-A 
primers. The amplification provides the first strand of the mRNAs, as cDNA, which will no 
longer be degraded by the RNase activity. Similarly, the enrichment can be achieved without 
RNase degradation by including adapters during the reverse transcription steps and/or 
ligation steps. Similar ligation steps can be performed for DNA enriched samples. Then the 
isolated DNA from a DNA sample or cDNA from an RNA sample is amplified by adding 
primers which are specific to the adapters introduced. There are other methods which involve 
physical separation of the mRNA transcripts. In this situation, the use of poly-A ligands is 
quite usual, also known as poly A capture enrichment. A common way of physical separation 
of nucleic acid material is by pulling down the DNA or RNA with magnetic beads. In the 
case of mRNA the poly-A ligand is attached to the beads and then the mRNA is hybridized 
and separated from the sample solution by the use of magnetic forces that pull the magnetic 
beads down. Another common method involves the use of filtration columns. In this 
situation, the nucleic acids are usually attached or captured to the stationary phase of the 
column by filtration or ligation (poly-A ligands for mRNA). In the majority of the described 
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enrichment cases, commercial kits may be available and used for the enrichment of DNA or 
RNA species such as mRNAs. It is important to note that some kits allow direct isolation of 
mRNAs without a previous step of total RNA extraction. As general recommendation, the 
evaluation of the performance of enrichment protocols and available kits is considered as 
good practice for the success of setting up any DNA- or RNA-based diagnostics test. Another 
method of enrichment is the polyacrylamide gel electrophoresis which is generally used to 
separate nucleic acid species of desired sequence length (Petrov et al., 2013). 
One of the limitations of handling RNA, opposite to DNA, is that is quite prone to fast 
degradation. Unless the analysis of the RNA is performed immediately after the sampling 
process, effective precautions against degradation must be taken. Preventing RNA 
degradation is of particular concern for quantitative analyses and the diagnosis of diseases 
where high sensitivity is required. There exist several procedures and reagents that are used 
to preserve the integrity of RNA. In the majority of cases, the use of these measures is highly 
recommended. An extensively used method for preserving the RNA is to snap freeze the 
samples, which can be done with liquid nitrogen followed by storage for a longer period at -
80C. Otherwise, during the collection of the samples, cells can be directly embedded in RNA 
safeguarding reagents or buffers which can preserve RNA from degradation. In this case, it 
may be possible to store the samples at a higher temperature depending on the approach and 
chemicals used during the collection. For all of the aforementioned cases, extra care has to be 
taken to maintain the samples at the lowest temperature possible during the handling and to 
work with appropriate RNase free solutions, material and working environment at all times 
(Devonshire et al., 2013). 
Although it is always preferred to use “fresh” biological material for the analysis of nucleic 
acids, particularly for RNA, the use of fresh material is not always an option. In some cases, 
tissue samples are needed for clinical diagnostics which involve a particularly difficult and 
painful process for obtaining the material such as renal biopsies. Hence, it is not surprising 
that the current trend for the development of new diagnostics tools is focused on sample 
sources that are more easily obtained, in addition to the advantage of using non-invasive 
methods such as blood, saliva and urine (Devonshire et al., 2013). 
When DNA or RNA is extracted from a biological sample for disease diagnostics we must 
also take into consideration that sample composition is another important variability 
introducing factor. Tissue samples, for instance, contain different cell types. Each cell type 
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will express its own gene repertoire or mutation profile. In the case of gene expression 
profiling, a sample’s mRNA composition may also be influenced by internal, and external 
factors (i.e. nutrition, circadian stage, cellular cycle, stress, exercise or disease state). 
Sasagawa et al., showed that single cell transcriptome analysis using RNA-Seq was able to 
identify and quantify non-genetic cellular heterogeneity, and even differentiate cell types and 
cell cycle phases of a single cell type (Sasagawa et al., 2013). Similarly, the accumulation of 
DNA mutations in clonal cancer cells, caused by the development of a cancer, can be 
quantified to reconstruct the phytogenic evolution and identify source or causal mutations 
(Bozic et al., 2016). Therefore, it is important to use appropriate methods for targeted cell 
type enrichment, if possible, such as laser capture micro dissection (LCM) for selecting tissue 
areas from tissue slides, cell sorting for enriching the cell fraction of interest, or 
centrifugation for separating the desired cell population (Todd and Kuo, 2002; Taussig et al., 
2010; Devonshire et al., 2013; Sasagawa et al., 2013; Gutierrez-Arcelus et al., 2015). 
Many of the aforementioned processes and techniques used for the extraction of nucleic acids 
are based on the use of a variety of solutions and chemicals. Unfortunately, the procedures 
are not perfect, which means that during the extraction there is a carry-over of chemicals and 
reminiscent sample components such as DNA (in the case of RNA isolation), proteins, and 
salts. Chemicals such as ethanol, chloroform or phenol, as well as monovalent cation salts 
such as ammonium acetate, lithium chloride and sodium acetate, may be present in the 
sample due to the extraction and precipitation approaches used (Walker and Lorsch, 2013). 
Carry-over genomic DNA may interfere with amplification or hybridization steps needed for 
RNA library preparations but can be easily removed from the sample by a DNase enzymatic 
treatment. Other remaining proteins can be readily removed by proteases. Sample stabilizers 
such as citrate, EDTA, and heparin may inhibit the reverse transcription (RT) and should also 
be removed. Several authors reported approaches for this purpose such as precipitating RNA 
with lithium chloride to get rid of sample heparin (Del Prete et al., 2007) or the use of 
ultracentrifugation (Ding et al., 2011). It is worth mentioning that any single effort towards 
the removal of potential contaminants may improve the outcome of the diagnostic test 
applied. These contaminants, in the end, may negatively influence the possible choices for 
downstream applications and in the worst case have a direct impact on the diagnostic assay 
and its outcome (Devonshire et al., 2013). 
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While keeping in mind that there are many possible sources of variability, one has to choose 
from a large series of isolation kits and methods. The choice should be made depending on 
the sample type to be analyzed. The ideal method is fast and easy, while allowing a 
reproducible extraction of nucleic acids that is immediately ready to use or store. Many of 
these kits already include cleaning steps from inhibitors and contaminants and could be 
automated. Additionally, in the case of RNA isolation, some of these kits may also directly 
extract not only total RNA but targeted subspecies of RNA such as mRNA, miRNA, and 
even viral RNAs, making the process much easier to set up for diagnostic applications. 
Several authors reviewed the performance of different isolation kits applied to a variety of 
tissue samples. A recent example of assessment of the performance of two purification kits 
was provided by Akutsu et al., (2015). The authors compared RNeasy Mini Kit (silica 
column based kit from Qiagen) and EZ1 RNA Tissue Mini Kit (automatic magnetic beads 
based from Qiagen). The extraction was applied to two different biofluid samples, saliva and 
blood, in the form of fresh and dried cotton swap stains. The results of this comparison 
showed that silica column based extraction provided a slightly better RNA quality on fresh 
samples, and substantially better on sample stains. Another comparison between two isolation 
kits for DNA extraction applied to FFPE cell lung carcinoma tissue samples showed that 
while both kits were suitable for the identification of mutations despite one of the kits 
outperformed its competitor in yield and quality (Hu et al., 2014). These comparisons 
between multiple kits highlighted that there may be kit-dependent differences in acid nucleic 
extraction that may impact downstream mutation analysis and gene expression measurements 
(Hu et al., 2014; Javadi et al., 2014; Jeffries et al., 2014). Differences in yield, and quality 
should be taken into account when selecting the best approach for processing clinical 
samples. Hence, when performing comparisons between studies, authors should be aware of 
the differences among different isolation procedures used. Currently available methods have 
advantages and disadvantages to consider depending on the approach used as well as any 
additional stabilizers used such as RNA Later and RNA Protect (Thorn et al., 2005; Schagat 
et al., 2008; Tavares et al., 2011; Hu et al., 2014; Javadi et al., 2014; Jeffries et al., 2014; Kim 
et al., 2014). 
During these past years, the majority of research efforts of NGS applications were focused on 
the understanding of the etiology of diseases including complex diseases (Devonshire et al., 
2013). Few of the research efforts result in a diagnostic test that is currently being used in a 
clinical setting. In some occasions, the diagnostic test for a certain disease could be reduced 
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to a few key genes making it much easier to handle with a simple and cost efficient qPCR or 
RT-qPCR test (e.g. BCR-ABL, BRCA1, BRCA2, PKD1, PKD2, retroviruses’ RNA). However, 
in multi-factorial diseases the number of relevant biomarkers is usually too high to be 
handled by a single PCR assay.  For diagnosing complex diseases, many small dedicated 
assays are being used in combination, such as in AML. Therefore, the analysis of a complete 
genome, exome or even transcriptome might be considered as a good alternative. Below, we 
will provide a number of examples showing useful approaches for the analysis of nucleic 
acids to diagnose inherited or acquired diseases. 
1.4.2. Clinical applications, cases and potential examples 
1.4.2.1. PCR-based applications 
The diagnostic use of PCR or RT-PCR is a very common practice and is frequently applied to 
detect hundreds of different diseases. The majority of clinical centers and diagnostic facilities 
offer a wide range catalog of services based on PCR kits to routinely diagnose patients. In 
this thesis, we will mention only few examples of PCR-based tests that are or could be 
routinely applied to diagnostics. Although PCR-based testing is not within the scope of our 
studies, PCR-based diagnostics still deserves a place in this chapter for its importance in the 
field of clinical diagnostics. 
Recent advances in PCR technologies have extended the range of possibilities to use PCR for 
applied diagnostics. These new PCR platforms, considered as the next generation real-time 
qPCR, include a wide variety of PCR settings such as micro-fluidic chips, digital-PCR, 
emulsion digital-PCR also known as digital droplet PCR (dPCR), micro-fluidic chip-based 
Table 7: Some examples of clinical applications for PCR-, microarray- and sequencing-based. 
 
Disease Tissue 
Target 
genes 
Type Method Application Source 
Diabetes after 
kidney transplant 
Peripheral 
blood 
ADIPOQ, 
CCL5 
SNPs qPCR Research (Nicoletto et al., 2013) 
Hepatitis 
Blood 
plasma 
HCV Retrovirus qPCR Commercial kit www.pcrdiagnostics.eu 
Septic Shock Blood 
100 gene 
signature 
Qual. and quant. 
Expression 
μ@ Biomarkers (Wong et al., 2009) 
Hereditary SNRS Blood 
446+ gene 
panel 
SNPs, SNVs WES 
Diagnostics and 
research 
Bristol Genetics, (McCarthy et al., 
2013) 
Transplant 
rejection 
Peripheral 
blood 
IL1R2, CXCR4, 
HLA-A, +7 
Expression RNAseq Research (Chen et al., 2013) 
ADPKD 
Tissue 
biopsy 
PKD1, PKD2 
SNV, large 
deletions 
WES 
Research and 
diagnostics 
 (Rossetti et al., 2012; Tan et al., 
2014; Eisenberger et al., 2015) 
*SRNS steroid-resistant nephrotic syndrome; ADPKD autosomal dominant polycystic kidney disease; μ@ microarray 
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dPCR, and steel chips. Many of these take advantage of micro and nano-fluidics combined 
with miniaturized systems to produce an increased number of reactions with a significant 
reduction of reagent used, sample volume, and costs. This allowed the increase of throughput 
of these platforms to thousands of reactions per sample making these platforms quite suitable 
for a rapid screening of relatively large series of biomarkers. For a comprehensive review 
about PCR-based technologies, advances, and advantages, as well as limitations, please refer 
to Devonshire et al., (2013). 
Infectious diseases represent some of the clearest examples of PCR use for diagnostic 
purposes, and taking advantage of some PCR tests that are available as commercialized kits. 
The purpose of these tests is to detect a particular nucleic acid sequence in the analyzed 
sample such as blood and buccal swaps. These tests have the purpose to be qualitative, 
providing the answer of presence or absence of a specific DNA or RNA, and in some cases, 
offer quantitative results. Some of these tests for infectious diseases are based on the 
detection of the RNA of pathogenic viruses such as the human immunodeficiency virus 
(HIV) or the hepatitis virus. An example of a commercially available test based on a qPCR 
kit for detecting HIV may be the AmpliSense HIV-Monitor-FRT kit from PCR Diagnostics. 
This test uses real-time hybridization-fluorescence to detect HIV type 1 RNA in plasma 
samples. Similar to this test, other commercially available tests exist for detecting infectious 
diseases targeting DNA or RNA in plasma samples as well as other tissue sources. Some 
examples of available tests are listed in Table 7as well as additional relevant test details and 
references. One of these examples, in the field of renal disorders, is the use of a few qPCR 
test to identify 3 different variants within the adiponectin and CCL5 gene sequences. These, 
showed to be associated with the onset of diabetes after renal transplantation (Nicoletto et al., 
2013). 
1.4.2.2. Microarrays-based applications 
The technology of micro-arrays is based on the design of multiple DNA probes that are 
bound on a solid surface such as a glass slide. Micro-array technologies have been widely 
used in research for measuring gene expression changes and elucidating the relationship 
between genotypes and phenotypes. They are quite cost effective for profiling gene 
expression. Micro-arrays have also been used in clinical diagnostics. Some of the most 
commonly used examples include the detection of copy number variants using SNP-arrays 
such as the Cytogenetics Whole-Genome array from Affymetrix or the HumanOmni1-Quad 
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BeadChip, and HumanCytoSNP-12 DNA Analysis BeadChip from Illumina.  In general, 
micro-arrays can be used for general screenings, gene expression profiling, genotyping and 
many other applications. However, like in PCR based applications, the use of predefined 
oligonucleotides (probes) is based on previous knowledge availability. Thus, micro-arrays are 
used for quantification or detection of known sequences and not for the discovery of new 
variants, transcripts or other unexpected transcriptomic features (Mortazavi et al., 2008).  
In order to fully illustrate the limitations of micro-array technology, we should briefly present 
some basic concepts. Micro-array detection is based on hybridization of sample DNA to 
nucleic acid probes, bound to the surface of a slide. The probes are oligonucleotides with a 
usual length of 25 to 120 nucleotides. To further measure the quantity of hybridization to 
each specific probe, the target sequence (DNA or cDNA) is labeled with fluorescent dyes. 
Then, after an image is taken and processed, signal intensities can be read and converted to 
normalized values in order to initiate the data analysis. Due to the nature of micro-array probe 
design, the capabilities of this method are apparently restricted to known sequences and 
therefore do not allow detection of target sequences beyond the current knowledge. This 
factor can be a disadvantage for non-model organisms, but diagnostics of well-characterized 
organisms, such as humans, is feasible, although it relies on the quality of the available 
bioinformatics data at the moment the micro-array was designed. Micro-arrays can be used 
for diagnostic transcriptome analysis. If properly designed, micro-arrays will not only 
Table 8: Technical comparison between PCR, micro-array and RNA-Seq methodologies. Adapted from 
(Mimura et al., 2014), and complemented with Devonshire et al., (2013) and personal experience and 
information. 
 
 PCR Micro-array DNA/RNA sequencing 
Principle Hybridization Hybridization Sequencing 
Resolution 25 bp -100 bp 25-120 bp Single base 
Dependence on available knowledge High High Low 
Background noise High High Low 
Identification of isoforms Limited Limited High 
Differentiate between allelic 
expressions 
Limited Limited High 
Maximum number of samples per run 384 2 ≥96 x 8 
Maximum number of targeted regions 
per sample 
1728 30,455*/950,000** 
Everything transcribed or 
amplified 
*As of number of CCDS genes from RefSeq Genes annotated and the number of hybridization probes designed 
for expression arrays. 
**As for the number of probes that can be included/designed for Genotyping SNP Arrays v6.0. 
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provide information on gene expression and expressed SNPs, but also detect exon junctions, 
and fusion genes (Stefano, 2014). 
Normalization and processing of micro-array data can involve quite complex bioinformatics 
methodologies and statistics. This is a consequence of the nature of the data produced by this 
technology that may become a limitation for someone not acquainted in the area. However, 
significant efforts were put into developing standardized procedures for micro-array analysis. 
Some of these procedures as well as suggestions, guidelines, metrics, and thresholds among 
other information, are publicly available under the micro-array quality control (MAQC) 
website, together with the publications that helped to reach consensus on these procedures. 
Reader are referred to the Micro-array Quality Control Project for further details (MicroArray 
Quality Control (MAQC)). 
The human genome has been long studied and annotated, making it easier to use the available 
information to develop micro-array probes for clinical diagnostics. As an example, Agendia 
N.V. (www.agendia.com) developed clinical tests for complex diseases such as breast and 
colon cancers, based on gene expression profiling micro-arrays. The Agendia ‘MammaPrint’ 
assay can be used to classify different types of breast cancer and to calculate the recurrence 
risk. This assay was tested on a cohort of 6694 early breast cancer patients in a phase III trial 
(MINDACT), to investigate the utility of the MammaPrint 70 gene signature for adjuvant 
chemotherapy (Viale et al., 2016). Similarly, another test for colon cancer could also classify 
different cancer types as well as calculate recurrence risk factors with an 18 gene-signature 
(Salazar et al., 2011). 
Genome wide micro-arrays can yield a global view of known polymorphisms or gene 
expression. Compared to custom designed arrays, genome wide array analyses provide a 
better opportunity of resolving complex and heterogeneous clinical syndromes. A review by 
Wong., (2012) of several approaches for sepsis and septic shock, shows the potential and 
applications of the genome wide microarray analysis (Wong, 2012). One of the outcomes of 
the studies carried out with septic shock, was the characterization of a 100-gene expression 
signature. The correlation of clinical phenotype of these pediatric patients with microarray 
data showed that this expression signature could classify septic shock of three different 
phenotypes. Being one of these, a severe phenotype with increased illness severity and higher 
mortality rate (Wong et al., 2009). The proper identification of phenotype-correlated marker 
genes may also lead researchers to find potential therapeutic targets. Hence, proper 
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classification to clinical phenotypes of septic shock would allow for the design of more 
specific and targeted therapies. With the review of many studies of septic shock showing 
similar results for genes such as MMP-8, highly expressed in patients with septic shock, it 
was possible to demonstrate that inhibition MMP-8 resulted in significant improvement of 
patient survival. Hence, genome wide micro-array approaches showed to provide insights in 
the pathology of complex diseases, help to classify patients in groups with specific 
characteristics, and allow the discovery of novel therapeutic targets (Wong, 2012). 
1.4.2.3. Sequencing-based diagnostics 
Advances in DNA sequencing, and in particular the advances of NGS, have significantly 
improved the quantity and quality of genomic information that can be obtained from clinical 
samples. The reduced cost of NGS as well as the increase in throughput made whole genome 
sequencing (WGS), as well as other NGS applications such as whole exome sequencing 
(WES) or RNA-Seq, a possible and reliable approach for clinical diagnosis. However, there 
are still some challenges such, as data storage, management, analysis, and interpretation, that 
have to be considered for the proper use of this technology in clinical applications (Su et al., 
2011). 
Many different platforms for massive parallel sequencing were developed. The first example, 
although currently obsolete, is the 454 Genome Sequencer from Roche Applied Sciences. 
Also outdated is the SOLID platform from Life Technologies. The still current and also most 
widely used technology is the Solexa ‘Sequencing-by-Synthesis’ technology that was 
acquired by Illumina in 2007. The strength of these technologies relies on a very high 
throughput at the expense of read accuracy and much shorter read length when compared to 
the well-known Sanger sequencing. However, the possibilities of use and applications of this 
technology led to significant scientific discoveries and diagnostic applications (Su et al., 
2011). Fortunately, some of the trade-offs are being reduced through continuous platform 
improvements and developments which resulted in more advanced sequencer versions such 
as the Ion Torrent and Ion Proton from Life Technologies, and the MiSeq, NextSeq and 
HiSeq from Illumina. In particular, the HiSeq versions have greatly improved in accuracy and 
read length in the most recent versions as well as in significantly higher throughput (e.g. 
HiSeq 4000). Meanwhile, the run time has been decreasing, making it suitable for diagnostic 
use. Advances, and ongoing efforts to improve these platforms even further have made the 
HiSeq platforms from Illumina the most widely used NGS sequencers. 
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Depending on the sequencing platform of preference many options are available for library 
preparations. The library preparation steps include all transformations the nucleic acids of 
interest may require prior to being completely ready for sequencing on the platform of 
choice. In general, NGS library preparations for sequencing-based analysis consist of cDNA 
synthesis (in the case of RNA) and extension of the DNA/cDNA with specific ligated 
adapters for sequencing. Furthermore, it is quite common that a minimum quantity of input 
material is required to ensure a minimal quality. In the case of RNA, standard protocols for 
RNA isolation from body fluids and tissues yield at least 10ng of RNA, which is often 
sufficient. While for samples containing degraded RNA, such as FFPE, a minimum of 100ng 
is strongly recommended (Wan et al., 2014). In addition, many adaptations to library 
preparation protocols are reported in order to cover different aspects of the complexity of 
DNA or/and RNA processes and regulations such as many types of DNA mutations, 
methylation and other epigenomic modifications, post-transcriptional modifications, gene 
expression, isoforms, regulation, splicing, and degradation (Dominissini et al., 2011; 
Sánchez-Pla et al., 2012; Feng et al., 2013; McGettigan, 2013). For a better overview of 
available published protocols please refer to available collections of preparation methods 
such as the sequencing methods review published from Illumina Technology 
(www.illumina.com/content/dam/illumina-marketing/documents/products/research_reviews/ 
sequencing-methods-review.pdf). 
The overwhelming quantity of data produced per sample, requires advanced bioinformatics 
analysis to address the wide variety of possible questions. There are many tools and software 
packages available that can analyze these massive datasets, make inferences from the data, 
and offer biological interpretations. Despite their differences, there are some data analysis 
steps that are usually shared amongst the different approaches. Common steps include: 
quality check of the sequencing data, sequence alignment to a reference genome or de novo 
assembly in some other cases, and the assessment of the specific experimental results in order 
to finally provide useful diagnostic information (Su et al., 2011; Shyr and Liu, 2013; Wan et 
al., 2014). It is accepted as good practice, to perform several quality checks at the different 
steps in the process of analyzing clinical samples. Several authors reviewed different quality 
measures and how to use them during the downstream analysis. A recent review by Li et al., 
exposed many sequencing quality checks specific for RNA-Seq experiments including checks 
assessing raw sequence quality, nucleotide composition, presence of rRNA or tRNA, as well 
as the presence of other contaminant nucleic acids (Li et al., 2015). Although these checks are 
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specific for RNA sequencing approaches, there are other important and shared steps with 
DNA-based sequencing approaches of importance, such as the alignment step of the 
sequenced reads against the reference genome, or transcriptome. The human genome is 
nowadays quite complete with the latest version 38 released on June 29th 2014 by the 
Genome Reference Consortium, patch 10 released January 6th 2017 (GRCh38.p10) (Human 
genome overview - Genome Reference Consortium). During the alignment, the human 
genome is used as matching reference for the sequenced reads. RNA-Seq data alignments 
differ substantially from the DNA-Seq alignments. The nature of read sequences in RNA-Seq 
provides extra levels of complexity due to the fact that RNA molecules are the product of 
transcription and post-transcriptional processes such as splicing and RNA editing. The 
splicing removes part of the transcribed sequences - the introns - leaving the exons present in 
the sequence. After the library preparation and its fragmentation step, which is an optional 
step and commonly performed by sonication, some of the shorter reads obtained may come 
from the region where two exons were joined. In this particular situation, the RNA-Seq 
aligners have to be flexible enough to be able to map part of the reads to one exon and the 
other part to another exon, spanning an exon junction (Au, 2015). There are many aligners 
available that can deal with RNA-Seq data, such as Bowtie2, GSNAP, STAR, and SpliceMap 
among many others. All RNA-seq aligners can deal with both DNA- and RNA-based 
sequence reads, but this is not true for most DNA aligners that would struggle with the 
allocation of split reads. Work has been done to review and report available alignment tools 
to help users through the, sometimes difficult, decision of selecting the best tools for 
applications in clinical diagnostics (Shyr and Liu, 2013; Wan et al., 2014). In general, all 
aligners offer the possibility to modify key parameters in order to adapt their algorithms 
according to the quality of available data and the question of relevance. Once a decent quality 
alignment is produced, the proper diagnosis is usually within reach. 
Particularly for RNA samples, a common approach is to retrieve transcript abundance, as 
gene counts, for gene expression profiles or differential expression. However, prior to 
comparing two RNA-Seq datasets, the raw counts should be normalized to account for some 
differences introduced by handling during the library preparation steps. Due to this inherent 
variability, normalization of raw counts is required since these are not directly comparable 
between or within samples (Dillies et al., 2013). There are many normalization methods, 
some correcting for gene length, GC content, library size (total number of reads), as well as 
other bias adjustments. For better understanding of the available normalization procedures, 
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Dillies et al., compared several normalization methods in order to clearly present their 
application in the context of RNA-Seq data. In summary, the available DESeq and TMM 
normalization methods showed to be able to maintain the power to detect differential 
expressed genes while properly controlling the false-positive rate (Dillies et al., 2013). 
Another way of normalization to deal with extra biases found in cross-platform or inter-
laboratory comparisons relies on the inclusion of synthetic spike-in materials. In some cases 
these external RNA controls developed by the External RNA Controls Consortium (ERCC) 
became available for the evaluation of cross-platform performance according to GC content, 
transcript length, and sequencing accuracy (Devonshire et al., 2013). Extended information 
on RNA-Seq practices as well as some additional recommendations, benchmarking 
technology comparisons, reproducibility assessments and evaluations of RNA-Seq for 
clinical applications was also published by the Sequencing Experiment Quality Control 
consortium (SEQC). The SEQC project is the third phase of the MAQC and it involves 12 
countries, 78 organizations and 180 researchers 
(http://www.fda.gov/ScienceResearch/BioinformaticsTools). 
Regardless of the source of sequencing, based on DNA or RNA, the precision of single base 
information can be easily used to extract the differences of a given sample from the reference 
genome sequence. The wide range of available bioinformatics tools offers the possibility to 
answer various biological and diagnostic questions. However, bioinformatics analysis may 
not be able to overcome some limitations that we can still face with NGS data such as highly 
repetitive sequences, 3' biases and biased GC content. In general, the small loss of 
information due to these limitations is of low impact compared with the significant insights 
that NGS provides. Repetitive sequences in the human genome are well characterized, 
making it easier to handle problems related to polymorphic copy number variation in these 
regions. During the alignment steps, reads that map to many locations of the genome (not 
uniquely mapped) with equal quality are usually filtered out. The enrichment of 3' end 
sequences of genes, also known as 3' bias, is a side effect of the fast degradation of mRNAs 
from the 5’end of the transcript, which may be even more prominent when using poly-A 
enrichment methods during the library preparation. This effect can be widely avoided by 
using higher quality RNA, which should be possible in a properly designed diagnostic 
setting. Additionally, 3' biases will not affect the outcome of DNA-based analysis and some 
RNA-based analysis, such as gene expression measurement, since it is considered that all 
transcripts exhibit similar degradation and the same library preparation was performed within 
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a particular well-controlled experiment. The last limitation, regarding some difficulties of 
sequencing high GC regions, is a problem that usually results from several causes. First, it is 
known that some polymerases may have increased difficulties to transcribe high GC content 
sequences. This, coupled with the inherent high repetitive nature of GC or AT enriched 
regions, makes these regions somehow tricky to analyze with higher levels of confidence. 
Though, not all high GC-rich sequences are affected at the same level due to differences in 
GC percentages and other nucleic acid composition, namely AT (Li et al., 2015). High GC 
regions will not only affect the resolution of SNPs, SNVs, or other genomic variants, but it 
may also interfere with measurements in gene expression values within GC-rich regions. 
Hansen et al., worked on an alternative normalization method to acquaint for the GC content 
as well as gene length of a particular gene using a conditional quartile normalization (Hansen 
et al., 2012). However, their method did not outperform other less sophisticated 
normalization methods (Dillies et al., 2013). 
Cancer is commonly regarded as an accumulation of genetic alterations such as single 
nucleotide variants (SNVs), altered DNA methylation patterns, and chromosomal 
abnormalities. As a consequence of DNA modifications there may be dysfunctional genes 
leading to over or under-activity and chimeric transcripts or gene fusions. These alterations 
may disrupt the proper function of the gene, which may become an oncogene, a 
malfunctioning tumor suppressor, or an incorrect DNA repair gene. The occurrence of one or 
more of these genetic alterations may affect cellular growth and lead to tumor development. 
Since the landscape of cancer is complex, sequencing-based approaches (DNA/RNA-Seq) 
can be very useful for clinical diagnostic applications, offering a wider range of screening 
possibilities to check for the whole diversity of cancer-related alterations in a single run (Shyr 
and Liu, 2013). Many studies have been carried out that contributed in the understanding of 
molecular determinants of tumor cell types. Cancer characterization is remarkably one of the 
research fields that has dedicated considerable efforts to adopt sequencing approaches, and in 
particular RNA-Seq, for research purposes and to assess its potential in clinical applications 
(Su et al., 2011; Shyr and Liu, 2013; Wan et al., 2014; Chaussabel, 2015). Since the 
accumulation of genetic alterations may be either inherited or somatically acquired, 
sequencing approaches becomes a strong complementary approach in screening and 
diagnostic applications.  
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Apart from complex diseases such as cancer, NGS showed great potential in other fields of 
clinical diagnostics such as immunology. Recent tendencies in immunological studies 
showed that large scale genomics and transcriptomics approaches are becoming more popular 
options for immunological studies. These global approaches can help to mitigate for instance 
the limitation of cellular heterogeneity in blood samples, even though, the measurement of 
cell composition in blood samples is not always perfect (Chaussabel, 2015). Despite this 
limitation, the use of a global approach, such as transcriptomic analysis of blood samples, has 
shown to provide very nice advantages towards clinical diagnostics as was seen in early 
research done on autoimmune disorders, cancer, and infectious diseases (Chaussabel, 2015). 
Transplant rejection of heart transplants has been assessed by an endo-myocardial biopsy test. 
But this is an invasive procedure that is characterized by greater risk of morbidity, discomfort 
for the patient, tissue sampling errors and late detection of rejection. Due to all these 
limitations, it was necessary to find an alternative to this type of invasive tests to detect heart 
transplant rejection, and to more accurately and early adapt patient treatment to avoid 
transplant rejections. With this in mind, Chen et al., (2013) used a NGS approach to analyze 
peripheral blood gene expression profiles, monitor the immune system and potentially avoid 
heart transplant rejection by early detection. For this study 12 patients were analyzed from 
grade 0 (6 quiescent patients) to grade 2R and 3R (6 rejection patients). The results were 
validated by qPCR of 47 individuals from three different rejection groups. A total of 10 genes 
(Table 7) were identified which provided a signature of high risk for severe rejection. This 
10-gene signature was also tested to be effective in other organ transplants (Chen et al., 
2013). 
In the case of patients with hereditary steroid-resistant nephrotic syndrome (SRNS), 
McCarthy et al., (2013) showed the potential of NGS to investigate the genetic variations of 
this group of patients in a single step. Causa variants were identified using a WES panel of 
446 genes which included the screening of the 24 genes currently associated with SRNS. The 
screening of >350 patients with this approach, showed to be reliable to identify previously 
known disease-associated variants in genes such as NPHS1, NPHS2, and PLCe1 as well as 
the potential of identifying de novo variants in unexpected genes such as COQ2 and COL4A4 
(McCarthy et al., 2013). 
Research work in the field of renal diseases also showed the potential of NGS to identify 
gene expression profiles, gene pathways, and alternative splicing linked to TGFB and SMAD3 
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signaling in chronic kidney diseases (CKD) (Zhou et al., 2015). In summary, research 
findings using animal models provided insight information about SMAD3 signaling and its 
function in renal injury, as well as highlighting potential targets for CKD therapies (Zhou et 
al., 2015). The study of SMAD3-dependent renal injury was performed using total RNA of 
kidneys from mice models with SMAD3 wild type and knockouts for immune and non-
immune mediated CKD (anti-glomerular basement membrane glomerulonephritis, and 
obstructive nephropathy, respectively). Zhou et al., reported 9 differentially expressed genes 
linked to SMAD3 (IGHG1, IGHG2C, IGKV12-41, IGHV14-3, IGHV5-6, IGHG2B, 
UGT2B37, SLC22A19 and MFSD2A) and showed that renal injury transcriptomes may 
mediate pathogenesis of CKD. 
Global as well as targeted NGS approaches showed to be suitable for unravelling the insights 
and progression of complex diseases such as CKD (Zhou et al., 2015). In addition, NGS 
approaches can facilitate the identification of inherited pathogenic mutations in key disease-
associated genes such as PKD1 or PKD2 for ADPKD (Rossetti et al., 2012). Overall, NGS 
approaches offer an alternative to classic/current diagnostics that deserve to be part of the 
daily basis of applied and personalized medicine and can be beneficial in the field of renal 
disorders. 
1.5. Scope 
The general aim of this thesis is to bridge between two very well stablished and distinct 
specializations, nephrology and sequencing data analysis, with the objective of providing new 
and advanced tools for the better understanding of renal diseases. With this purpose, the 
studies described within this thesis will use different cutting edge sequencing approaches to 
exemplify the use of NGS in three distinct renal disorders: ADPKD, AKI, and 
glomerulosclerosis. We will discuss the potential advantages of using sequencing approaches 
in each different case. 
ADPKD: In Chapter 2 we provide a new methodology for the diagnosis of ADPKD based on 
cutting edge NGS approaches with long-read single molecule sequencing (PacBio). 
Particularly, we show that long-read sequencing can overcome the difficulties and 
complexities associated with PKD1. 
AKI: In Chapter 3 we provide a clear example of the use of RNA-sequencing for expression 
profiling of a complex disease such as AKI. In addition, we show the potential uses of 
34 
 
genome wide transcriptomics approaches to elucidate a complex genetic mechanism, which 
includes signalling pathways that are activated in the presence or absence of a given gene 
such as Gdf15. In return, we show that AKI expression profiling with NGS approaches can 
identify the driving transcription factors of an AKI phenotype. 
Glomerulosclerosis: In Chapter 4, we evaluate RNA-sequencing of FFPE tissue with the aim 
of characterizing glomerular expression profiles of sclerotic glomeruli isolated with LCM. In 
addition, we define the minimal requirements for a successful sequencing approach of RNA 
isolated from FFPE samples. 
Finally, we will elaborate on the future perspectives of sequencing technologies and their 
potential uses in future diagnostics applications. 
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2.1. Abstract 
A genetic diagnosis of autosomal dominant polycystic kidney disease (ADPKD) is challenging 
due to allelic heterogeneity, high GC-content, and homology of the PKD1 gene with six 
pseudogenes. Short-read next-generation sequencing (NGS) approaches, such as whole genome 
(WGS) and whole exome sequencing (WES), often fail at reliably characterizing complex 
regions such as PKD1. However, long-read single-molecule sequencing has been shown to be an 
alternative strategy that could overcome PKD1 complexities and discriminate between 
homologous regions of PKD1 and its pseudogenes. In this study, we present the increased power 
of resolution for complex regions using long-read sequencing to characterize a cohort of 19 
patients with ADPKD. Our approach provided high sensitivity in identifying PKD1 pathogenic 
variants, diagnosing 94.7% of the patients. We show that reliable screening of ADPKD patients 
in a single test without interference of PKD1 homologous sequences, commonly introduced by 
residual amplification of PKD1 pseudogenes, by direct long-read sequencing is now possible. 
This strategy can be implemented in diagnostics and is highly suitable to sequence and resolve 
complex genomic regions that are of clinical relevance. 
2.2. Keywords 
DNA diagnostics, PKD1, ADPKD, complex genomic regions, variant detection, Single-
Molecule Real-Time sequencing, long-read sequencing, PacBio. 
2.3. Introduction 
DNA sequencing technologies have been widely applied in biomedical and biological research as 
well as diagnostics. Relatively low cost and high-throughput are major advantages of next-
generation sequencing (NGS) over standard diagnostic assays (Su et al., 2011; Mardis, 2013; 
Oliver et al., 2015). However, despite widespread use of NGS-based diagnostics strategies 
(Ozsolak and Milos, 2011; de Ligt et al., 2012; Chang and Li, 2013; von and Huber, 2013; Yang 
et al., 2013; Dewey et al., 2014; LaDuca et al., 2014; Codina-Solà et al., 2015; Sun et al., 2015; 
Willig et al., 2015), short-read sequencing approaches such as whole genome (WGS) and whole 
exome sequencing (WES), often fail at reliably characterizing complex regions of the human 
genome (Lee and Schatz, 2012; Chaisson et al., 2015). These regions are often associated with 
extreme GC-content, segmental duplications (SDs), low complexity sequences and gaps in the 
human reference sequence (Lee and Schatz, 2012; Steinberg et al., 2014; Chaisson et al., 2015). 
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Single-molecule long-read sequencing can improve our understanding of genetic variations in 
complex but clinically relevant genomic regions (Guo et al., 2013; Loomis et al., 2013; Laver et 
al., 2016; Qiao et al., 2016). 
In this study, we aim to show the value of single-molecule long-read sequencing as a tool to 
characterize genetic variants associated with autosomal dominant polycystic kidney disease 
(ADPKD). ADPKD is a common inherited disease that accounts for 5% to 10% of end-stage 
renal disease (ESRD) (Harris and Rossetti, 2010; Spithoven et al., 2014). Most ADPKD 
pathogenic variants occur in PKD1 (MIM* 601313) and PKD2 (MIM* 173910) genes with a 
reported prevalence of 85% and 15%, respectively (Barua et al., 2009; Harris and Rossetti, 
2010). The mutation spectrums in PKD1 and PKD2 are highly heterogeneous, with no mutation 
hotspots present, indicating that pathogenic variants in either PKD1 or PKD2 are usually private 
(Gout et al., 2007; Harris and Rossetti, 2010). The screening of PKD1 is challenging due to 
difficulties in amplification and low resolution of its complex locus (Rossetti et al., 2007; Tan et 
al., 2009; Qi et al., 2013). This is partly due to its high homology for most of PKD1 sequence 
with six pseudogenes as well as high GC content (Rossetti et al., 2007; Tan et al., 2009; Qi et al., 
2013). In this study, we used PKD1 as an excellent example of a challenging and complex locus. 
Several attempts have been made to improve the screening of PKD1 gene by using short-read 
NGS approaches to replace the standard diagnostics based on Sanger sequencing and multiplex 
ligation-dependent probe amplification (MLPA) assays (Rossetti et al., 2012; Qi et al., 2013; Tan 
et al., 2014; Trujillano et al., 2014; Eisenberger et al., 2015; Mallawaarachchi et al., 2016). These 
strategies provided a clear diagnosis with high sensitivity and specificity (97% - 100%) for 115 
out of 183 (Rossetti et al., 2012), 16 out of 25 (Tan et al., 2014), 10 out of 12 (Trujillano et al., 
2014), 35 out of 55 (Eisenberger et al., 2015), and 24 out of 28 (Mallawaarachchi et al., 2016) 
screened ADPKD patients. Duplicated and high GC-content genomic regions, such as that of 
PKD1 gene, can lead to ambiguous identification of variants when analyzed with short-read NGS 
strategies (Lee and Schatz, 2012). These ambiguities produced low true positive variant detection 
rates of 28% to 50% for the duplicated region of PKD1 (Qi et al., 2013), and many false 
positives (10%) due to misalignments, low quality alignments and contamination by residual 
amplification of pseudogenes (Rossetti et al., 2012). Hence, diagnostic assays based on NGS 
short-reads (e.g. Sanger or Illumina) may not be fully suited for reliable ADPKD diagnostics. 
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In this study, we utilized the single-molecule long-read Pacific Biosciences RSII (PacBio) 
sequencing technology to assess its potential value in molecular diagnostics of ADPKD patients. 
We show that direct sequencing of long-range PCR (LR-PCR) products eliminates the 
interference of residual amplification of PKD1 pseudogenes, as well as alignment ambiguities. 
This also enabled a reliable identification of pathogenic variants, from single nucleotide variants 
(SNVs) to large deletions. 
2.4. Materials and Methods 
2.4.1. Selection of Subjects and DNA Isolation 
Nineteen genotyped patient samples were selected for this study from the diagnostic laboratory 
in which at least one pathogenic mutation was detected by Sanger sequencing or MLPA. The 
selection aimed to include different types of mutations (eg. SNVs, as well as small and larger 
insertions and deletions (indels)) that are located in exons or in immediately flanking intronic 
sequences, for both the duplicated regions as well as the unique part of PKD1. Although PKD2 is 
not a complex gene and is not the focus of this study, the sequencing of LR-PCR fragments for 
PKD2 was performed as a proof of principle of long-read sequencing and detection of variants 
also for PKD2. Genomic DNA isolation was performed from peripheral blood samples using 
PUREGENETM nucleic acid purification chemistry on the AUTOPURE LS 98 Instrument 
(Qiagen).  
2.4.2. Long-read sequencing and variant identification for ADPKD genes 
2.4.2.1. LR-PCR amplification  
To cover the entire PKD1 and PKD2 coding regions (including exon boundaries), a total of 5 and 
9 LR-PCR fragments were designed, respectively. Primers were optimized to produce amplicons 
of similar sizes (>4Kb) that could be pooled to improve sequencing efficiency and loading 
capacity for SMRT sequencing (Supp. Table S1; Supp. Figure S1). The major part of PKD1 
intron 1 was excluded from the design due to its large size and the lack of previously reported 
pathogenic variants in this region. Fragments were amplified from 50ng of genomic DNA using 
1x ExtensorTM Hi-Fidelity Long Range PCR Master Mix (Thermo Scientific) on a 25 µl of PCR 
reaction volume with 200 nM of M13-tagged primers. Initial denaturation was performed for 10 
min at 98°, followed by 35 cycles of 15 secs at 98° and 10 min at 68°. Final extension was 10 
min at 68°. Products were size selected using the BluePippin DNA size selection system to 
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classify them in 3 different groups of sizes 4.3-6-1 Kb, 7.1-7.5 Kb, and 7.6-8.1 KB (Supp. Table 
S1; Supp. Figure S1). Fragments of equal size were pooled equimolar, and were visually 
inspected by band intensity on agarose gel. Finally, all pools were purified with a 0.6x v/v ratio 
of AMPure XP Beads (Beckman-Coulter). 
2.4.2.2. SMRT-sequencing library preparation  
Sample indexes for patient tracking were added to the LR-PCR fragments using an additional 
five cycle PCR with the previous LR-PCR conditions. Barcoded pools were then purified with 
AMPure XP Beads, and pooled equimolar according to their size. Molar concentration was 
verified on a Bioanalyzer 12000 chip (Agilent). For each barcoded pool, a SMRT-bell library 
was prepared according to the PacBio’s 5 or 10 Kb Template Preparation procedures. Pooled 
amplicons were sequenced on 5 SMRT cells on the PacBio RSII system with the P6 sequencing 
 
 
Figure 1: Flowchart of the applied analytical approach for the identification of potentially pathogenic variants 
and VUCS in ADPKD patient samples. Key processes in the workflow describe details and thresholds used for 
(1.) sequencing of pooled LR-PCR amplified fragments with PacBio RSII and postprocessing of reads including 
alignments and read quality filters; (2.) identification of variants using two independent strategies including the 
reconstruction of allelic sequences, and small variant calling using Quiver; (3.) standardization of variant 
nomenclature to represent a correct HGVS description and facilitate the comparison between datasets; (4.) 
enrichment of variant annotations with VEP (including effect prediction, ClinVar, SIFT, PolyPhen, 1000 
Genomes Project, dbSNP, and SwissProt annotations among others), and selection of high confidence variants; 
(5.) identification of potentially pathogenic variants and VUCS based on their confidence, effect prediction, and 
population frequencies. 
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chemistry. Data collected from 360-minute movie-time was preprocessed using the standard 
primary analysis tools (Figure 1). 
2.4.2.3. Sequence Alignment and Variant Calling 
We used the RS_Resequencing protocol from SMRT Analysis Suite v.2.3 to align long-reads 
against the human reference genome, downloaded from the Genome Reference Consortium 
version 37 patch 13 (GRCh37.p13). Samples were de-multiplexed into individual files (H5 and 
BAM formats) using known barcode sequences and a minimum barcode identity score of 22 
(Figure 1). Alignments were filtered to contain mapped reads with a mapping quality threshold 
of 30 Phred score using Samtools v.1.2 (Supp. Table S2). Read coverage and targeted PCR 
statistics for LR-PCR amplicons were computed with BedTools v.2.25.0, and PicardTools 
v.1.1.40 (Supp. Table S2; Supp. Table S3; Supp. Table S4). Variant calling was performed using 
Quiver (allowing for diploid calling and maximum coverage of 10,000). Variants with a Quiver 
confidence score lower than 40 were filtered out from downstream analysis (Figure 1). 
2.4.2.4. Reconstruction of Allelic Sequences 
PKD1 and PKD2 allelic sequences were reconstructed by using the Long Amplicon Analysis 
(LAA) available in SMRT Analysis Suite 2.3. Only reads longer than 3,000 base pairs (bp) and 
average signal to noise ratio of 3 were used for the reconstruction (Figure 1). Based on this 
reference-free subread (full-length and non-full-length reads) clustering, chimeric sequences 
were identified and comprehend ≤0.85% (6,288/738,822) of subreads that were subsequently 
removed from the analysis. Allelic sequences of PKD1 and PKD2 were aligned to the human 
reference genome GRCh37.p13 using BLASR (Chaisson and Tesler, 2012), and reporting a 
single best-scoring alignment. Variants were extracted by comparison between the reconstructed 
alleles and the human reference sequence with the Variant Description Extractor from the 
Mutalyzer Suite 2.0.21 (Vis et al., 2015). 
2.4.2.5. Loss of Heterozygosity (LoH) Analysis 
Loss of heterozygosity (LoH) for each amplified fragment was assessed to identify patients with 
potential large deletions for PKD1. We first identified heterozygous substitutions within the 
amplified fragments with a variant frequency between 25% and 75%. Amplified fragments with 
zero heterozygous substitutions were identified as LoH. Large deletions produce multiple LR-
PCR fragments dropouts, and were identified by the detection of consecutive LoH fragments. 
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The detection of consecutive LoH fragments was not a direct identification of large deletions per 
se, rather than an indication of the presence of large deletions in the amplified LR-PCR fragment 
regions. Identified LoH regions were then compared with large deletions detected by MLPA. 
2.4.3. ADPKD Variant Nomenclature and Genotyping 
Variant descriptions were standardized to concord with HGVS guidelines (den Dunnen et al., 
2016), using the Mutalyzer Name Checker tool (Wildeman et al., 2008). Genomic HGVS 
descriptions were converted to coding notations using the Position Converter from Mutalyzer 
(Wildeman et al., 2008). Only changes in RefSeq annotated canonical transcripts for PKD1 
(NM_001009944.2) and PKD2 (NM_000297.3) were further analyzed. HGVS descriptions of 
deletion-insertions (delins) were manually inspected to avoid variant redundancies and undesired 
clustering of neighboring independent events (Figure 1; Supp. Table S5). Then, standardized 
variants were annotated using the Variant Effect Predictor (VEP), from Ensembl tools v.83 
(McLaren et al., 2010), with additional parameters “-everything”, and “-refseq” (Figure 1). All 
variant annotations reported by VEP are fully disclosed in the raw VCF files 
(EGAS00001002106). Variant frequency and coverage were used to filter low confidence 
variants by applying thresholds for: (a.) sequencing depth of ≥50x subreads and ≥15x reads 
which ensures a sufficient control over the SMRT sequencing random error rate (1% mismatches 
and 13% indels); (b.) minimum variant frequency of 10% for substitutions and 15% for deletions 
and insertions (Figure 1). For interpreting insertion and deletion frequencies, neighboring bases 
were also examined. The selection of strong pathogenic variant candidates or variants of 
unknown clinical significance (VUCS) was based on the following criteria: (1.) high predicted 
effect on the coding sequence or splice site region (e.g. missense, in-frame indels, frameshifts, 
and splice site acceptor or donor variants); (2.) population frequency in the 1000 genomes 
project <1%; (3.) unique occurrence (1/19) (~5%) in the patient cohort since, in ADPKD, no 
single disease causing variant accounts for more than 2% of affected families (Harris and 
Rossetti, 2010), or more than 1.7% of ADPKD reported cases in the ADPKD database (PKDB) 
(http://pkdb.mayo.edu/; accessed version 3.1) (Gout et al., 2007) (Figure 1).  
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2.4.4. Clinical diagnostics pipeline for ADPKD genotyping 
2.4.4.1. Sanger Sequencing  
The current diagnostics pipeline for ADPKD genotyping, including Sanger sequencing and 
MLPA, used a different set of LR-PCR primers to target the duplicated part of PKD1 (exons 1 to 
32) (Supp. Table S6). The non-duplicated region of PKD1 (exons 33 to 46), and PKD2 regions 
(exons 1 to 5) were amplified using targeted standard PCR reactions (Supp. Figure S1), with 100 
ng of input genomic DNA with M13 tail primers. The nested and standard PCR amplicons were 
designed to cover the complete coding regions and splice sites with at least 20 bp of flanking 
intronic sequences (Supp. Table S7; Supp. Table S8). The duplicated part of PKD1, which 
includes exons 1 to 32, was amplified using 4 different LR-PCR fragments that covered exons 1, 
2-13, 14-21, and 22-32, respectively (Supp. Table S6). LR-PCR amplification was performed 
using Thermo Scientific 2x Extensor Long Range PCR Master Mix on 50 ng of DNA. Then, a 
nested-PCR was carried out on 4 μl 100-250x of diluted product to obtain the final Sanger 
sequencing fragments. The nested-PCR primers with an M13 tail were used to amplify the 
coding region including 5 to 20 bp of intronic sequences (Supp. Figure S1). Large exons such as 
exon 5, 10, 11, 15, and 23 were amplified using overlapping nested PCR products, although 10 
bases of exon 15 (c.6503-6514) were not covered. Nested PCR and standard PCR of the non-
duplicated part of PKD1, and PKD2, was carried out in a final volume of 15 μl in GoTaq 
Colorless Taq Reaction buffer with 0.6 U of Taq DNA-polymerase (Promega) at a final 
concentration 5 pM for each primer, 200 μM of each dNTP. After a hot start at 95 °C, a 
denaturation was performed for 5 min at 95 °C, followed by 35 cycles of 45 sec at 94°C, 45 sec 
at 60°C, and 30 sec at 72 °C. The final extension was of 5 min at 72 °C in a T-Professional 
Thermocycler (Biometra, Westburg). All liquid handling steps were automated using the 
SciClone (ALH-HV96 pipetting station, Perkin Elmer) or Biomek FX workstation (Beckman). 
PCR products (20 to 50 ng) were purified using an Ampure XP PCR purification kit and 
sequenced using BigDye Terminator v3.1 sequencing reactions (Applied Biosystems) with 
PAGE purified –21M13 or M13REV sequencing primer. The excess of dye terminatiors was 
removed by gel filtration using the Edge Biosystem Dye Terminator Removal (DTR) with a 96 
wells plate. After electrophoresis on an ABI Prism 3730 (XL) DNA analyzer (Life technologies, 
Applied Biosystems) data processing was automated using SeqPatient software (Sequence Pilot, 
JSI medical systems, GMbH). 
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2.4.4.2. Multiplex Ligation-dependent Probe Amplification (MLPA) 
To detect large deletions and duplications, two commercially available MLPA kits (P351-B2 and 
P352-C1; MRC-Holland, Amsterdam, The Netherlands) were used following manufacturer’s 
protocols and manuals. 
2.4.5. Comparative Analysis of SMRT sequencing and current ADPKD diagnostic assay 
The overlap between identified variants based on PacBio and Sanger sequencing data was 
achieved by assessing identical standardized HGVS descriptions. Only variants with predicted 
effects on coding DNA or splice site regions were considered (Supp. Table S5). PacBio and 
Sanger variants were manually inspected to detect overlapping variants with discordant 
descriptions between the two datasets. To facilitate interpretation, each unique variant was 
further annotated with its PKDB clinical significance, Single Nucleotide Polymorphism database 
version 144 (dbSNP) identifier, and the number of patients where it was detected in the cohort. 
Surrounding bases were evaluated to identify and remove potential sequencing artifacts 
occurring in homopolymer stretches. Finally, variants were considered as high-confident variants 
if previously reported in PKDB or dbSNP, showed strong PacBio sequencing evidence of being 
present, or detected in any patient by both Sanger and PacBio. 
2.4.6. Short-read loss of power for known PKD1 pathogenic variants in WGS and WES 
Previously known pathogenic variants for PKD1 gene were obtained from PKDB. Only variants 
that were classified as “definitely pathogenic” were selected for further analysis. Large deletions 
(few hundred bp to several Kbp long) were excluded from the analysis as they are not usually 
detected with common variant calling algorithms. For the genomic position of each pathogenic 
variant, sequencing depth was extracted from 9 publicly available WGS and whole-exome 
sequencing (WES) datasets (Sun et al., 2015). In addition, we included the sequencing depth of 9 
randomly selected libraries from the study of Rossetti et al, 2012, in which the authors used a 
similar strategy based on LR-PCR followed by short-read sequencing. Each library represents an 
equimolar pool of DNA from 4 different patient samples that were not possible to further de-
multiplex because individuals were not barcoded. Variant positions with low sequencing depth 
(< 8 reads, or < 32 for the short-read LR-PCR approach) were marked as inaccessible positions 
of clinical significance using BedTools v2.25.0. Finally, variant positions were classified into 
three categories based on the number of individuals with poor coverage at each position: (1.) 
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variants with sufficient coverage in all 9 individuals; (2.) variants reported inaccessible in 2–4 
individuals; and (3.) variants reported inaccessible in 5 or more individuals. 
2.4.7. Data Availability 
 Sequencing data and alignments in BAM format can be accessed through the European 
Genome-phenome Archive (EGA), as well as raw variants in VCF file format, under the EGA 
study identifier EGAS00001002106. Coding or splice site variants were also uploaded to the 
Leiden Open Variation Database (LOVD). Description and examples of custom scripts used in 
this manuscript are accessible upon request from a local GitLab repository. 
2.5. Results  
2.5.1. Targeted sequencing of ADPKD genes 
Direct sequencing of LR-PCR fragments (designed to specifically and uniquely amplify PKD1, 
and PKD2 gene regions) (Supp. Figure S1; Supp. Table S1) was performed to evaluate the utility 
of long-read sequencing in resolving ADPKD for molecular diagnostics. All PKD1 and PKD2 
exons (including the duplicated part of PKD1, as well as 20bps of flanking intron regions) from 
19 ADPKD patients could be completely covered using long-reads, sequenced on the PacBio 
RSII platform (Figure 2; Supp. Figure S2). Most of long-reads (94.4%) were uniquely mapped to 
PKD1 and PKD2 (Supp. Table S2). Reads originating from residual off-target amplification 
(5.6%; Supp. Table S2) introduced during the LR-PCR steps were identified, and discriminated, 
by their unique alignment to the PKD1 pseudogenes (Figure 2; Supp. Table S2). All PKD1 and 
PKD2 protein-coding and flanking intron sequences (±20 bp) were covered at average 
sequencing depth ≥421x (min. ≥19x; max. 1528x), with ≥97.36% of bases over ≥30x, which was 
well above the applied threshold of ≥15x reads (Supp. Table S2; Supp. Table S4). Amplicons 
that cover the first and last exons of PKD1 were underrepresented when compared to other LR-
PCR fragments, with a total of ≥593 average reads (min. ≥300; max 1580) and ≥87 (min. ≥35; 
max 153) for PKD1 fragments A and E, respectively (Figure 2B; Supp. Table S3). The usually 
difficult to sequence first exons of both, PKD1 and PKD2 genes were covered, on average ≥55x 
(min. ≥24x; max. 91x) and ≥71x (min. ≥43x; max. 111x), respectively (Supp. Table S4). Most of 
sequenced reads (>99.9%) were uniquely mapped to PKD1 and PKD2 (Figure 2B; Supp. Figure 
S2). 
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Figure 2: SMRT sequencing and variant calling of LR-PCR amplicons. (A) Sequencing depth (DP; in number 
of reads) of the alignments to chromosome 16 and chromosome 4. Number of uniquely aligned reads (y axis, 
blue line) sequenced with PacBio that mapped to PKD1 and PKD2. Off-target amplification is discriminated 
from the main PKD1 gene sequences showing alignments to pseudogene homologous sequences at proximal 
loci (e.g. PKD1P1, PKD1P5, PKD1P6) (blue boxes). (B) Mapping quality (MQ; in Phred quality scores; values 
>90 were scaled down for visualization purposes), and sequencing depth (DP; in number of reads) of uniquely 
aligned molecules to PKD1 (NM_001009944.2) for the 5 LR-PCR fragments amplified. Mapping quality of 
alignments with even coverage distribution along the amplified fragments (Fragments), including regions with 
segmental duplications (SD), repetitive elements (Repeats) and high GC-content (GC%). Despite fragments A 
and E show lower coverage, compared to the average sequencing depth of ≥421x (min. ≥19x; max. 1528x), they 
had sufficient coverage for variant calling within the exon regions, including the first exons of PKD1, with 
average coverage of ≥55x (min. ≥24x; max. 91x) (Supp. Table S4). (C) We detected 1,506 intron variants (blue) 
and 177 coding or splice site variants (yellow). The predicted transcript effects of coding and splice site variants 
were quantified (bar chart) as log10 count (x axis). 
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2.5.2. Sensitive detection of ADPKD small variants 
PKD1 is known to be a highly polymorphic gene with many variants reported in addition to the 
disease causing or pathogenic variants (Gout et al., 2007). Hence, the required sensitivity to 
resolve PKD1 was achieved by the combination of variant calling using Quiver and the 
reconstruction of amplified allelic sequences. Overall, we identified 1,683 variants (404 SNPs) 
across 19 ADPKD patients, from which 177 variants (119 SNPs) were located in coding or splice 
site regions (Figure 2C). Variants were distributed along PKD1 (Supp. Figure S3A) including 
regions with large segmental duplications and high GC-content. The mismatch rate of PacBio 
data was empirically assessed based on average frequency of mismatches at each position. We 
observed an average of 1.2% mismatch rate across the entire PKD1 gene (Supp. Figure S3A). 
This correlates with the random sequencing mismatch rate of 1% for PacBio and thus, the 
applied minimum frequency threshold of 10% for substitutions is well above the observed noise 
introduced by random PacBio errors.  
2.5.3. Large deletions in PKD1 
Detection of allele dropouts and large deletions in PKD1 was assessed by performing a loss of 
heterozygosity (LoH) analysis for each of the amplified regions (Figure 3). We identified 17 LR-
PCR fragments with LoH among all 19 patients sequenced. Most of these (10) corresponding to 
LoH regions identified in fragment E (Figure 3). Only 2 patients showed consecutive LoH 
fragments indicating the presence of large deletions spanning between two or more LR-PCR 
fragments. These consecutive LoH fragments are not a direct identification of the deletions per 
se but an indication of the presence of large deletions in the amplified region.  The two patients 
that showed two or more consecutive fragments with LoH (Figure 3) were in concordance with 
large deletions identified by MLPA as pathogenic variants in the same ADPKD patients. A 
deletion of ≥1,543 bps (c.(2097+1_2098-1)_3640del; exons 11-15) and a deletion of ≥9,108 bps 
(c.(287+1_288-1)_(9397+1_9398-1)del; exons 3-26) were detected by MLPA for patient sample 
7 and 13, respectively (Figure 3). With the current experimental design, however, the exact 
location of the breakpoints for each large deletion could not be determined with either method. 
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2.5.4. Comparative Analysis between SMRT-Seq and the ADPKD diagnostic assay 
The evaluation of 167 coding or splice site variants identified by standard ADPKD diagnostic 
assay, showed that 159 out of 167 were correctly detected by PacBio (Supp. Figure S3C). The 
overall observed sensitivity and specificity in detecting coding variants was of 95.2% (159/167) 
and 88.8% (159/179), respectively. Eight variants were solely detected by Sanger (Supp. Figure 
S3A: crosses), from which, despite of high sequencing depth, the majority (6/8) had low number 
of reads supporting the presence of these variants in PacBio sequencing data with variant 
frequency below the applied frequency thresholds (Supp. Figure S3B: yellow dots). The 
remaining 2/8 variants (Supp. Figure S3B: red dots) constitute a pathogenic insertion 
(c.6223_6224insTT) and one polymorphic substitution (c.12630T>C) (Supp. Table S9; Supp. 
Figure S4).  
 
 
Figure 3: Comparison of long-read detected pathogenic variants or VUCS, uniquely identified per patient (y 
axis), with the screening results for the PKD1 gene locus (x axis; NM_001009944.2). Most of pathogenic 
variants (red) could be confirmed by our long-read strategy (red bars) with high sensitivity for PKD1. Only a 
single insertion could not be confirmed for patient 16. Other identified non-pathogenic variants or VUCS are 
shown as black bars and dots for PacBio and Sanger, respectively. The LoH analysis performed (pink or grey 
boxes) support the presence of the 2 large deletions also reported by MLPA (pink boxes). LoH regions are not a 
direct identification of large deletions but a clear indication of their presence within the amplified LR-PCR 
fragments.   
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From 179 variants detected by PacBio, 20 were solely identified by PacBio (Supp. Figure S3C; 
Supp. Table S9). Of these, 17/20 were high-confident variants not detected in Sanger. The 
remaining 3/20 were low confidence variants from the reconstruction of allelic sequences for the 
variant c.6657_6671del (Supp. Table S9). 
The sensitivity assessment for PKD1 pathogenic variants was performed by comparing the list of 
potentially pathogenic variants and VUCS, uniquely identified by our direct long-read 
sequencing approach, with the results from the standard ADPKD diagnostic assay. Although we 
expected a single dominant pathogenic variant per patient, two of the patients had a combination 
of two pathogenic variants resulting in 21 PKD1 pathogenic variants. We identified 20 out of 21 
pathogenic variants (95.2%) in addition to 7 VUCS from which 2 were uniquely detected by 
PacBio (Table 1; Figure 3). Only a single pathogenic insertion (c.6223_6224insTT) was missed 
by PacBio variant calling despite of sufficient read support (43.3% variant frequency; read depth 
Table 1: Uniquely identified pathogenic variants or variants of unknown clinical significance, identified by PacBio 
sequencing. 
 
 
Patient 
Genomic 
position 
Exon c. notation p. notation SNP ID Freq (%) Depth PolyPhen VEP impact 
Comparison with 
Sanger 
1 chr16 2,152,543 25 c.9034_9039del p.(Thr3012_Ser3013del)  40.9 314  MODERATE Overlap 
2 chr16 2,156,674 18 c.7214G>T p.(Trp2405Leu)  29.4 666 
probably damaging 
(0.983) 
MODERATE Overlap 
3 chr16 2,161,525 15 c.3643C>G p.(Leu1215Val) rs144338515 49.2 576 
possibly damaging 
(0.899) 
MODERATE Overlap 
3 chr16 2,160,693 15 c.4475G>C p.(Arg1492Pro)  32.8 563 
possibly damaging 
(0.665) 
MODERATE Overlap 
3 chr16 2,157,963 16 c.6986G>A p.(Arg2329Gln) rs575211353 43.3 538 benign (0.37) MODERATE Overlap 
3 chr16 2,152,134 26 c.9324del p.(Ile3109SerfsTer207) rs780284643 26 302  HIGH Overlap 
4 chr16 2,164,333 11 c.2681_2690del p.(Phe894Ter)  53.7 143  HIGH Overlap 
5 chr16 2,185,509 1 c.182C>T p.(Pro61Leu)  28.8 43 benign (0.119) MODERATE PacBio 
5 chr16 2,152,061 26 c.9397+1G>A   23.3 330  HIGH Overlap 
6 chr16 2,167,614 6 c.1261C>T p.(Arg421Cys)  38.7 273 
possibly damaging 
(0.836) 
MODERATE Overlap 
6 chr16 2,155,399 21 c.7940C>T p.(Thr2647Met) rs748496650 44 357 probably damaging (1) MODERATE Overlap 
7 chr16 2,161,527  
c.(2097+1_2098-
1)_3640del 
      PacBio 
8 chr16 2,152,903 24 c.8859dup p.(Glu2954Ter)  44.1 583  HIGH Overlap 
9 chr16 2,158,496 15 c.6657_6671del p.(Arg2220_Pro2224del)  41.5 466  MODERATE Overlap 
10 chr16 2,141,910 40 c.11412-3C>A   27.7 20  LOW Overlap 
11 chr16 2,167,589 6 c.1286G>T p.(Trp429Leu)  32.7 313 
probably damaging 
(0.999) 
MODERATE Overlap 
11 chr16 2,153,765 23 c.8293C>T p.(Arg2765Cys) 
CM092156 
rs144979397 
41.1 572 
probably damaging 
(0.988) 
MODERATE Overlap 
11 chr16 2,152,396 25 c.9187C>T p.(Arg3063Cys) rs145906459 36.1 557 benign (0.39) MODERATE Overlap 
12 chr16 2,154,643 21 c.8017-2_8017-1del   48.5 527  HIGH Overlap 
13 chr16 2,152,062  
c.(287+1_288-1)_ 
(9397+1_9398-1)del 
      PacBio 
14 chr16 2,141,581 42 c.11554del p.(Leu3852TrpfsTer93) rs724159823 41.3 46  HIGH Overlap 
14 chr16 2,162,850 13 c.3100A>G p.(Asn1034Asp) rs369180760 36.5 321 benign (0.098) MODERATE Overlap 
15 chr16 2,158,944 15 c.6223_6224insTT p.(Arg2075LeufsTer42)  43.3 1,203  HIGH Sanger 
16 chr16 2,164,754 11 c.2269del p.(Gln757SerfsTer28) rs775710328 28.4 519  HIGH Overlap 
17 chr16 2,160,198 15 c.4968_4969delinsC p.(Arg1657GlyfsTer65)  41.2 1,120  HIGH Overlap 
18 chr16 2,157,954 16 c.6994_7000dup p.(Ala2332GlyfsTer90)  23.4 913  HIGH Overlap 
19 chr16 2,139,750 46 c.12890A>G p.(Lys4297Arg) rs758833703 14.1 46 benign (0.07) MODERATE PacBio 
19 chr16 2,160,919 15 c.4248dup p.(Gly1417TrpfsTer14)  24.8 979  HIGH Overlap 
Sanger detected pathogenic variants are shown in bold. PacBio variants were filtered by coding sequence predicted 
effects (frameshifts, missense, in-frame deletions, and splicing variants), as well as DP>15 and >50 subreads, and 
variant frequency (>10% for substitutions, and >15% for insertions and deletions) (RefSeq NM_001009944.2). 
Additional information of each variant including SIFT classification, and 1000G frequencies among other 
annotations can be obtained from the VCF files uploaded to EGA with accession number EGAS00001002106.  
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1,203) (Table 1). In summary, 18 out of 19 ADPKD patients could be resolved by our method 
(Figure 3). This provided a diagnosis for 94.7% of the patients, resulting in the correct detection 
of all PKD1 substitutions, single-nucleotide deletions, large deletions, one deletion-insertion, and 
3 out of 4 insertions or duplications (Table 1). 
2.5.5. Loss of PKD1 diagnostic power in short-read (Illumina) NGS 
The potential loss of diagnostic power when resolving PKD1 by short-read NGS was evaluated 
based on 797 pathogenic variants that were previously reported and validated, and are publicly 
available in PKDB. The repetitive nature of PKD1 gene hampers proper alignment of short 
Illumina NGS reads (Supp. Figure S5). Over 12% of the reported pathogenic variants would 
have been missed in WGS and WES data purely due to poor sequencing depth (Supp. Figure S6). 
In comparison, other short-read approaches based on LR-PCR enrichment show lower 
percentage (1.3%) of reported pathogenic variants that would have been missed because of low 
sequencing depth. However, this approach required very high sequencing depth which can be 
appreciated from the observed high variability in coverage ranging from <8x to >30,000x (Supp. 
Figure S6). Moreover, several exonic regions may be expected to be missed in many samples 
irrespective of the short-read sequencing strategy used (Supp. Figure S6). 
2.6. Discussion 
Accurate diagnosis is a difficult task when performed in complex genetic regions such as PKD1 
(Rossetti et al., 2007; Tan et al., 2009; Qi et al., 2013). To facilitate the diagnosis, we have 
developed and applied a new methodology using direct long-read sequencing of amplified LR-
PCR fragments on PacBio. Because of the repetitive nature of PKD1, current diagnostics is 
performed by Sanger sequencing using LR-PCR fragments generated for approximately two 
thirds of the PKD1 gene that serve as a template for the exon specific nested-PCR amplification. 
In contrast, in this study we directly sequenced all LR-PCR fragments amplified from the 
duplicated and unique parts of PKD1 gene as well as PKD2. On top of reducing the PCR 
amplification steps required and limiting the implicit PCR artifacts, single molecule sequencing 
improves sequence alignments and aids in discriminating between homologous or repeated 
sequences, such as PKD1 pseudogenes. This provides a cleaner dataset for variant calling, free of 
chimeric (0.85%) and pseudogene (5.6%; Supp. Table S2) reads that are introduced by the LR-
PCR amplification. Finally, by using this approach, we identified 20 out of 21 (95.2%) PKD1 
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disease causing variants diagnosed by Sanger sequencing or MLPA, providing a correct 
diagnosis for 18 out of 19 ADPKD patients (94.7%) with at least one pathogenic variant in 
PKD1.  
In comparison to current ADPKD diagnostic assays, based on Sanger sequencing and MLPA, we 
show that direct long-read sequencing can aid in resolving PKD1 for ADPKD diagnostics. 
Longer sequencing reads discriminate between PKD1 and pseudogenes (Figure 2A), and 
improve the mapping quality of PKD1 (Figure 2B). The improved mappability, reduced the 
interference of homologous sequences, high GC-content, or repetitive elements for ADPKD 
diagnosis (Qi et al., 2013). This allowed us to develop a long-read based sequencing assay for 
detecting a broad spectrum of variants, from SNVs to large deletions (Table 1). In contrast, 
Sanger sequencing is very labor-intensive and requires many phases of overlapping PCR 
amplification steps prior to sequencing, including LR-PCR and nested-PCR. Despite the 
amplification of PKD1 being based on unique PCR primers, these are of limited number for 
PKD1 and have been shown to produce residual amplification of homologous regions that would 
still interfere with the aggregated signal of Sanger sequencing (Rossetti et al., 2012; Tan et al., 
2014). Based on our approach, we confirmed the presence of residual amplification of PKD1 
pseudogenes, introduced by the LR-PCR (5.6%) (Figure 2A; Supp. Table S2). This, most likely 
led to the identification of 24 false-positive or false-negative variants detected by Sanger (Supp. 
Table S9; Supp. Figure S4). One of the major drawbacks of our method, however, is the noise 
associated with PacBio sequencing, and the sophisticated algorithms required to overcome it. 
This noise is likely to be the cause of most of 324 homopolymer deletion artifacts that were 
solely identified by PacBio (Supp. Table S10). In addition, this noise was the most likely cause 
of the single pathogenic insertion that was missed despite ample sequencing depth. However, 
based on a recent release of the new circular-consensus calling algorithm for PacBio sequencing 
data (www.pacb.com: “An improved circular consensus algorithm with an application to detect 
HIV-1 drug-resistance associated with mutations (DRAMS)”), we expect that calling of true 
homopolymer-associated variants will be significantly improved. 
In recent years, several attempts have been made to replace the standard ADPKD diagnostics by 
NGS approaches that would improve the screening of PKD1 gene (Rossetti et al., 2012; Qi et al., 
2013; Tan et al., 2014; Trujillano et al., 2014; Eisenberger et al., 2015; Mallawaarachchi et al., 
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2016). These screenings were based on analyzing WGS or WES data (Qi et al., 2013; 
Mallawaarachchi et al., 2016), on the enrichment of PKD1 using LR-PCR (Rossetti et al., 2012; 
Tan et al., 2014), or the hybridization-capture of PKD1 (Trujillano et al., 2014; Eisenberger et 
al., 2015). Two of these studies were performed on short-read NGS using targeted enrichment of 
PKD1 or PKD2 genes by LR-PCR (Rossetti et al., 2012; Tan et al., 2014). In both studies, the 
use of short reads was the source of difficulties associated with misalignments and lack of 
sufficient coverage, such as the PKD1 exon 1 region (Tan et al., 2014), as well as false positive 
(10%) and false negative variant calls (5%) (Rossetti et al., 2012). We show that these challenges 
were mitigated with long-read sequencing which provided 100% coverage >10x (min. >19x; 
avg. >421x; max. 1528x) for all PKD1 and PKD2 exons and flanking intron regions (±20 bp) 
(Supp. Table S2; Supp. Table S4), including 100% of PKD1 exon 1 at average coverage of >55x 
(±20 bp of flanking intron regions included) (Supp. Table S4). Other WES-based strategies were 
reported to resolve only 50% of true positive variants in the duplicated regions of PKD1 (Qi et 
al., 2013). It was argued that increasing the sequencing depth was insufficient to overcome the 
limitations and pitfalls of short-read NGS approaches (Qi et al., 2013; Eisenberger et al., 2015).  
Similar to these short-read NGS strategies (Rossetti et al., 2012; Qi et al., 2013; Tan et al., 2014; 
Trujillano et al., 2014; Eisenberger et al., 2015; Mallawaarachchi et al., 2016), our targeted 
approach combined with multiplexed sequencing can further accelerate ADPKD diagnostics, 
compared to the labor-intensive Sanger sequencing (Rossetti et al., 2012; Tan et al., 2014). 
Despite the rather limited sample size, sufficient numbers were included in this study for a 
methodology evaluation. However, future studies including larger cohorts would be needed to 
reliably implement the proposed methodology into the clinic. In addition, our method can benefit 
from recent advancements in library preparation methods with minimal or no amplification, such 
as single-strand adaptor-ligation (Karlsson et al., 2015), which would eliminate most of biases 
introduced during LR-PCR amplification steps (Schirmer et al., 2015; Hestand et al., 2016; 
Laver et al., 2016). Overall, our method provides high sensitivity in identifying PKD1 genetic 
variants when compared to the standard ADPKD diagnostic assay and showed an added value to 
become a reliable alternative. In addition, the method presented here is comparable to other 
Illumina short-read NGS-based approaches. However, further studies including a larger cohort 
may be required to decipher the true diagnostic power of our approach compared to that of 
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standard ADPKD diagnostic assays using Sanger and MLPA, and to Illumina short-read NGS-
based methods. 
In conclusion, we showed that direct sequencing of LR-PCR fragments for the screening of 
ADPKD patients in a single diagnostic-test application is now possible. Accurate screening of 
PKD1 with high sensitivity and low interference of homologous sequences constitutes a clear 
example. This method is highly valuable for a diagnostic setting, as it increases the resolution 
power of clinically relevant but difficult to sequence or to resolve genomic regions. 
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2.9. Annex I: supplementary material of Chapter 2 
 
 
 
Supp. Figure S1: Enrichment of PKD1 gene (NM_001009944.2) with 5 LR-PCR fragments used for PacBio, and 4 
for Sanger sequencing followed by nested-PCR amplification for obtaining Sanger sequencing reads. 
 
 
 
 
 
 
Supp. Figure S2: Mapping quality (MQ; in Phred quality scores; values >90 were scaled down for visualization 
purposes) and sequencing depth (DP; in number of reads) of uniquely aligned sequenced molecules to PKD2 
(NM_000297.3) for 9 LR-PCR fragments amplified. Mapping quality of alignments with even coverage 
distribution along the amplified fragments (Fragments), including regions with repetitive elements (Repeats) and 
high GC-content (GC%). Despite fragment A showing lower coverage compared to other fragments, it had 
sufficient coverage for variant calling within the exon regions, e.g. the first exon of PKD2 with average coverage 
≥71x (min. ≥43x; max. 111x) (Supp. Table S4). 
 
63 
 
 
64 
 
Supp. Figure S3: Comparison with current diagnostic assay. (A.) Small variants identified by PacBio were 
randomly distributed along the length of the amplified regions of PKD1 gene locus (x axis; NM_001009944.2) 
showing no blind spots where no variants could not be detected. When compared to Sanger sequencing results, 
variants detected with both diagnostic approaches distributed over PKD1 gene could be visualized (circles). The 
variant frequency (y axis) of variants solely detected by Sanger (crosses) or PacBio (triangles) which are majorly 
located in regions where no Sanger sequencing data was available, mostly introns (black). The average per-base 
mismatch rates (grey dots and average trend line) show the high sensitivity of our long-read sequencing method to 
detect substitutions. To highlight variants of high significance, coding or splice site variants (red) were colored to 
be visually identified from other intronic variants (black). (B.) The variant frequencies (x axis) with respect to the 
applied thresholds (dotted line) of all exonic and splice site variants detected either by Sanger or PacBio show the 2 
Sanger variants that were not confirmed in PacBio (red) despite having sufficient sequencing depth (y axis) and 
variant frequency to be called. However, other 6 variants were potentially considered as PCR artifacts detected in 
Sanger sequencing despite high sequencing depth (yellow), which showed low variant frequency below the applied 
frequency thresholds (vertical dotted lines). Variants that passed the applied sequencing-based filtering thresholds 
and were detected by both diagnostic methods are shown as blue dots, whereas the variants that were detected by 
PacBio only are shown as grey dots. (C.) Overall, the comparison between our long-read sequencing approach with 
the standard ADPKD diagnostics assays show that from the 179 coding or splice site variants that were detected by 
PacBio, 2 were large deletions also identified by MLPA, and 157 were small variants also identified by Sanger 
(yellow). Only 8 small variants were not confirmed by PacBio from which 6 showed low sequencing data support 
(Supp. Figure S5B). The remaining 20 variants solely identified by PacBio comprehend 17 likely Sanger false 
negatives, and 3 low-confident calls of the allelic reconstruction of c.6657_6671del (Supp. Table S9). 
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Supp. Figure S4: Discordances identified between Sanger and PacBio sequencing are a clear example to show the 
sensitivity of direct long-read sequencing. (A.) The polymorphic substitution c.12133A>G correctly identified in 
patient 11 by Sanger (AI) and PacBio (AII) was clearly missed by Sanger sequencing in patient 8 
(NM_001009944.2). (B.) Similarly, the polymorphism c.9195_9196delinsCC was not identified by Sanger 
sequencing due to unspecific forward signal (BI), whereas in PacBio at least the substitution c.9195G>C was 
identified (BII) (RefSeq NM_001009944.2). 
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Supp. Figure S5: Impact of PKD1 (NM_001009944.2) inaccessible and unresolvable regions using NGS data. 
Mapping quality (MQ) and depth (DP) are affected by the presence of repetitive elements (Repeats), percentage of 
GC content (GC%), and segmental duplications (SD). Inaccessible and unresolvable regions, detected using a 
publicly available 9 WGS dataset (Sun et al. 2015), disrupt the MQ and DP where SDs from multiple PKD1 
pseudogenes interferes with the alignments of NGS short-reads. Dips in DP and MQ occur where repeats and high 
GC% overlap, even within gene coding regions (blue). 
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Supp. Figure S6: Loss of power to detect pathogenic variants with NGS approaches for PKD1 gene (RefSeq 
NM_001009944.2). 12% of known pathogenic variants from the ADPKD database (PKDB) would be missed due to 
poor sequencing depth (red dots) regardless of the NGS sequencing strategy utilized for (WGS or WES) (exons 1, 
5, 11, 12, 26, 35, 36, 41, 42 and 46). These poorly sequenced variants appear to be enriched in regions with 
segmental duplications (SD), repetitive elements (Repeats), and mainly with high percentage of GC-content (GC%) 
such is the case for exon 1. Short-read sequencing using LR-PCR enrichment of PKD1 regions substantially 
improves the coverage of known pathogenic variants with only a 1.3% of missed variants due to low or poor 
coverage.  
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Supp. Table S1: Amplified LR-PCR fragments and sequencing pools for the SMRT library preparation of PKD1 
and PKD2. 
Amplified 
fragments 
Exons 
covered 
Fragment size 
(Kb) 
Sequencing 
pool* 
Strand** LR-PCR Primer sequence (5’-3’)*** 
PKD1 A 35-46 7.5 B 
FW GAGCAGGCTCATGGGGCTTTGTAGGAGC 
RV ACAGCCCGCTGTACCTGAGGACTCG 
PKD1 B 22-34 8.1 C 
FW ATGTGAAGAGGTGCCTTGTGTGGT 
RV TTAAAAACCCGCCCATAATTTCTCACTGC 
PKD1 C 14-21 7.6 C 
FW GTTTCCCTGTCTGTTGGGAGGTAAC 
RV CTGCGTTCACACAGGACAGAACG 
PKD1 D 2-13 8 C 
FW CCGAGTAGCTGGAACTACAGTTACACACT 
RV CACCCAGTTACCTCCCAACAGAC 
PKD1 E 1 4.3 A 
FW GCGGAGCGTGAAAAATAGCTCGT 
RV TACTGCTTTGCTTGACCAGCCTTAAAGA 
PKD2 A 1 7.2 B 
FW GCAGGATTCTGTTGCTAGAAGTCAGTGC 
RV CCTTTCTATCTAGCTTCTTTCCATCCCAGC 
PKD2 B 2 7.9 C 
FW CCTGTAACTCCCACCATGGAATGGGC 
RV AGGTAGGCTTGGAGGGTGCAACTGG 
PKD2 C 3 7.5 B 
FW TACCCCTTAAAGATTTTCCTCACA 
RV CTGTCGATACTCATGCATTGAAA 
PKD2 D 3-5 8 C 
FW CTGTGTTGGGGCCTGTGCAGATCAGC 
RV GGGGGACTTGGTGATGGAACATGTGGC 
PKD2 E 5-6 7.4 B 
FW TTGGGACTACATTGACCTCACTAA 
RV TTCATTCCTGTATCCCCAGTGC 
PKD2 F 7-8 7.1 B 
FW GTTTTCTGAGCACCTACTATGTACTTGC 
RV TAAACCTTGACAACAGTCACCCTCG 
PKD2 G 9-10 7.4 B 
FW TGAACTCCAGGGCCTCACACTGTCC 
RV GCGAACTTTAGACCTGACCTTGCTTTGC 
PKD2 H 11-13 4.9 A 
FW AAATGTTGGGGCTGGACATGGTGGC 
RV ATGCACAAGGAACATTCTTCAGGACG 
PKD2 I 14-15 6.2 A 
FW CAGGTCTTTGTCTGCTAAGTCTGA 
RV TTTGCAAGTGAAATGAAAAACAGT 
*Pooling of similar size fragments was performed to optimize loading and sequencing efficiency. 
**FW, forward strand; RV, reverse strand.  
***Primers included a 5’ M13-tail (TGTAAAACGACGGCCAGT for FW primers, and 
CAGGAAACAGCTATGACC for RV primers). 
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Supp. Table S2: Per patient targeted PCR amplification and alignment statistics of number of reads and unique 
molecules, sequenced with SMRT-Seq.  
Patient # Subreads 
# Unique molecules (reads) Base coverage per exon (±20 bp)* 
PKD1 PKD2 PKD1 Pseudog. >10x >20x >30x 
1 47,842 2,217 5,756 581 100% 100% 93.64% 
2 31,889 1,932 3,611 427 100% 100% 99.95% 
3 29,200 1,631 2,980 367 100% 100% 99.53% 
4 16,929 1,008 1,719 158 100% 99.84% 84.63% 
5 31,925 1,584 3,757 236 100% 100% 100% 
6 23,344 1,405 2,413 159 100% 99.95% 89.32% 
7 26,497 1,268 3,043 276 100% 100% 99.995% 
8 36,737 2,208 4,469 202 100% 100% 100% 
9 38,224 1,979 4,973 203 100% 99.15% 98.6% 
10 44,782 2,667 4,976 684 100% 91.22% 84.12% 
11 51,389 2,520 6,054 631 100% 100% 100% 
12 42,132 2,357 5,043 412 100% 100% 100% 
13 41,092 2,205 4,517 627 100% 100% 100% 
14 46,520 2,530 5,010 570 100% 100% 100% 
15 46,276 2,880 5,294 254 100% 100% 100% 
16 48,624 3,958 5,543 562 100% 100% 100% 
17 46,126 3,163 4,948 557 100% 100% 100% 
18 44,009 2,671 5,485 334 100% 100% 99.99% 
19 45,185 2,684 5,439 332 100% 100% 100% 
Mean: 38,902 2,256 4,478 399 100% 99.48% 97.36% 
Reads were filtered by read length >500 bp and read quality over 75% within SMRT Analysis. Only properly 
mapped sequences with mapping quality over >30 that were primary alignments and not PCR or optical 
duplicates were counted. 
*Per exon percentages calculated using the total number of exon (±20 bp) bases from the targeted design 
(18,259 bp). 
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Supp. Table S3: Total number of unique molecules (reads) sequenced for each amplicon. 
Amplified fragments Exons covered 
# Unique Molecules (reads) 
Total Mean Min. Max. 
PKD1 A 35-46 11,271 593 300 1,580 
PKD1 B 22-34 14,439 760 396 1,814 
PKD1 C 14-21 23,526 1,238 487 1,845 
PKD1 D 2-13 24,281 1,278 519 1,830 
PKD1 E 1 1,650 87 35 153 
PKD2 A 1 7,982 420 221 737 
PKD2 B 2 8,737 460 220 831 
PKD2 C 3 24,132 1,270 480 1,748 
PKD2 D 3-5 32,089 1,689 610 2,459 
PKD2 E 5-6 25,433 1,339 478 2,079 
PKD2 F 7-8 23,673 1,246 483 2,197 
PKD2 G 9-10 24,187 1,273 436 2,196 
PKD2 H 11-13 16,372 862 256 1,547 
PKD2 I 14-15 12,007 632 240 886 
 
Supp. Table S4: Base coverage statistics as average min, average mean, and average maximum, calculated 
from coverage stats retrieved for each patient and exon (±20bp). 
Gene Exon 
Base coverage 
Gene Exon 
Base coverage 
Mean Min. Max. Mean Min. Max. 
PKD1 1 55 24 91 PKD2 1 71 43 111 
PKD1 2 422 175 646 PKD2 2 303 111 617 
PKD1 3 420 168 638 PKD2 3 1.097 388 1,509 
PKD1 4 414 163 627 PKD2 4 384 122 672 
PKD1 5 408 150 616 PKD2 5 833 270 1,249 
PKD1 6 403 150 586 PKD2 6 477 121 866 
PKD1 7 402 149 577 PKD2 7 452 190 984 
PKD1 8 402 150 573 PKD2 8 436 167 1,138 
PKD1 9 400 147 563 PKD2 9 295 49 572 
PKD1 10 401 145 564 PKD2 10 272 47 632 
PKD1 11 400 141 558 PKD2 11 514 137 766 
PKD1 12 392 139 545 PKD2 12 508 134 762 
PKD1 13 378 139 528 PKD2 13 491 130 748 
PKD1 14 756 306 1,224 PKD2 14 507 183 714 
PKD1 15 754 257 1,256 PKD2 15 510 188 711 
PKD1 16 734 258 1,186      
PKD1 17 739 250 1,199      
PKD1 18 744 252 1,201      
PKD1 19 743 253 1,198      
PKD1 20 738 253 1,187      
PKD1 21 713 244 1,155      
PKD1 22 550 308 1,252      
PKD1 23 564 312 1,349      
PKD1 24 559 309 1,358      
PKD1 25 555 304 1,361      
PKD1 26 551 294 1,366      
PKD1 27 548 281 1,432      
PKD1 28 547 283 1,436      
PKD1 29 544 279 1,442      
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PKD1 30 543 279 1,446      
PKD1 31 544 275 1,525      
PKD1 32 542 275 1,528      
PKD1 33 532 269 1,521      
PKD1 34 523 264 1,504      
PKD1 35 59 24 138      
PKD1 36 57 21 134      
PKD1 37 56 22 133      
PKD1 38 54 20 127      
PKD1 39 53 21 125      
PKD1 40 51 20 122      
PKD1 41 51 20 118      
PKD1 42 51 19 115      
PKD1 43 51 19 113      
PKD1 44 51 19 110      
PKD1 45 51 21 110      
PKD1 46 49 19 108      
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Supp. Table S5: Details of variants identified by the Sanger sequencing or PacBio long-read sequencing approach. 
c. notation** p.notation Chr. Pos. # PB # S # O PKDB* dbSNP Note 
PKD1 
c.12897C>T p.(=) chr16 2,139,743 1 0 0   HC; D; Likely S FN 
c.12890A>G p.(Lys4297Arg) chr16 2,139,750 1 0 0  rs758833703 HC; D; Likely S FN 
c.12780T>C p.(=) chr16 2,139,860 1 0 0   HC; D; Likely S FN 
c.12630T>C p.(=) chr16 2,140,010 8 8 7 LN rs7203729 (C) HC; Likely PB FN; Likely S FN 
c.12409C>T p.(=) chr16 2,140,321 3 3 3 LN rs79899502 (C) HC 
c.12276A>G p.(=) chr16 2,140,454 10 8 8 LN rs3087632 (C) HC; Likely S FN 
c.12182C>T p.(Ala4061Val) chr16 2,140,548 1 1 1  rs372105572 HC; Likely S FP 
c.12176C>T p.(Ala4059Val) chr16 2,140,554 4 3 3 LN rs3209986 (C) HC; Likely S FN 
c.12133A>G p.(Ile4045Val) chr16 2,140,680 10 8 8 LN rs10960 (C) HC; Likely S FN 
c.11916C>T p.(=) chr16 2,140,972 2 2 2 LN rs77634115 HC 
c.11682C>T p.(=) chr16 2,141,454 1 1 1 LN rs567482892 HC 
c.11554del p.(Leu3852TrpfsTer93) chr16 2,141,581 1 1 1 DP rs724159823 HC 
c.11412-3C>A p.? chr16 2,141,910 1 1 1   HC 
c.10768C>T p.(=) chr16 2,143,865 2 2 2 LN rs116114803 HC 
c.10535C>T p.(Ala3512Val) chr16 2,144,176 3 3 3 LN rs34197769 (C) HC 
c.9957C>T p.(=) chr16 2,149,738 1 1 1 LN rs141101590 HC 
c.9397+1G>A p.? chr16 2,152,061 1 1 1 DP  HC 
c.9330T>C p.(=) chr16 2,152,129 6 6 6 LN rs12926160 rs144582212 (C) HC 
c.9324del p.(Ile3109SerfsTer207) chr16 2,152,134 1 1 1  rs780284643 HC 
c.9195_9196delinsCC p.(Phe3066Leu) chr16 2,152,387 5 5 5 LN rs372874584 HC 
c.9195G>C p.(=) chr16 2,152,388 1 0 0 LN rs9935834 (C) HC; D; Likely S FN 
c.9187C>T p.(Arg3063Cys) chr16 2,152,396 1 1 1 LN rs145906459 HC 
c.9034_9039del p.(Thr3012_Ser3013del) chr16 2,152,543 1 1 1   HC 
c.8859dup p.(Glu2954Ter) chr16 2,152,903 1 1 1   HC 
c.8440G>A p.(Gly2814Arg) chr16 2,153,618 1 1 1 LN rs149151043 HC 
c.8293C>T p.(Arg2765Cys) chr16 2,153,765 1 1 1 LH rs144979397 HC 
c.8161+8G>A p.? chr16 2,154,491 1 1 1 LN rs199569003 HC 
c.8123C>T p.(Thr2708Met) chr16 2,154,537 1 1 1 LN rs147350387 HC 
c.8020C>T p.(Pro2674Ser) chr16 2,154,640 1 1 1 LN rs144557371 HC 
c.8017-2_8017-1del p.? chr16 2,154,643 1 1 1 DP  HC 
c.7940C>T p.(Thr2647Met) chr16 2,155,399 1 1 1  rs748496650 HC 
c.7913A>G p.(His2638Arg) chr16 2,155,426 5 5 5 LN rs9936785 (C) HC 
c.7708T>C p.(=) chr16 2,156,021 5 5 5 LN rs28575767 (C) HC 
c.7441C>T p.(=) chr16 2,156,447 7 7 7 LN rs2003782 (C) HC 
c.7214G>T p.(Trp2405Leu) chr16 2,156,674 1 1 1   HC 
c.7165T>C p.(=) chr16 2,156,850 7 7 7 LN rs2457533 (C) HC 
c.6994_7000dup p.(Ala2332GlyfsTer90) chr16 2,157,954 1 1 1 DP  HC 
c.6986G>A p.(Arg2329Gln) chr16 2,157,963 1 1 1 LN rs575211353 HC 
c.6670_6673del p.(Pro2224TrpfsTer17) chr16 2,158,494 1 0 0   Likely LAA Low Confidence Assembly 
c.6657_6671del p.(Arg2220_Pro2224del) chr16 2,158,496 1 1 1   HC; Complete PB LAA Confident Assembly 
c.6666_6667del p.(Leu2223AlafsTer38) chr16 2,158,500 1 0 0   Likely LAA Low Confidence Assembly 
c.6656_6659del p.(Pro2219ArgfsTer22) chr16 2,158,508 1 0 0   Likely LAA Low Confidence Assembly 
c.6488G>A p.(Arg2163Gln) chr16 2,158,680 1 0 0 LN rs145217118 HC; D; Likely S FN 
c.6223_6224insTT p.(Arg2075LeufsTer42) chr16 2,158,944 0 1 0   Likely PB FN 
c.5763G>A p.(=) chr16 2,159,405 2 2 2 LN rs2575313 (C) HC  
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c.5172C>T p.(=) chr16 2,159,996 7 7 7 LN rs9935526 (C) HC 
c.4968_4969delinsC p.(Arg1657GlyfsTer65) chr16 2,160,198 1 1 1   HC 
c.4968T>C p.(=) chr16 2,160,200 1 0 0  rs777909326 HC; D; Likely S FN 
c.4917C>T p.(=) chr16 2,160,251 1 1 1 LN rs148852027 HC 
c.4674G>A p.(=) chr16 2,160,494 1 1 1 LN rs79884128 (C) HC 
c.4665A>C p.(=) chr16 2,160,503 1 7 1 LN rs71385734 (C) HC; D; Likely S FP  
c.4475G>C p.(Arg1492Pro) chr16 2,160,693 1 1 1   HC 
c.4248dup p.(Gly1417TrpfsTer14) chr16 2,160,919 1 1 1   HC 
c.4195T>C p.(Trp1399Arg) chr16 2,160,973 5 5 5 LN rs116092985 (C) HC 
c.3643C>G p.(Leu1215Val) chr16 2,161,525 1 1 1  rs144338515 HC 
c.3513C>G p.(=) chr16 2,161,655 1 1 1 LN rs143784787 HC 
c.3375C>T p.(=) chr16 2,161,793 5 5 5 LN rs74331768 (C) HC 
c.3372C>T p.(=) chr16 2,161,796 5 5 5 LN rs75510884 (C) HC 
c.3275T>C p.(Met1092Thr) chr16 2,162,361 5 5 5 LN rs2549677 (C) HC 
c.3111A>G p.(=) chr16 2,162,839 3 3 3 LN rs2099534 (C) HC 
c.3100A>G p.(Asn1034Asp) chr16 2,162,850 1 1 1  rs369180760 HC 
c.3063T>C p.(=) chr16 2,162,887 5 5 5 LN rs2369068 (C) HC 
c.2730C>T p.(=) chr16 2,164,294 2 2 2 LN rs35965348 (C) HC 
c.2700G>A p.(=) chr16 2,164,324 2 2 2 LN rs35667726 (C) HC 
c.2694A>C p.(=) chr16 2,164,330 2 2 2 LN rs142357713 HC 
c.2681_2690del p.(Phe894Ter) chr16 2,164,333 1 1 1   HC 
c.2269del p.(Gln757SerfsTer28) chr16 2,164,754 1 1 1  rs775710328 HC 
c.2109C>T p.(=) chr16 2,164,915 1 1 1 LN rs527655141 HC 
c.1850-4A>G p.? chr16 2,165,630 7 7 7 LN rs35929659 (C) HC 
c.1602C>T p.(=) chr16 2,166,838 1 1 1 LN rs759092782 HC 
c.1286G>T p.(Trp429Leu) chr16 2,167,589 1 1 1 HLP  HC 
c.1261C>T p.(Arg421Cys) chr16 2,167,614 1 1 1   HC 
c.182C>T p.(Pro61Leu) chr16 2,185,509 1 0 0 LN  HC; D; Likely S FN 
c.129C>T p.(=) chr16 2,185,562 1 0 0   HC; D; Likely S FN 
c.122C>T p.(Pro41Leu) chr16 2,185,569 2 0 0   HC; D; Likely S FN 
c.96C>T p.(=) chr16 2,185,595 1 0 0   HC; D; Likely S FN 
PKD2 
c.53C>T p.(Pro18Leu) chr4 88,928,938 1 0 0   D; Likely S FN 
c.83G>C p.(Arg28Pro) chr4 88,928,968 11 9 9 LN rs1805044 (C) HC; Likely S FN 
c.361G>T p.(Gly121Cys) chr4 88,929,246 1 1 1  rs371898195 HC 
c.420G>A p.(=) chr4 88,929,305 5 5 5 LN rs2728118 (C) HC 
c.568G>A p.(Ala190Thr) chr4 88,929,453 1 1 1 LN rs117078377 (C) HC 
c.720C>G p.(=) chr4 88,957,382 0 2 0   D; Likely S FP 
c.1459T>C p.(Tyr487His) chr4 88,967,933 1 1 1 LN rs201328200 HC 
* Bold=Pathogenic; DP=Definitely Pathogenic; HLP=Highly Likely Pathogenic; LH=Likely Hypomorphic; LN=Likely Neutral; C=Common; HC=High-Confident; FP=False Positive; FN=False 
Negative; D=Discordant; PB=PacBio; S=Sanger; O=Overlap. 
+ Deletion-insertions were manually inspected and HGVS description modified to avoid variant redundancies or undesired complex descriptions by clustering of neighbouring variants (e.g. 
c.9195_9196delinsCC and c.6994_7000dup). Individual substitutions c.9195G>C and/or c9196T>C from the polymorphic site c.9195_9196delinsCC were removed as redundant variants if 
c.9195_9196delinsCC was identified as well in the same patient. The pathogenic duplication c.6994_7000dup was originally detected as c.6982_6983delinsAGCGGCTG when reconstructing the PKD1 
allelic sequence and was split into two independent descriptions c.6994_7000dup, and c.6982del. 
** The 177 coding or splice site variants listed in this table were either reported by Sanger sequencing or detected by our direct long-read sequencing approach in at least one patient within the cohort 
of 19 screened ADPKD patients. 157 variants are high-confidence variants identified on the same set of patients by both approaches. 8 Sanger variants were not confirmed by PacBio, from which 6 had 
low sequencing data support. The remaining 20 variants were solely detected by PacBio from which 3 are low-confident variants called by the reconstructions of allelic sequences of c.6657_6671del. 
** RefSeq NM_001009944.2 or NM_000297.3 for PKD1 and PKD2, respectively. 
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Supp. Table S6: Amplified LR-PCR primer sequences for Sanger sequencing. 
 
 
 
 
 
 
 
 
 
Supp. Table S7: Nested PCR primer sequences for PKD1 Sanger sequencing. 
 
Exons covered Size (bp) Strand* Nested PCR Primer sequences (5'-3')** 
1 (frag. 1) 256 
FW CCTGAGCTGCGGCCTCCG 
RV CAGTTGACGCGGCAGGCG 
1 (frag. 2) 216 
FW TGCGAGCCCCCCTGCCTC 
RV AACCCGCCCACGCCCGCCCGTCC 
2-3 340 
FW TAGGGGCTCTGGCCCTGAC 
RV CCAGCCAGGACCCCACCCAAAG 
4 266 
FW CATAGACCCTTCCCACCAG 
RV CCTGGCTGGGAAGGACAGA 
5 (frag. 1) 389 
FW TGGAGCCAGGAGGAGCAGAA 
RV CAGAGGGACAGGCAGGCAAA 
5 (frag. 2) 431 
FW AGCCCTCCAGTGCCTCCTTT 
RV GCACGGCCGTCACGTGATAG 
6 280 
FW ACCGTTGACACCCTCGTTCC 
RV CTCTGCCCCAGTGCTTCAG 
7 329 
FW CTGTGAGGGTGGGAGGATGG 
RV CTAACCACAGCCAGCGTCTC 
8 226 
FW GCGGCTCGGTCCCCAGTCT 
RV GGAGGGCAGGTTGTAGAACGTG 
9 (frag. 1) 295 
FW GGAGTCTGGGCTTCAGGCTG 
RV CTGGGAACCACTCTGGTGGC 
9 (frag. 2) 228 
FW GGAGTCTGGGCTTCAGGCTG 
RV CACCCACCACCCAGAGTCCC 
10 (frag. 1) 184 
FW GGCCTGTGGGCAAATCAGGG 
RV TGGGGGTGGCAGGAGGCGTC 
10 (frag. 2) 201 
FW AGGGGGACGCTGGTGCCCTG 
RV GGGAACAGACCCAGGTCAGG 
11 (frag. 1) 425 
FW GTCCACGGGCCATGACCG 
RV CCAGCCACTGGGGAGACCAC 
11 (frag. 2) 257 FW GGCAGAGGTGGGCAATGG 
Exons 
covered 
Fragment size (Kb) Strand* LR-PCR Primer sequence (5’-3’)** 
1 2.2 FW CGCAGCCTTACCATCCACCT 
RV TCATCGCCCCTTCCTAAGCA 
2-13 7.9 FW CCGAGTAGCTGGAACTACAGTTACACA
CT 
RV CACCCAGTTACCTCCCAACAGAC 
14-21 7.6 FW GTTTCCCTGTCTGTTGGGAGGTAAC 
RV CTGCGTTCACACAGGACAGAACG 
22-34 7.5 FW CCGTGTAGAGAGGAGGGCGTGTGCAA
GGA 
RV TCGGCAAGGACCTGCTGGATCAG 
*FW, forward strand; RV, reverse strand.  
**Primers included a 5’ M13-tail (TGTAAAACGACGGCCAGT for FW primers, and 
CAGGAAACAGCTATGACC for RV primers). 
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RV AGCCGGGCACGAAGGTGGC 
11 (frag. 3) 326 
FW GTGTCAGCGCCCGCTTTG 
RV CTGTGTGAGCACCCTGTCTGC 
12 241 
FW GTGTGTCCAGGAGGCGA 
RV AGAGGTGAAGGTGGAGC 
13 244 
FW CTGCCACCTGGGCTCACTG 
RV TGCCCACCCCAAACCGGC 
14 198 
FW CTCACTGCGTCCCACCGC 
RV CTGAAAGGCAGTGGCCCC 
15 (frag. 1) 382 
FW TGGGGAGCAGGTGGGGGTGC 
RV AGACGCGCACATCCGCCTGGGCCG 
15 (frag. 2) 363 
FW CGTGCGCCTGGAGGTCAAC 
RV GGCTGCGTGGGGATGCAG 
15 (frag. 3) 373 
FW CGTGCTGGTCTTCGTCCTGG 
RV TGTAGCGGTAGGGGAACGG 
15 (frag. 4) 380 
FW GTTTGTGCAGCTCGGGGAC 
RV AAGCGTGGGTGACCTCCG 
15 (frag. 5) 376 
FW CCCGCCAGCTACCTGTGG 
RV GCGGAGCCCACCTCGTTC 
15 (frag. 6) 378 
FW CTTCCGCTCCGTGGGCAC 
RV GGAGGCGGCCACCATCAG 
15 (frag. 7) 374 
FW AGCGCCTGGGCCGACTGCAC 
RV AGCTGCCCCCAAAAGGGC 
15 (frag .8) 363 
FW GAGCCCGGAGGCAGCTTC 
RV GGGAGCACCTCGGGGTTG 
15 (frag. 9) 377 
FW AGCTGTCACCTTCCGCCTG 
RV GCACCTGGATCTCCAACAGCC 
15 (frag. 10) 340 
FW GCTGGTCATCCTGTCGGGC 
RV CACCAGGTTGGAGGCGTTC 
15 (frag. 11) 567 
FW CCAGGGCCGAGCACTCCTAC 
RV TGGGGTCGTAGGACTCGCTC 
15 (frag. 12) 196 
FW CGCCTGGTGCCCATCATTG 
RV GGACGGGTGAGGGGCATG 
16 230 
FW AGGCCACGTCGCCCCTTG 
RV GAGGCTGGGCTGTCCAAGG 
17 203 
FW GAGGTAACCCCACTCCCACG 
RV ATCCCCAGCCCGCCCACAC 
18 353 
FW AGAGGGTTGCGCCCCCTC 
RV ATCCCGCTGCTCCCCCCACGC AGG 
19 286 
FW TCCCGTGATGCCGTGGGG 
RV CAGGTGGCAGTCTCGGGG 
20 260 
FW CCACCTGCTCACCACCCC 
RV GCAGGGGTACAGGTCTTGGTC CC 
21 226 
FW GCGCTGCTGACAGCTTGC 
RV ATGCGGGGCAGGGTGAGC 
22 220 
FW AGTGGGGCCAGGAGCGGG 
RV GGGCGGGTGGCATGGGGC 
23 (frag. 1) 349 
FW CCCTCCCTCTACCTCCCTGTC 
RV CACTGAGGTTGGCCAGGGC 
23 (frag. 2) 431 
FW GGGCCTGGCTGCCACTTC 
RV AAGGCCAGGGGGCCGCGTG 
24 222 
FW CAGGCGTGTGACCTGCGC 
RV TGCCCTGCCCTGCCAGGCTG 
25 313 
FW CTGGGCTCACGTCCGCTAC 
RV GCTCCCAGGAGCACAGGGTC 
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26 289 
FW GAGAAGGCACAGCTTGCACG 
RV AGAGCAGGGGAGGCCCTG 
27 240 
FW GCAGACCGAGCCTCCCAC 
RV AGGGGCAGAGCTTGGCAG 
28 217 
FW TGCGAGCCTGACCTCCCTC 
RV CCAACCTCCCACGGAGTGG 
29 316 
FW TTGGGCAGGGTGGTCCTG 
RV GGAAGGGCTGGGCAGGAAG 
30 202 
FW CAGCCTCACCTGTGTGGCC 
RV TCCATTCCCAGTACTCCCGG 
31-32 338 
FW GAGCAGGTCTGAGCTGCCG 
RV GCACCAGGGCTCGAGGTTTC 
33-34 473 
FW GGTGGGCTGTGTGTGTGAC 
RV CCCCTCCTCTGGCAATCC 
35-36 576 
FW CAGGTTAACATGGGCTTGG 
RV GAGGGGGTGGCTTCAGAG 
37 341 
FW GGTAGGCTACAGGCCTCCAT 
RV GAGGTGGGAGACAAGAGACG 
38 304 
FW AAAGCCCTGCTGTCACTGTGG 
RV TAGGGTCTGGCTGGACTAAAG 
39 301 
FW GGGTCTCTGGTGGCCGCTCAC 
RV ATGCCAGAGCTCCGCTAAAGG 
40-41 565 
FW GCAGGAAACACTCCTGTTGG 
RV GCTCCTGGCTGGTGACTG 
42 608 
FW GAGCCCACCCTCACTCCTC 
RV AACAGCAGCAGGCACACCT 
43 660 
FW CTCTGCTCACCTCGGTACG 
RV CGGACGAGAAATCTGTCTGC 
44 361 
FW CGCCGCTTCACTAGCTTCGAC 
RV AGTCCCAGGGCACAGCACCAA 
45 486 
FW GGGAGGGCGTCTTAGCTC 
RV CACAGGGGCTCAGTCAGTC 
46 680 
FW CAAGGTCAAGGAGGTGGGTA 
RV TTGACAGCGGCAGAAAGTAA 
*FW, forward strand; RV, reverse strand. 
**Primers included a 5’ M13-tail (TGTAAAACGACGGCCAGT for FW 
primers, and CAGGAAACAGCTATGACC for RV primers). 
 
 
Supp. Table S8: Nested PCR primer sequences for PKD2 Sanger sequencing. 
Exon covered Size (bp) Strand* Oligo sequence (5’-3’)** 
1 (frag. 1) 421 FW GAAAGGAACATGGCTCCTGA 
RV ACCTCCTCCTCCTCCTCCTC 
1 (frag. 2) 454 FW CCCTTCTCCTCCGCTCTC 
RV CGTTCTGGTTCGTGCATCT 
02 320 FW GTGCTTTATTTTCCCTTTTG 
RV GGTGCATACACACTTCCTTT 
03 330 FW CTTTGTGAAGGCTGCTGGT 
RV TCCTGTCGATACTCATGCATTG 
04 435 FW TTGGTTATGCAAACGATG 
RV GAATGGTGGGAGTTCAGAG 
05 414 FW CCTCAAGTGTTCCACTGATT 
RV GTAGCTAACTGCAGGCAAAG 
06 401 FW CTGGCTGTATTCATGTGTTG 
RV AATGCTGAGGAGATCAAAGA 
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07 336 FW GGTAAGTTTCATATTTCTAAAACACT 
RV TTCCATGATTTTGTGGAACT 
08 329 FW CACACCATTTTGTTTATCCA 
RV TTCTTGAGAAGCAGTGACAA 
09 277 FW TGCATCAACTAGTGGACATT 
RV GAGAAGACAAGGATTTACGAAG 
10 259 FW TTCCAAATTATGTTTCTTCCTT 
RV AAAATCTGGGTGAAACAATG 
11 278 FW AAAACAGATGCAAAAGGAGA 
RV CCAGGAATTTATCTTTAGAAGC 
12 266 FW GAACTGGGTACAAGGAATGA 
RV TTTGATACATCTGTGGTGTTG 
13 322 FW GTCCTTGGTGAGGCTTCT 
RV CTGGTCTCATGTGGACTCTT 
14 285 FW AAAGACAATGACAAGCACTTT 
RV TCATTAATAACACCATGCTCA 
15 417 FW ATTATTTGGTCCCTGGACTT 
RV GTGCTTGTTACAGCAATTCA 
*FW, forward strand; RV, reverse strand. 
**Primers included a 5’ M13-tail (TGTAAAACGACGGCCAGT for FW, and 
CAGGAAACAGCTATGACC for RV). 
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Supp. Table S9: Discordant variant calls between Sanger sequencing and PacBio long-read sequencing approach. 
 
c. notation p.notation Chr pos # PB # S # O PKDB* dbSNP Note 
PKD1 
c.12897C>T p.(=) chr16 2,139,743 1 0 0   HC; D; Likely S FN 
c.12890A>G p.(Lys4297Arg) chr16 2,139,750 1 0 0  rs758833703 HC; D; Likely S FN 
c.12780T>C p.(=) chr16 2,139,860 1 0 0   HC; D; Likely S FN 
c.12630T>C p.(=) chr16 2,140,010 8 8 7 LN rs7203729 (C) HC; Likely PB FN; Likely S FN 
c.12276A>G p.(=) chr16 2,140,454 10 8 8 LN rs3087632 (C) HC; Likely S FN 
c.12176C>T p.(Ala4059Val) chr16 2,140,554 4 3 3 LN rs3209986 (C) HC; Likely S FN 
c.12133A>G p.(Ile4045Val) chr16 2,140,680 10 8 8 LN rs10960 (C) HC; Likely S FN 
c.9195G>C p.(=) chr16 2,152,388 1 0 0 LN rs9935834 (C) HC; D; Likely S FN 
c.6670_6673del p.(Pro2224TrpfsTer17) chr16 2,158,494 1 0 0   Likely LAA Low Confidence Assembly 
c.6666_6667del p.(Leu2223AlafsTer38) chr16 2,158,500 1 0 0   Likely LAA Low Confidence Assembly 
c.6656_6659del p.(Pro2219ArgfsTer22) chr16 2,158,508 1 0 0   Likely LAA Low Confidence Assembly 
c.6488G>A p.(Arg2163Gln) chr16 2,158,680 1 0 0 LN rs145217118 HC; D; Likely S FN 
c.6223_6224insTT p.(Arg2075LeufsTer42) chr16 2,158,944 0 1 0   Likely PB FN 
c.4968T>C p.(=) chr16 2,160,200 1 0 0  rs777909326 HC; D; Likely S FN 
c.4665A>C p.(=) chr16 2,160,503 1 7 1 LN rs71385734 (C) HC; D 
c.182C>T p.(Pro61Leu) chr16 2,185,509 1 0 0 LN  HC; D; Likely S FN 
c.129C>T p.(=) chr16 2,185,562 1 0 0   HC; D; Likely S FN 
c.122C>T p.(Pro41Leu) chr16 2,185,569 2 0 0   HC; D; Likely S FN 
c.96C>T p.(=) chr16 2,185,595 1 0 0   HC; D; Likely S FN 
PKD2 
c.53C>T p.(Pro18Leu) chr4 88,928,938 1 0 0   D; Likely S FN 
c.83G>C p.(Arg28Pro) chr4 88,928,968 11 9 9 LN rs1805044 (C) HC; Likely S FN 
c.720C>G p.(=) chr4 88,957,382 0 2 0   D; Likely S FP 
* Bold=Pathogenic;  LN=Likely Neutral; C=Common; HC=High-Confident; FP=False Positive; FN=False Negative;D=Discordant; 
PB=PacBio; S=Sanger; O=Overlap. 
** RefSeq NM_001009944.2 or NM_000297.3 for PKD1 and PKD2, respectively. 
+ Discordances shown in this table are represented in Supp. Figure S2B as yellow dots for likely S FP variants,red dots for likely PB FN 
variants, and grey dots for Likely S FN. 
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Supp. Table S10: Variants detected in homopolymer stretches using long-read sequencing approach. 
 
c. notation** p.notation Chr pos # PB # S # O PKDB* dbSNP Note 
PKD1 
c.12530del p.(Pro4177HisfsTer21) chr16 2,140,109 3 0 0  rs767438361 HS; Likely PB Artifact 
c.12518del p.(Pro4173ArgfsTer25) chr16 2,140,121 5 0 0  rs778397103 HS; Likely PB Artifact 
c.12445-3del p.? chr16 2,140,197 5 0 0  rs770813339 HS; Likely PB Artifact 
c.12139-5del p.? chr16 2,140,595 2 0 0 LN rs146430229 HS; Likely PB Artifact 
c.12085del p.(Val4029SerfsTer10) chr16 2,140,727 1 0 0  rs781278135 HS; Likely PB Artifact 
c.11713-5del p.? chr16 2,141,179 8 0 0   HS; Likely PB Artifact 
c.11240del p.(Pro3747HisfsTer79) chr16 2,142,509 6 0 0   HS; Likely PB Artifact 
c.10948del p.(His3650ThrfsTer34) chr16 2,143,612 1 0 0   HS; Likely PB Artifact 
c.10822-8del p.? chr16 2,143,746 12 0 0 LN rs373684171 rs9924796 (C) HS; Likely PB Artifact 
c.10745del p.(Pro3582ArgfsTer3) chr16 2,143,887 11 0 0 DP CD076868 HS; Likely PB Artifact 
c.9518del p.(Pro3173ArgfsTer143) chr16 2,150,446 1 0 0  rs772608027 HS; Likely PB Artifact 
c.9176del p.(Pro3059GlnfsTer15) chr16 2,152,406 10 0 0  rs759773922 HS; Likely PB Artifact 
c.9097del p.(Leu3033TrpfsTer41) chr16 2,152,485 1 0 0   HS; Likely PB Artifact 
c.8586del p.(Ile2863SerfsTer12) chr16 2,153,471 1 0 0 DP  HS; Likely PB Artifact 
c.8427del p.(Glu2810ArgfsTer65) chr16 2,153,630 1 0 0  rs746703342 HS; Likely PB Artifact 
c.8019del p.(Ser2675AlafsTer10) chr16 2,154,640 1 0 0   HS; Likely PB Artifact 
c.7864-3del p.? chr16 2,155,477 1 0 0  rs756848270 HS; Likely PB Artifact 
c.7622del p.(Pro2541ArgfsTer79) chr16 2,156,172 1 0 0  rs538031465 HS; Likely PB Artifact 
c.7401del p.(Asn2468ThrfsTer152) chr16 2,156,486 7 0 0  rs745812853 HS; Likely PB Artifact 
c.6759del p.(Glu2254SerfsTer60) chr16 2,158,408 18 0 0   HS; Likely PB Artifact 
c.6469del p.(Leu2157CysfsTer4) chr16 2,158,698 1 0 0   HS; Likely PB Artifact 
c.5824del p.(Arg1942AlafsTer7) chr16 2,159,343 18 0 0  rs780100275 HS; Likely PB Artifact 
c.5784del p.(Glu1929ArgfsTer20) chr16 2,159,383 1 0 0   HS; Likely PB Artifact 
c.4485del p.(Ala1496ProfsTer38) chr16 2,160,682 1 0 0  rs578064441 HS; Likely PB Artifact 
c.4269del p.(Thr1424ProfsTer8) chr16 2,160,898 1 0 0   HS; Likely PB Artifact 
c.4220del p.(Pro1407ArgfsTer25) chr16 2,160,947 3 0 0  rs140412120 HS; Likely PB Artifact 
c.4069del p.(Leu1357TrpfsTer9) chr16 2,161,098 16 0 0 DP CD085910 HS; Likely PB Artifact 
c.3684del p.(Val1229TrpfsTer44) chr16 2,161,483 6 0 0 DP rs781384791 HS; Likely PB Artifact 
c.3240del p.(Ser1081ArgfsTer23) chr16 2,162,395 2 0 0  rs777145613 HS; Likely PB Artifact 
c.3099del p.(Asn1034MetfsTer4) chr16 2,162,850 12 0 0 DP rs372461622 HS; Likely PB Artifact 
c.2854-5del p.? chr16 2,163,297 19 0 0  rs114846412 HS; Likely PB Artifact 
c.2823del p.(Glu942ArgfsTer9) chr16 2,164,200 1 0 0  rs767322474 HS; Likely PB Artifact 
c.2494del p.(Arg832AlafsTer66) chr16 2,164,529 19 0 0 DP  HS; Likely PB Artifact 
c.2222del p.(Pro741ArgfsTer44) chr16 2,164,801 1 0 0  rs779605081 HS; Likely PB Artifact 
c.2085del p.(Ala696ArgfsTer89) chr16 2,165,390 19 0 0  rs760496344 HS; Likely PB Artifact 
c.2037del p.(Tyr680MetfsTer105) chr16 2,165,438 13 0 0   HS; Likely PB Artifact 
c.1987del p.(Gln663ArgfsTer122) chr16 2,165,488 11 0 0 DP  HS; Likely PB Artifact 
c.1914del p.(Ala639ArgfsTer146) chr16 2,165,561 11 0 0 DP rs777208671 HS; Likely PB Artifact 
c.1386-3del p.? chr16 2,167,056 11 0 0   HS; Likely PB Artifact 
c.1221del p.(Ser408ArgfsTer57) chr16 2,167,653 4 0 0  rs768893401 HS; Likely PB Artifact 
c.771del p.(Thr258ProfsTer32) chr16 2,168,221 11 0 0   HS; Likely PB Artifact 
c.755del p.(Pro252ArgfsTer38) chr16 2,168,237 19 0 0   HS; Likely PB Artifact 
c.198del p.(Ala67ArgfsTer6) chr16 2,185,492 1 0 0   HS; Likely PB Artifact 
c.108del p.(Cys37AlafsTer36) chr16 2,185,582 14 0 0   HS; Likely PB Artifact 
c.78del p.(Arg28AlafsTer45) chr16 2,185,612 13 0 0   HS; Likely PB Artifact 
PKD2 
c.128del p.(Pro43ArgfsTer74) chr4 88,929,012 2 0 0 DP CD982885 HS; Likely PB Artifact 
c.203del p.(Pro68ArgfsTer49) chr4 88,929,087 19 0 0 DP rs751221093 HS; Likely PB Artifact 
c.538del p.(Leu180TrpfsTer53) chr4 88,929,422 6 0 0   HS; Likely PB Artifact 
c.783del p.(Val262CysfsTer55) chr4 88,957,444 6 0 0  rs766343471 HS; Likely PB Artifact 
c.1003del p.(Gln335ArgfsTer3) chr4 88,959,561 18 0 0   HS; Likely PB Artifact 
* DP=Definitely Pathogenic; LN=Likely Neutral; C=Common; HS=Homopolymer Stretch; PB=PacBio; O=Overlap. 
** RefSeq NM_001009944.2 or NM_000297.3 for PKD1 and PKD2, respectively. 
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3.1. Abstract 
Acute kidney injury (AKI) can occur in hospitalized and critically ill patients, particularly 
with sepsis, and admitted into the intensive care unit with up to 20% to 60% prevalence. This 
syndrome of kidney damage or failure occurs within a brief lapse of time, few hours to few 
days, with high mortality within those critically ill patients (≈50%). There is currently no 
therapy that reduces the severity or accelerates recovery from AKI. Previous research 
suggested that Gdf15 gene was associated with a protective mechanism against kidney 
tubular damage.  We used Gdf15 knock-out mice to investigate these mechanisms, using an 
unbiased RNA sequencing approach for experimental nephrotoxic AKI (folic acid 
nephropathy in mice). This allowed us to identify differentially expressed genes that 
associated with biological processes and pathway in an AKI generic response, as well as in a 
Gdf15-driven AKI response. Our results show that Gdf15 has a primary role in the regulation 
of processes involving proliferation, inflammation, necrosis, fibrosis, and apoptosis among 
other processes regulated by these pathways. In addition, we could identify the transcription 
factor signatures that are potentially modulating the generic AKI and Gdf15-specific AKI 
responses, that could be used for to the discovery of new therapeutic targets for AKI. 
3.2. Introduction 
Acute kidney injury (AKI) is a syndrome of kidney damage or failure that occurs within a 
brief lapse of time, from few hours to few days. The reduction of kidney function causes 
accumulation of products in blood that should have been filtered by normal kidney function 
(Bellomo et al., 2012). AKI episodes are a frequent event in clinical patients, such as surgery 
or critically ill patients, as well as in patients treated with certain drugs, including antibiotics, 
immunosuppressant drugs, cancer chemotherapy, non-steroidal anti-inflammatory drugs and 
blood pressure lowering drugs, among others (Bellomo et al., 2012). For these critically ill 
patients, mortality during the AKI episode hovers around 50% (Bellomo et al., 2012). AKI 
increases the risk of death for at least a year after its occurrence and contributes to 
progression of chronic kidney disease (CKD) (Breit et al., 2012). However, there is no 
therapy that reduces the severity or accelerates recovery from AKI. Therapeutic intervention 
is limited to replacement of renal function by hemodialysis or renal transplantation (Vallon, 
2016). Clearly, an improved understanding of the molecular drivers of AKI is required. 
Growth differentiation factor 15 (Gdf15), also known as macrophage inhibitory cytokine-1 
(MIC-1), is a member of the transforming growth factor β (TGF-β) superfamily. It has been 
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identified in an acute liver injury and regeneration study (Hsiao et al., 2000). Gdf15 was 
expressed in a wide range of tissue and cell types. Expression was increased in response to 
stress and injury such as tissue hypoxia, oxidative stress, inflammation, and acute injury 
(Hsiao et al., 2000; Breit et al., 2012; Hellemons et al., 2012; Mazagova et al., 2013; Adela 
and Banerjee, 2015; Sándor et al., 2015; Yatsuga et al., 2015; Li et al., 2016). In CKD 
patients undergoing hemodialysis within the first 3 years of starting the treatment, circulating 
Gdf15 was increased and independently associated to an increased mortality risk (Breit et al., 
2012). Furthermore, it was identified as a predictive marker for transition between 
albuminuria stages in type 2 diabetes mellitus patients (Hellemons et al., 2012). However, the 
Gdf15 gene does not appear to be a net contributor to tissue injury. Rather, its expression may 
represent an adaptive, tissue protective response. According to Adela and Banerjee., 2015, 
Gdf15 protects endothelial cells from cellular injury, apoptosis and cell death in 
cardiovascular and diabetes diseases by inhibiting Jnk (c-Jun N-terminal kinase) or activating 
Smad signaling pathways among other signaling pathways (Adela and Banerjee, 2015). 
Furthermore, Gdf15 gene knock-out (KO) mice displayed more severe tubular and interstitial 
damage, but no effect on the glomerular sclerosis rate, suggesting a protective effect of Gdf15 
in a preclinical model of diabetes-associated CKD (Mazagova et al., 2013). Gdf15 seems to 
protect from kidney damage reducing inflammatory cell recruitment and enhancing tubular 
epithelial cell proliferation (Mazagova et al., 2013). However, the molecular pathways 
modulated by Gdf15 during kidney injury, and its potential role in AKI have not been fully 
characterized (Breit et al., 2012; Mazagova et al., 2013; Vallon, 2016). 
We have now addressed the molecular mechanisms contributing to AKI and their modulation 
by Gdf15 in mice, using an unbiased RNA sequencing approach to evaluate the gene 
expression profiles of wild type (WT) and Gdf15 knock-out (GDF15-KO) mice kidneys. 
3.3. Methods 
3.3.1. Mice strains, Gdf15 null and AKI induction 
A total of 28 mice were studied, including WT, GDF15-KO, and transgenic mice 
overexpressing Gdf15 (GDF15-Tg) as positive control. Knock-out mice (GDF15-KO) were 
developed using a target construct transfection into R1 embryonic stem cells and were kindly 
donated by Prof. Se-Jin Lee, Johns Hopkins University (Hsiao et al., 2000). Transgenic 
GDF15-Tg that ubiquitously express human GDF15 protein under the control of CAG, using 
traditional pronuclear microinjection on the C57/BL6 background, were kindly donated by 
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Prof Thomas Eiling (NIH-NIEHS) (Baek et al., 2006). Mice were maintained at IIS-
Fundación Jiménez Díaz (FJD), Madrid. AKI was induced in WT and GDF15-KO mice by a 
single injection of folic acid. Mice received a single intraperitoneal injection of folic acid 
(Sigma) 250 mg/kg in 0.3 mol/L sodium bicarbonate or vehicle and were sacrificed 24 h after 
injection (Ortiz et al., 2017). In total, 5 groups of mice were sacrificed at 24h of induction 
that correspond to WT controls without AKI induction (WT-Control, n=6), WT with AKI 
induction (WT-AKI, n=6), GDF15-KO controls without AKI induction (GDF15-KO-Control, 
n=6), GDF15-KO with AKI induction (GDF15-KO-AKI, n=7), and GDF15-Tg without AKI 
induction (n=3). Studies were conducted in accordance with the NIH Guide for the Care and 
Use of Laboratory Animals (Guide for the Care and Use of Laboratory Animals: Eighth 
Edition, 2011).  
3.3.2. Tissue sampling and RNA isolation 
The kidneys were perfused in situ with cold saline before removal. Half of the kidney from 
each mouse was fixed in buffered formalin, embedded in paraffin and used for 
immunohistochemistry and the other half was snap-frozen in liquid nitrogen for RNA and 
protein studies and stored at -80 °C for preservation of the RNA (Ortiz et al., 2017). Total 
RNA isolation was performed using (Pure Link RNA mini kit, Ambion) following the 
manufacturer’s standard guidelines. 
3.3.3. Messenger RNA library preparation and sequencing 
Total RNA samples were sequenced at GenomeScan B.V., and processed under the ISO/IEC 
17025 accredited messenger-RNA (mRNA) sequencing pipeline. The enrichment of mRNA 
species was performed by poly-A capture with oligo-dT magnetic beads (NEBNext Ultra 
Directional RNA Library Prep Kit for Illumina). Sample libraries were prepared following 
manufacturer’s protocol (NEB #E7420S/L). Then, the quality and yield of the RNA was 
measured before and after the sample preparation with a Fragment Analyzer (Thermo Fisher) 
(Table 1). Resulting mRNA library size was checked for consistency with the expected size 
distribution (300 to 500 bps) and concentration. Sequencing was performed using an Illumina 
HiSeq 2500 platform for a 125 paired-end (PE) library. 
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Table 1: Quality control checks of RNA samples. Before (Sample QC), and after the process of mRNA 
sequencing library preparation (Library QC).  
3.3.4. Data analysis 
Sequence read clipping and filtering was performed using fast-A quality files (fastQ) for PE 
sequenced reads (Table 1), pre-processed to remove sequencing adapters and low quality 
base calls. Using Trimmomatic v.0.36 we performed the adapter clipping, minimum read 
length filtering (>20 bps), and average base quality trimming of Q >15 Phred on a 5 
consecutive base sliding window. 
Alignment and feature quantification for mouse reference sequence GRCm38. On average, 
>49M PE reads per sample (Table 1) were aligned to the mouse reference sequence version 
GRCm38 patch 4. Reference files were downloaded from GENCODE version M9 with the 
 
Sample QC Library QC 
Sample Conc. (ng/µl) RQN 28S/18S ng/µL nmol/L Avg. Size Reads (#) Quality (%>=Q30) 
WT Control 1 793.689 9.7 1.3 3.486 12.23 469 55,927,139 89.81 
WT Control 2 650.2 9.6 1.3 3.6948 13.556 448 52,310,573 90.32 
WT Control 3 241.5 9.8 1.4 4.1204 14.742 460 51,165,664 90.48 
WT Control 4 359.7 9.8 1.3 3.7006 12.274 496 49,532,713 89.44 
WT Control 5 334.4 9.6 1.3 2.2532 8.212 451 57,573,731 90.44 
WT Control 6 417.6 9.5 1.3 3.6536 12.896 466 63,430,234 89.91 
WT AKI 1 846.7 9 1.4 4.2538 15.478 452 66,589,846 89.85 
WT AKI 2 1,180.9 8.7 1.7 3.8178 13.706 458 43,832,642 89.67 
WT AKI 3 1,240.3 9.3 1.5 3.6762 13.12 461 58,700,358 89.87 
WT AKI 4 201.9 9.1 1.3 2.4916 8.942 458 41,122,213 89.84 
WT AKI 5 695.4 9.5 1.3 2.699 9.65 460 43,823,846 90.24 
WT AKI 6 965.9 8.3 0.8 1.0934 3.78 476 42,771,320 89.87 
GDF15 KO Control 1 290.8 9.1 1.2 2.0286 7.22 462 40,444,400 89.95 
GDF15 KO Control 2 313.1 8.3 1.1 1.9946 6.97 471 50,653,012 89.73 
GDF15 KO Control 3 336.4 8.8 1.1 2.1004 7.532 459 50,140,826 90.05 
GDF15 KO Control 4 490.6 8.7 1.3 2.9698 10.93 447 53,706,306 90.41 
GDF15 KO Control 5 201.2 8 1.2 1.4302 5.082 463 57,499,527 89.85 
GDF15 KO Control 6 155.3 9 1.3 2.9312 10.476 460 43,979,500 89.76 
GDF15 KO AKI 1 2,363.3 9.4 1.6 2.526 9.014 461 43,064,788 90.05 
GDF15 KO AKI 2 1,203.7 9.6 1.6 2.6226 9.508 454 47,802,649 89.87 
GDF15 KO AKI 3 1,793.2 9.2 1.7 1.937 6.818 467 40,799,842 89.33 
GDF15 KO AKI 4 1,018.6 9.4 1.5 2.2208 7.876 464 49,150,240 89.9 
GDF15 KO AKI 5 2,797.4 9.2 1.7 1.6674 5.83 471 40,630,787 89.78 
GDF15 KO AKI 6 2,399.3 9.5 1.6 2.272 8.16 458 43,275,128 89.88 
GDF15 KO AKI 7 667.4 9.8 1.5 2.9904 11.114 443 51,500,862 89.97 
GDF15 Tg Control 1 1,283.3 6.1 1.1 0.5224 1.686 510 40,877,158 89.55 
GDF15 Tg Control 2 1,124.5 4.9 0.3 1.081 3.778 471 44,055,503 89.45 
GDF15 Tg Control 3 1,232.4 5.3 1.3 2.64 9.292 468 47,609,579 89.73 
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corresponding feature annotation tables as GFF/GTF files. Alignment was performed using 
the STAR v.2.4.2a aligner with a two-step alignment approach to incorporate known and 
novel junction indexes. The first alignment was performed against an indexed reference 
containing known splice sites, and the second against a newly re-built indexed reference 
including the novel splice sites inferred from the first alignment step. Sorted alignments were 
stored as sequence alignment map (B/SAM) files for further processing. Only high quality 
alignments (Phred score > 30) (Table 1) for Gencode M9 annotated features were counted 
using HTSeq-counts v.0.6.1p1. Gene expression counts were then uploaded to R statistical 
computing software v.3.3.1 (R), and further processed with the RNA-seq analysis package 
DESeq2 v.1.10.1 (DESeq) to perform library size normalization, and differential expression 
comparisons. 
 
Figure 1: Expression of Gdf15 in log2 transformed normalized read counts. For all 5 
groups of mouse samples plus 3 non-responder WT mice (WT_AKI_NR). 
 
Effectiveness of gene deletion procedure to create GDF15-KO mice was qualitatively 
evaluated by assessing the expression levels and local alignments of Gdf15 for all 28 
samples. Normalized Gdf15 expression in gene counts (Figure 1) was contrasted with Gdf15 
alignments (Supp. Figure S1) to confirm GDF15-KO and validate the functionality of Gdf15 
transcripts. 
Confirmation of data-driven sample groups and clusters defined in the experimental design 
was assessed by data-driven group similarities within and between groups. Stratification or 
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batch effects of samples and groups was assessed by principal component analysis (PCA) 
(Figure 2). Then, unsupervised hierarchical clusters were generated from the normalized gene 
expression data, and hierarchical cluster probabilities were calculated with a bootstrap 
approach using pvclust v.2.0 package for R (Supp. Figure S2). The profile of the top 100 
expressed genes, as well as sample distance matrices, were also evaluated as a measure to 
confirm the major trends of the observed sample clusters and grouping (Supp. Figure S3; 
Supp. Figure S4). Possible sample outliers, such as WT-AKI-NR, deviating from the original 
grouping were then separated for further downstream analysis as shown in the PCA plot  
 (Figure 2). 
 
 
Figure 2: Scheme of the differential expression analysis for up- (red) and down-regulated (green) gene 
expression profiles associated with AKI and AKI potentially driven by Gdf15. 
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Differential expression comparison of sample groups was performed to identify the genetic 
differences associated with each annotated factor. Statistical comparisons were performed 
using DESeq package to identify the most significant features of sample group phenotypes. 
The intersection of differentially expressed genes in Wt_Control vs. WT_AKI and GDF15-
KO-Control vs. GDF15-KO-AKI was extracted to assess the genetically driving differences 
between AKI treated samples and their respective controls. Bonferroni adjusted p-value < 
0.01 (p-adj), and fold change 2.5 (FC) with the same numerical sign in both comparisons 
were considered as AKI associated differentially expressed genes (Figure 2). Opposite trends, 
were considered as an AKI response associated with Gdf15 (p-adj < 0.1; FC 1.2 with opposite 
numerical sign) (Figure 2). 
Enrichment analysis and functional annotation (gene ontology) was performed by evaluating 
the lists of differentially expressed genes as a network statistical visualization using ClueGO 
package v.2.2.6 (ClueGO) for Cytoskape v.3.4.0 (Cytoskape). For each comparison, groups 
of genes defined as up- or down-regulated were used as input categories in ClueGO to 
perform the enrichment and clustering of gene ontology (GO) biological processes. 
Visualization parameters were manually inspected to obtain an unsaturated and clearer 
network visualization. 
 
Figure 3: Principal component analysis of all 28 mRNA samples. PC1 (x axis) that accounts for 67% of the 
variance observed in the dataset is shown to discriminate between AKI and Control samples. PC2 (y axis) 
accounts for only 9% of the variance within the dataset and seems to be linked with GDF15-Tg samples. 
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Enrichment of renal and AKI disease-terms associated genes was performed using a 
reduction of identified differentially expressed genes by selecting those previously associated 
or linked with a disease term. Disease-term associations were obtained using a STRING 
database querying for a: genes associated with kidney disease or CKD, ischemia, 
nephrosclerosis, renal fibrosis, and kidney failure; and b: STRING genes associated with 
renal injury extracted from a PubMed query such as [renal[All Fields] OR ("kidney"[MeSH 
Terms] OR "kidney"[All Fields])) AND ("wounds and injuries"[MeSH Terms] OR 
("wounds"[All Fields] AND "injuries"[All Fields]) OR "wounds and injuries"[All Fields] OR 
"injury"[All Fields]]. The list of disease genes included 2001 genes associated with renal 
injury, 1900 kidney disease, 1603 ischemia, 1035 kidney failure, 715 chronic kidney disease, 
359 renal fibrosis, and 112 nephrosclerosis for a total of 3645 unique disease-terms 
associated genes. 
Transcription factors driving the expression profiles were identified by comparing the 
differentially expressed genes lists with the transcription factors described for mouse model 
in the animal transcription factor database for (AnimalTFDB) (Zhang et al., 2012), or the 
Riken Transcription factor database (TFdb) (http://genome.gsc.riken.jp/TFdb/). 
Evaluation of pathway involved in the AKI gene expression response was assessed using 
Pathvisio v.3.2.2 for the pathway statistical analysis. Biological pathway files were obtained 
from Pathvisio wiki pathways collection for Mus musculus, publicly available online 
(Kutmon et al., 2016). Statistics were based on an hypergeometric distribution test coupled to 
1000 time permutation test of Z-scores for p-value calculation (Kutmon et al., 2015). Input 
data provided included all detected genes (> 1 read) and gene section for positive hits of p-adj 
< 0.1 and FC 1.2. 
3.4. Results 
3.4.1. High quality messenger-RNA sequencing identified wild type mice not responsive 
to folic acid induction 
Deep-sequencing mRNA high quality libraries were obtained for a total of 28 kidney RNA 
samples (>49M PE reads on average). Alignments against the GRCm38 reference sequence, 
showed an exome representation of average 76.8% (Table 2). Observed GC-content of 47.4% 
was higher than the average genomic GC-content of 41.7% (), but matched the average 
exonic GC-content of 47.5% (Supp. Figure S5). Messenger RNAs expression values were 
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normalized to account for differences related to sequencing and the library preparation for 
each independent library. 
The assessment of the high-quality expression profiles, combined with available sequence 
alignments, could identify 3 WT-AKI samples (WT-AKI-1, 4, and 5) that presented different 
expression profiles more correlated with non-AKI WT profiles. These samples were marked 
as outliers by re-naming them as non-responders (WT-AKI-NR) (Figure 1;Figure 3; Supp. 
Figure S1). Expression of top 100 genes within these three samples showed similar levels as 
the WT-Controls (Supp. Figure S3), and was confirmed by the hierarchical bootstrap analysis 
(Supp. Figure S2), as well as the sample distance vectors (Supp. Figure S4). 
Table 2: RNA-sequencing of poly-A captured RNA. Basic read and alignment statistics for the 28 kidney mice 
samples. 
Sample Aligned Aligned pairs Insert size Phred Aligned to exons (%) 3’/5’ GC% 
WT Control 1 114,706,762 56,837,513 368 22.1 78,211,324 80.54% 1.15 47.0 
WT Control 2 105,028,232 52,028,891 337 24.3 68,366,112 77.49% 1.18 47.3 
WT Control 3 104,061,772 51,572,275 345 23.1 70,136,718 79.65% 1.17 47.3 
WT Control 4 103,924,539 51,448,537 388 24.4 68,438,647 78.89% 1.2 46.6 
WT Control 5 116,569,558 57,755,378 338 22.0 75,679,482 77.35% 1.19 47.3 
WT Control 6 129,245,563 64,035,007 340 23.7 84,145,297 77.50% 1.22 47.0 
WT AKI 1 132,256,229 65,327,172 303 25.7 79,893,457 73.11% 1.21 48.1 
WT AKI 2 88,034,650 43,446,603 331 25.6 55,550,948 75.57% 1.17 48.3 
WT AKI 3 121,080,566 59,744,258 347 23.0 76,178,387 76.82% 1.16 47.7 
WT AKI 4 83,158,844 41,168,751 341 26.9 52,497,798 75.87% 1.27 46.9 
WT AKI 5 88,499,263 43,832,027 346 23.9 57,572,442 77.50% 1.2 47.2 
WT AKI 6 86,548,478 42,739,683 342 23.2 55,024,939 77.07% 1.16 47.5 
GDF15 KO Control 1 81,828,667 40,523,760 346 24.0 52,704,895 77.47% 1.24 46.9 
GDF15 KO Control 2 103,670,604 51,323,280 355 23.8 67,287,247 78.44% 1.25 46.8 
GDF15 KO Control 3 101,109,634 50,074,753 329 25.2 63,937,069 76.03% 1.25 46.9 
GDF15 KO Control 4 107,641,180 53,333,009 326 23.6 68,792,743 76.12% 1.22 47.2 
GDF15 KO Control 5 115,295,416 57,081,040 345 24.3 72,929,399 75.81% 1.23 47.2 
GDF15 KO Control 6 89,583,323 44,349,691 353 23.8 57,812,739 76.96% 1.22 47.1 
GDF15 KO AKI 1 87,793,188 43,373,268 362 23.3 57,144,431 77.77% 1.1 48.0 
GDF15 KO AKI 2 96,434,008 47,607,202 361 22.6 62,633,298 77.15% 1.15 48.2 
GDF15 KO AKI 3 83,631,609 41,239,226 364 23.4 53,331,754 77.46% 1.16 48.0 
GDF15 KO AKI 4 100,577,250 49,671,665 372 22.7 65,623,653 77.90% 1.13 47.9 
GDF15 KO AKI 5 83,588,255 41,219,940 354 22.4 52,164,956 76.91% 1.16 48.0 
GDF15 KO AKI 6 87,202,229 43,128,322 362 22.4 56,930,660 77.61% 1.15 47.7 
GDF15 KO AKI 7 106,248,349 52,409,037 354 22.2 67,812,747 78.07% 1.16 48.0 
GDF15 Tg Control 1 86,469,404 42,633,873 348 32.6 53,167,273 76.83% 1.27 46.4 
GDF15 Tg Control 2 90,144,863 44,123,702 333 38.9 49,546,706 68.13% 1.23 46.3 
GDF15 Tg Control 3 96,297,277 47,635,345 345 26.7 59,691,384 75.29% 1.22 46.9 
Average 99,665,347 49,273,686 348 24.6 63,685,947 76.83% 1.19 47.3 
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3.4.2. Underlying AKI-driving gene expression mechanisms, independent from Gdf15 
expression 
Overall gene expression response to AKI, independent from Gdf15, showed that 1661 genes 
are differentially expressed (p-adj < 0.01), and regulated in the same manner up- or down- 
regulated (FC 2.5) in both comparisons (“Wt_Control vs. WT_AKI” and “GDF15-KO-
Control vs. GDF15-KO-AKI”), from which 1422 are protein coding (Figure 2). The first 
comparison WT_Control vs. WT_AKI yielded 2094 differentially expressed genes (1773 
protein coding) and had a 79.3% of gene overlap with the GDF15-KO comparison (Figure 2). 
The GDF15-KO comparison (GDF15-KO vs. GDF15-KO-AKI) yielded 2433 differentially 
expressed genes (1992 protein coding) and showed a 68.2% of gene overlap with the WT 
comparison (Figure 2). 
 
Figure 4: Enriched Gene Ontology Biological Processes lead by differentially expressed genes that are 
independent of Gdf15 protective mechanisms. Up- and down-regulated genes in both WT and GDF15-KO 
mice during AKI were considered to be Gdf15-independent. Circles represent enriched terms that are shown 
to be up-regulated (red), down-regulated (green), or no clear up- or down-regulated tendency (grey) during 
AKI. Terms have been clustered by term or process similarities and only the description of the major process 
that defines the cluster is shown (text). GO parent-child relationships between terms are shown as lines. 
 
91 
 
Gene ontology biological processes driven by differentially expressed genes in response to 
AKI show the underlying processes in AKI that are independent of Gdf15 expression (Figure 
3). Up- and down-regulated genes in both WT and GDF15-KO mice comparisons during an 
AKI episode produce a separated clustering of enriched biological process: up-regulated 
genes were driving cell regulation processes mainly involved in cell death and regulation of 
cell death, regulation of cellular processes, cell migration, proliferation and response to stress 
among others (Figure 3; Supp. Figure S6); whereas down-regulated genes were regulating 
metabolic processes, such as small molecule and organonitrogen compound metabolic 
processes, anion transport, cofactor metabolic process, chemical homeostasis, and oxidation-
reduction processes among other metabolic processes as well as transport processes (Figure 
3; Supp. Figure S7). 
 
Figure 5: Enriched Gene Ontology Biological Processes lead by differentially expressed and 
disease associate genes with transcription factor activity that are independent of Gdf15 
protective mechanisms. Circles represent enriched terms that shown to be up-regulated (red), 
down-regulated (green), or no clear up- or down-regulated tendency (grey) in WT-AKI mice. 
Terms have been clustered by term or process similarities and only the description of the 
major process that defines the cluster is shown (text). GO parent-child relationships between 
terms are shown as lines. 
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Evaluation of disease-term associated genes in AKI expression profile identified 415 protein-
coding genes involved in renal disorders that were highly differentially expressed in the 
dataset (96.4% p-adj <0.001). In addition, we identified 1 long intergenic non-coding RNA 
(Pvt1), and 3 “non-coding” processed transcripts or pseudogenes (Sngh1, Mpcp1-ps, and 
Pdxk-ps) also associated with disease-terms. The identified disease-associated genes in AKI 
show to be up-regulating processes such as cell regulation, morphogenesis, and migration 
processes such as positive regulation of cell migration, morphogenesis of epithelial tube, 
negative regulation of apoptosis, and regulation of inflammatory response among other 
immune system, transport and morphogenic processes and responses (Supp. Figure S8). The 
down-regulated genes were enriched in terms associated with kidney development, an/ion 
transport, inorganic ion homeostasis, water transport, apoptotic signaling in response to 
hypoxia, and macrophage derived cell differentiation (Supp. Figure S9). 
Table 3: Disease-associated transcription factors driving an AKI response in both comparisons “WT_Control 
vs. WT_AKI” and “GDF15-KO-Control vs. GDF15-KO-AKI”. 
*Mean calculated as average expression from samples included in each the comparison. 
 
GDF15-KO changes in AKI WT changes in AKI Genomic information 
 
Gene p-adj FC 
Mean 
expression* 
p-adj FC 
Mean 
expression* 
Chrom Start End Human name 
Ppp1r1b 2.1E-66 -20.61 1,333 2.6E-96 -26.88 2,097 11 98,348,404 98,357,796 PPP1R1B 
Cml3 3.9E-03 -6.18 432 1.6E-68 -11.79 525 6 85,732,513 85,765,754 NAT8 
Sirt3 3.5E-67 -6.00 1,519 1.4E-77 -5.46 1,995 7 140,863,670 140,882,309 SIRT3 
Fah 1.6E-21 -5.79 5,895 3.6E-111 -4.32 7,337 7 84,585,159 84,606,722 FAH 
Gcdh 1.3E-40 -5.08 7,306 1.3E-139 -4.58 10,056 8 84,886,393 84,893,921 GCDH 
Hnf4a 1.7E-08 -5.01 15,950 9.1E-40 -4.13 21,250 2 163,506,808 163,572,910 HNF4A 
Klf15 1.7E-56 -4.42 1,805 6.3E-10 -2.98 1,975 6 90,462,576 90,475,238 KLF15 
Lhx1 1.2E-23 -4.24 635 7.7E-38 -3.67 917 11 84,518,284 84,525,535 LHX1 
Nr0b2 1.9E-05 -4.01 31 8.7E-09 -5.51 49 4 133,553,376 133,556,536 NR0B2 
Ar 4.4E-34 -3.76 2,420 2.7E-24 -2.80 2,500 X 98,149,721 98,323,215 AR 
Hmx2 2.6E-14 -3.74 177 3.9E-09 -2.92 297 7 131,548,773 131,558,014 HMX2 
Ppara 3.7E-15 -3.73 1,635 1.8E-13 -3.34 2,574 15 85,734,983 85,802,819 PPARA 
Maf 2.7E-26 -3.37 6,289 1.8E-17 -2.82 8,918 8 115,682,942 115,707,794 MAF 
Esr1 5.3E-22 -3.24 311 1.8E-10 -2.83 401 10 4,611,593 5,005,614 ESR1 
Vdr 7.5E-25 -3.16 4,476 2.3E-36 -3.33 6,429 15 97,854,425 97,910,630 VDR 
Ppargc1a 1.9E-22 -3.13 2,701 3.1E-38 -3.34 3,896 5 51,454,250 51,567,726 PPARGC1A 
Jun 3.7E-17 2.66 2,691 3.2E-07 2.64 2,573 4 95,049,034 95,052,222 JUN 
Pax8 8.6E-17 2.70 5,166 6.4E-44 3.21 4,895 2 24,420,560 24,475,599 PAX8 
Trp53 1.2E-48 3.20 1,840 2.1E-12 2.80 1,586 11 69,580,359 69,591,873 TP53 
Sqstm1 8.3E-18 3.25 29,263 4.9E-08 2.74 24,717 11 50,199,366 50,210,827 SQSTM1 
Stat3 4.0E-109 3.37 6,849 7.4E-09 3.09 6,825 11 100,885,098 100,939,540 STAT3 
Relb 6.5E-54 3.93 492 1.4E-06 2.75 462 7 19,606,217 19,629,438 RELB 
Cebpb 8.5E-30 5.54 289 2.5E-18 5.25 214 2 167,688,915 167,690,418 CEBPB 
Fos 8.9E-17 5.74 190 1.8E-24 6.29 157 12 85,473,890 85,477,273 FOS 
Fosl2 3.9E-78 6.83 3,038 1.7E-63 6.00 2,929 5 32,135,801 32,157,842 FOSL2 
Fosb 8.3E-27 7.60 44 3.4E-10 6.46 47 7 19,302,696 19,310,051 FOSB 
Hesx1 1.6E-79 8.44 121 1.5E-39 10.54 87 14 27,000,362 27,002,329 HESX1 
Egr1 9.5E-46 9.22 1,386 4.0E-13 8.14 1,373 18 34,859,823 34,864,984 EGR1 
Atf3 3.2E-32 11.77 610 6.6E-44 16.21 414 1 191,170,296 191,218,039 ATF3 
Bcl3 4.8E-83 14.17 651 1.7E-06 8.34 490 7 19,808,462 19,822,770 BCL3 
Myc 4.0E-60 17.18 2,146 1.5E-153 15.91 1,506 15 61,985,341 61,990,374 MYC 
Sox9 3.1E-69 20.70 403 8.8E-84 16.47 279 11 112,782,224 112,787,760 SOX9 
Egr2 1.6E-50 30.93 200 4.8E-66 25.20 183 10 67,535,475 67,542,188 EGR2 
Hmga2 5.2E-28 35.03 201 4.5E-50 31.15 135 10 120,361,275 120,476,469 HMGA2 
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RNA-seq identified transcription factors driving the gene expression response to AKI. We 
detected, a total of 48 up-regulated and 41 down-regulated mRNAs coding for transcription 
factors, from which 33 were found to be disease term associated (Table 3; Figure 4). 
3.4.3. Mechanisms of AKI activation driven by expression of Gdf15 
Genetic response specific to Gdf15 expression was modulated by 100 differentially expressed 
genes (p-adj < 0.1, FC > 1.2) (Figure 2). Overall, 45 genes were up-regulated, and 55 were 
down-regulated in GDF15-KO-AKI with inversely related pattern of expression when 
compared to the WT-AKI/WT-Control comparison. 
Biological processes driven by Gdf15 associated gene expression showed that up-regulated 
genes in GDF15-KO-AKI mice were related to processes such as epithelium development, 
tissue and cell morphogenesis, elastin biosynthetic process, positive regulation of microtubule 
motor activity, and regulation of membrane depolarization among other biological processes 
 
Figure 6: Enriched Gene Ontology Biological Processes lead by differentially expressed genes that are associated with a 
Gdf15 driven AKI response. Circles represent enriched terms that have an up-regulated (red), down-regulated (green), or no 
clear up- or down-regulated tendency (grey) in GDF15-KO-AKI. Terms have been clustered by term or process similarities 
and only the description of the major processes that define the clusters are shown (text). GO parent-child relationships 
between terms are shown as lines. 
94 
 
(Figure 5; Supp. Figure S10). Down-regulated genes showed to be related to biological 
processes such as regulation of transcription from RNA polymerase II promoter involved in 
definitive endodermal cell fate specialization, xenobiotic gluconoridation, negative regulation 
of catalytic activity and arachidonic acid secretion, response to interferon and type I 
interferon signaling, endocytosis, and cell aging among other immune system, catalytic and 
metabolic biological processes (Figure 5; Supp. Figure S11). 
Assessment of disease associated genes linked to Gdf15 expression revealed a total of 17 
genes that were found differentially expressed with inversed regulation GDF15-KO and WT 
comparisons (Figure 6). No up-regulated and disease associated gene was found in an 
enriched and up-regulated biological processes (Figure 6). However, some down-regulated 
and disease associated genes were fount associated with down-regulated processes such as 
negative regulation of molecular function and catalytic activity, type I interferon signaling, 
and cell aging. 
Table 4: Transcription factors driving the Gdf15-associated AKI response. 
 
GDF15-KO changes in AKI WT change in AKI Genomic information 
Gene* p-adj FC 
Mean 
expression 
p-adj FC 
Mean 
expression 
Chrom Start End 
Human 
name 
Irf7 7.7E-03 -4.69 1,679 1 1.14 733 chr7 141,262,706 141,266,481 IRF7 
Id3 3.6E-10 -2.37 2,021 1 1.15 1,861 chr4 136,143,497 136,145,755 ID3 
Id1 1.2E-03 -1.98 1,095 1 1.60 913 chr2 152,736,251 152,737,410 ID1 
Peg3 1.0E-07 -1.77 1,115 1 1.12 1,763 chr7 6,703,892 6,730,431 PEG3 
Ebf1 1.8E-10 -1.60 368 1 1.00 466 chr11 44,617,317 45,008,091 EBF1 
Sox17 6.2E-03 -1.30 363 1 1.13 448 chr1 4,490,931 4,497,354 SOX17 
Zfp729b 1 1.02 511 6.1E-03 -1.51 686 chr13 67,589,443 67,609,707 ZNF729 
4930522-L14Rik 1 1.10 107 7.0E-02 -1.86 154 chr5 109,735,990 109,751,886 ZNF788 
Zfp26 6.7E-04 1.25 772 1 -1.00 966 chr9 20,432,972 20,460,162 
 
Irf6 2.4E-04 1.42 1,077 1 -1.02 1,340 chr1 193,153,111 193,172,023 IRF6 
Zfp867 3.1E-02 1.42 210 1 -1.03 259 chr11 59,461,197 59,472,474 
 
Bcl6b 1.2E-03 1.57 341 1 -1.10 394 chr11 70,224,128 70,229,798 BCL6B 
Rsl1 4.0E-11 1.67 175 1 -1.07 186 chr13 67,173,207 67,183,126 
 
*Bold indicates a previous association with renal disease terms. 
 
Evaluation of genetic drivers of AKI response identified 13 transcription factors associated to 
Gdf15 expression, from which, 8 were previously associated with AKI disease-terms (Table 
4). Up-regulated transcription factors were found enriching biological processes such as 
tissue development (Figure 6). Whereas down-regulated transcription factors were enriching 
biological processes such as type I interferon signalling and negative regulation of molecular 
function (Figure 6). 
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Figure 7: Enriched Gene Ontology Biological Processes lead by DE and disease associate genes with 
transcription factor activity that are associated to Gdf15 expression. Circles represent enriched terms that 
shown to be up-regulated (red), down-regulated (green), or no clear up- or down-regulated tendency 
(grey), using GDF15-KO-AKI mice as reference for up- or down- regulation. Terms have been clustered 
by term or process similarities and only the description of the major process that defines the cluster is 
shown (text). GO parent-child relationships between terms are shown as lines. Smaller circles represent 
genes enriching the annotated processes including disease associated genes (black border), and 
transcription factors genes (diamonds). 
 
3.4.4. Biological pathways modulated by a transcription factor-driven AKI response 
In the context of curated biological pathways, the assessment of a generic and a Gdf15-driven 
AKI associated genes enriched 71 biological pathways, 35 being up-regulated, and 35 down-
regulated (Table 5). In addition, 24 up-regulated pathways included identified transcription 
factors, 4 pathways with both AKI and Gdf15 associated transcription factors, 19 with AKI-
only associated transcription factors, and 1 with Gdf15-only associated transcription factors. 
The down-regulated pathways included 7 pathways with AKI-only associated transcription 
factors. Only one pathway was enriched using both up- and down- regulated genes and 
showed no clear trend of being driven by up- or down-regulated expression. 
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Table 5: Enriched pathways in AKI. 
 
Pathway names 
Genes* 
(r/n) 
% Z (all) 
p-value* 
(all) 
Z (up) 
p-value* 
(up) 
Z (down) 
p-value* 
(down) 
TF* 
(Gdf15/AKI) 
U
p
-r
eg
u
la
te
d
 P
a
th
w
a
y
s 
Cytoplasmic Ribosomal Proteins 76/78 97.4 7.61 0 12.5 0 -4.7 0 0/0 
TNF-alpha NF-kB Signaling Pathway 129/179 72.1 4.7 0 8.09 0 -3.31 0.002 3/23.1 
mRNA processing 255/436 58.5 1.57 0.114 7.91 0 -6.77 0 0/15.4 
Proteasome Degradation 43/58 74.1 2.96 0.001 6.54 0 -3.65 0 0/0 
DNA Replication 33/41 80.5 3.3 0.001 6.51 0 -3.22 0.001 0/46.2 
Translation Factors 34/48 70.8 2.23 0.022 5.34 0 -3.2 0.001 0/0 
G1 to S cell cycle control 45/61 73.8 2.98 0.005 5 0 -1.96 0.064 0/38.5 
EGFR1 Signaling Pathway 115/174 66.1 3.02 0.006 4.46 0 -1.33 0.192 0/57.7 
Podocyte prot-prot interactions (PodNet) 200/313 63.9 3.3 0 4.09 0 -0.59 0.554 0/3.8 
Alpha6-Beta4 Integrin Signaling Pathway 46/67 68.7 2.28 0.016 4.01 0 -1.71 0.085 0/7.7 
Podocyte prot-prot interactions, (XPodNet) ** 472/813 58.1 1.97 0.059 3.6 0 -1.62 0.111 0/23.1 
miRNA regulation of DNA Damage Response 41/66 62.1 1.18 0.222 3.59 0 -2.53 0.01 0/30.8 
Nucleotide Metabolism 16/19 84.2 2.57 0.006 3.51 0.001 -0.82 0.432 0/0 
p38 MAPK Signaling Pathway 24/34 70.6 1.84 0.068 3.49 0.001 -1.65 0.089 0/15.4 
Focal Adhesion 108/185 58.4 0.97 0.332 3.45 0 -2.63 0.01 0/7.7 
TGF Beta Signaling Pathway 32/51 62.8 1.13 0.239 3.37 0.001 -2.35 0.013 0/30.8 
Integrin-mediated Cell Adhesion 59/99 59.6 0.95 0.329 3.32 0.001 -2.51 0.01 0/0 
Primary FSGS 46/69 66.7 1.98 0.044 3.27 0 -1.25 0.228 1.5/0 
Hypertrophy Model 13/18 72.2 1.48 0.121 3.26 0 -1.82 0.066 0/7.7 
Regulation of Actin Cytoskeleton 81/145 55.9 0.23 0.818 3.06 0.003 -3.06 0.001 0/0 
IL-1 Signaling Pathway 24/37 64.9 1.22 0.236 3.02 0.004 -1.86 0.066 0/0 
Lung fibrosis 36/59 61.0 0.95 0.343 3 0.002 -2.16 0.032 0/3.8 
Homologous recombination 9/13 69.2 1.04 0.278 2.97 0.004 -2.01 0.03 0/0 
Toll Like Receptor signalling 21/33 63.6 1.01 0.307 2.91 0.003 -1.98 0.035 0/0 
IL-3 Signaling Pathway 58/97 59.8 0.98 0.343 2.83 0.005 -1.94 0.057 3/7.7 
PluriNetWork 140/273 51.3 -1.24 0.197 2.81 0.007 -4.51 0 1.5/84.6 
MAPK signaling pathway 85/158 53.8 -0.29 0.757 2.75 0.014 -3.33 0 0/34.6 
FAS-pathway/Stress-induction of HSP regulation 22/37 59.5 0.56 0.597 2.66 0.004 -2.24 0.021 0/7.7 
EBV LMP1 signaling 14/21 66.7 1.08 0.327 2.58 0.006 -1.53 0.131 0/0 
Insulin Signaling 95/156 60.9 1.53 0.14 2.53 0.008 -0.96 0.334 0/30.8 
IL-6 signaling Pathway 60/99 60.6 1.15 0.259 2.44 0.014 -1.31 0.204 0/100 
Mismatch repair 6/9 66.7 0.71 0.425 2.3 0.013 -1.68 0.075 0/0 
Apoptosis 44/82 53.7 -0.23 0.811 2.27 0.031 -2.74 0.006 6.1/23.1 
Signaling of Hepatocyte Growth Factor Receptor 19/34 55.9 0.11 0.889 2.01 0.049 -2.05 0.041 0/23.1 
Electron Transport Chain 89/100 89.0 6.92 0 -6.79 0 15.48 0 0/0 
D
o
w
n
-r
eg
u
la
te
d
 p
a
th
w
a
y
s 
Oxidative phosphorylation 54/59 91.5 5.68 0 -5.2 0 12.3 0 0/0 
TCA Cycle 26/30 86.7 3.51 0 -3.3 0.001 7.69 0 0/0 
One carbon metabolism and related pathways 37/49 75.5 2.91 0.006 -3.18 0.001 6.87 0 0/0 
PPAR signaling pathway 52/74 70.3 2.67 0.008 -3.05 0.003 6.45 0 0/3.8 
Fatty Acid Beta Oxidation 25/33 75.8 2.41 0.014 -2.75 0.004 5.81 0 0/7.7 
Amino Acid metabolism 67/92 72.8 3.48 0.002 -1.51 0.136 5.72 0 0/3.8 
Mitochondrial LC-Fatty Acid Beta-Oxidation 14/16 87.5 2.62 0.008 -2.15 0.027 5.41 0 0/0 
Glutathione and one carbon metabolism 24/31 77.4 2.53 0.011 -2.2 0.028 5.35 0 0/0 
Fatty acid oxidation 9/10 90 2.23 0.023 -2.13 0.035 4.93 0 0/0 
Metapathway biotransformation 79/132 59.9 1.16 0.247 -3.26 0.001 4.9 0 0/0 
Tryptophan metabolism 27/42 64.3 1.23 0.217 -3.04 0.003 4.74 0 0/15.4 
Selenium Micronutrient Network 18/23 78.3 2.26 0.027 -1.88 0.067 4.68 0 0/0 
Glutathione metabolism 16/19 84.2 2.57 0.013 -1.45 0.144 4.58 0 0/0 
Fatty Acid Biosynthesis 18/22 81.8 2.54 0.008 -1.32 0.176 4.41 0 0/0 
Folic Acid Network 19/23 82.6 2.68 0.011 -0.98 0.351 4.19 0 0/0 
Synthesis and Degradation of Ketone Bodies 5/5 100 2.03 0.043 -1.51 0.122 4.01 0.001 0/0 
Glycolysis and Gluconeogenesis 29/46 63.0 1.11 0.287 -2.35 0.022 3.85 0 0/0 
One Carbon Metabolism 21/29 72.4 1.9 0.049 -1.22 0.234 3.55 0.001 0/0 
Glucocorticoid & Mineralcorticoid Metabolism 7/11 63.6 0.58 0.566 -2.23 0.036 3.11 0.002 0/0 
Arachidonate Epoxygenase   Epoxide Hydrolase 3/3 100 1.57 0.113 -1.17 0.241 3.1 0.001 0/0 
Statin Pathway 13/17 76.5 1.79 0.086 -0.68 0.517 2.83 0.006 0/0 
Steroid Biosynthesis 8/12 66.7 0.82 0.437 -1.71 0.096 2.82 0.001 0/0 
Alanine and aspartate metabolism 8/12 66.7 0.82 0.423 -1.71 0.102 2.82 0.003 0/0 
Nuclear Receptors 19/38 50.0 -0.61 0.55 -3.11 0.001 2.67 0.003 0/53.8 
Eicosanoid Synthesis 11/18 61.1 0.53 0.588 -1.84 0.052 2.62 0.005 0/0 
Methylation 7/8 87.5 1.85 0.048 -0.38 0.687 2.58 0.005 0/0 
Glucuronidation 9/13 69.2 1.04 0.318 -1.23 0.234 2.55 0.008 0/0 
Amino acid conjugation of benzoic acid 2/2 100 1.28 0.224 -0.95 0.348 2.53 0.008 0/0 
Selenium metabolism/Selenoproteins 34/46 73.9 2.6 0.012 0.53 0.598 2.46 0.012 0/15.4 
Polyol pathway 3/4 75.0 0.81 0.396 -1.35 0.188 2.41 0.013 0/0 
Oxidative Stress 23/28 82.1 2.9 0.003 0.93 0.369 2.38 0.016 0/11.5 
Heme Biosynthesis 5/9 55.6 0.04 0.992 -2.02 0.052 2.24 0.021 0/0 
Aflatoxin B1 metabolism 3/5 60.0 0.23 0.867 -1.51 0.117 1.91 0.042 0/0 
Prostaglandin Synthesis and Regulation 21/29 72.4 1.9 0.044 1.19 0.222 0.92 0.317 0/0 
 
* Bold: significant p-value < 0.05. Genes found differentially expressed in the pathway (r) or measured in the dataset (n). Percentage of 
differentially expressed transcription factors (TF) in the pathway.   ** “…and expanded by STRING”. 
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3.5. Discussion 
Accumulated nitrogen metabolites (urea and creatinine as well as other unmeasured waste 
products), acids, potassium, and others are characteristics of the AKI syndrome among other 
effects such as decreased urine output (Bellomo et al., 2012). AKI commonly occurs in 
hospitalized or critically ill patients with a prevalence between 20% to 60% for patients at 
admission to the intensive care unit when sepsis is present (Bellomo et al., 2012). Toxin 
exposure, usually corresponding to nephrotoxic drugs, is among the three most common 
causes of AKI seen in humans (Yang et al., 2010). The other two major causes are ischemia, 
and urinary obstructions. 
An accepted model for toxin exposure is folic acid nephropathy which has also been reported 
in humans (Metz-Kurschel et al., 1990). Acute folate nephropathy causes reversible increase 
in serum creatinine and urea, tubular cell death, compensatory tubular cell proliferation, 
activation of an inflammatory response and eventual progression to mild fibrosis (Fang et al., 
2005; Doi et al., 2006; Ortega et al., 2006). Therefore, we employed a folic acid overdose 
induced animal model representative for toxic exposure AKI, in wild type and Gdf15 
deficient mice. In this study, we used an mRNA sequencing-based non-biased approach to 
elucidate driver gene expression determinants of biological processes and pathway 
mechanisms of AKI, as well as the Gdf15-associated tubular damage protection-related 
mechanisms. 
Most of the pathways previously known to be commonly involved in AKI could be 
confirmed with our transcriptomics approach, including a locally activated coagulation 
system, leucocyte infiltrates, inflammation, injured endothelium and expressed adhesion 
molecules, release of cytokines, induced toll-like receptor, vasoconstriction, transport activity 
and homeostasis, fibrosis, necrosis, and apoptosis (Table 5) (Bellomo et al., 2012; Vallon, 
2016). In addition, in most of these or related pathways we identified, possible transcription 
factors driving the gene expression response to AKI for both AKI- and Gdf15-associated 
responses (Table 5). Notably, transcription factors associated with Gdf15 deficiency are 
driving up-regulated pathways such as TNF-alpha NF-B Signaling Pathway, Primary Focal 
Segmental Glomerulosclerosis (FSGS), IL-3 Signaling Pathway, and Apoptosis (Table 5), 
whereas no Gdf15-associated transcription factor was identified for down-regulated pathways 
(Table5), suggesting a primary role of Gdf15 in the regulation of processes involved with 
proliferation, inflammation, necrosis, fibrosis, and apoptosis among other processes regulated 
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by these pathways. AKI also results in interstitial inflammation, development of fibrosis and 
the production of pro-fibrotic cytokines that depend on proximal tubule epithelial cells arrest 
in G2/M during the cell cycle (Yang et al., 2010). Bypassing the tubular cells G2/M arrest in 
murine AKI prevented the transition from AKI to CKD (Yang et al., 2010). Our results show 
an upregulation of cell cycle stage G2 genes (Supp. Figure S13). However, also other stages 
of the cell cycle showed upregulated genes (Supp. Figure S13). This is consistent with cell 
cycle arrest in some cells, thus promoting chronicity and cell cycle progression in other cells, 
resulting in possible recovery from injury. In addition, we observed that only AKI-associated 
transcription factors are modulating the up-regulated cell cycle pathway G1 to S cell cycle 
control (Table 5). However, in Gdf15 deficient mice, with a more severe AKI, this 
upregulation was not observed, suggesting a role of Gdf15 on the cell cycle arrest, directly or 
indirectly, that could have an impact in the protection or recovery after tubular damage (Yang 
et al., 2010). 
Using a proteomics approach on the same AKI mouse model, Husi et al., (2013) reported that 
signal transduction cascades in AKI end in kidney apoptosis and necrosis through the N-
methyl-D-aspartate (NMDA) receptor (Husi et al., 2013). mRNA-seq data correlated with 
many of the key upregulated proteins reported by Husi et al., 2013 (Supp. Figure S12). 
However, the expression of some genes was not similarly upregulated, or even inversely 
regulated compared to the proteins they encoded (Supp. Figure S12). Similar observations 
were previously reported by Poveda et al., 2016, where NFBiz, one of the most upregulated 
NFB-related genes during AKI, showed decreased protein levels, thus favoring chemokine 
production (Poveda et al., 2016). Messenger-RNA/protein level inconsistencies can be 
explained by per-transcript differences in transcript/protein relative expression abundance of 
17/50,000 on average, as well as different protein and transcript half-life values of average 
46h and 9h, respectively (Schwanhäusser et al., 2011). Possibly, taking into consideration 
each individual transcript and protein half-life as a metabolic response factor, the differences 
observed between transcript and protein at the same sampling point may simply reflect the 
differences in their metabolic rates. Further work is still required to characterize the cellular 
status and changes from the induction of AKI and its damaging mechanisms to the kidney, 
until the recovery of the renal function at both the transcriptomic and proteomic level. 
Overall, mRNA sequencing revealed the expression profiles associated with the generic AKI 
response of folic acid induced AKI mice, as well as the specific response of AKI as modified 
by Gdf15 deficiency. Furthermore, we identified the transcription factors associated to each 
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of these transcriptomes that are driving the generic and Gdf15-specific AKI trnscriptomic 
response. This information may be used to design novel therapeutic approaches for AKI. 
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3.7. Annex II: Supplementary material of Chapter 3 
 
 
Supp. Figure S1:  Sequence alignments of all RNA-seq samples, represented as coverage and spliced reads 
for the Gdf15 gene region. 
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Supp. Figure S2: Unsupervised hierarchical clustering of samples based on the top 10,000 expressed genes. 
Cluster strengths shown as approximately unbiased (AU), and bootstrap probability (BP) p-values in red and 
green, respectively. 
 
 
 
Supp. Figure S3: Heatmap of the top 100 expressed genes. Top clustered tree represents the grouping of each 
sample respective to the treatment received. 
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Supp. Figure S4: Heatmap of sample distances which can clearly discriminate between AKI responder and 
non-AKI responder samples. 
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Supp. Figure S5: GC content distribution of all sequenced samples. 
 
 
Supp. Figure S6: Gene count of a cluster of enriched processes that contain up-regulated genes in an AKI 
generic response. 
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Supp. Figure S7: Gene count of a cluster of enriched processes that contain down-regulated genes in an AKI 
generic response. 
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Supp. Figure S8: Gene count of a cluster of enriched processes that contain up-regulated genes in an AKI 
generic response that were previously associated with kidney disease terms. 
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Supp. Figure S9: Gene count of a cluster of enriched processes that contain down-regulated genes in an AKI 
generic response that were previously associated with kidney disease terms. 
 
 
 
Supp. Figure S10: Gene count of a cluster of enriched processes that contain up-regulated genes in a Gdf15-
specific AKI response. 
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Supp. Figure S11: Gene count of a cluster of enriched processes that contain down-regulated genes in a Gdf15-
specific AKI response. 
 
 
 
Supp. Figure S12: Gene expression visualization of the AKI pathway published by Husi et al, 2013. Left and 
right fill color represent the fold change observed in the dataset for WT and GDF15-KO mice comparisons, 
respectively (red up- and green down- regulated). Genes not expressed in the dataset are shown in grey, and 
genes expressed but not differentially expressed in yellow. 
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Supp. Figure S13: Expression profile visualization of the cell cycle genes. Left and right fill colors represent 
the fold change observed in the dataset for WT and GDF15-KO mice comparisons, respectively (red up- and 
green down- regulated). Genes not expressed in the dataset are shown in grey, and genes expressed but not 
differentially expressed in yellow. 
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4.1. Introduction 
 Analysis of renal biopsies combined with blood and urine parameters can be very informative 
for patients suffering from chronic kidney diseases (CKD). It can be used to determine 
disease stages and progression rates (Haider et al., 2014; Wouters et al., 2015). Further 
research is required to unravel risk factors for CKD progression (Wouters et al., 2015). 
Systems-wide and systems biology approaches can be beneficial to further evaluate the 
impact of different models and kidney damage outcomes (Wouters et al., 2015; Eikrem et al., 
2016). Even though fresh frozen biopsies would be an optimal source to perform this task, the 
availability of fresh-frozen tissue is limited compared to formalin-fixed, paraffin-embedded 
(FFPE) renal biopsies (Coudry et al., 2007; Hodgin et al., 2010; Eikrem et al., 2016). Biopsies 
are commonly fixed after extraction and further stored for sectioning and diagnosis of 
glomerular damage type. The strength of storing biopsies in FFPE is that these can be easily 
stored for long periods of time, allowing for large archives. The analysis of these archives 
would allow the characterization of large patient cohorts with many years of follow-up data 
collection. However, isolation of RNA species from FFPE material is still challenging due to 
chemical alterations and important RNA fragmentation (Masuda et al., 1999). Nevertheless, 
successful advances on isolating RNA from FFPE tissue have been reported (Coudry et al., 
2007; Hodgin et al., 2010; Eikrem et al., 2016), increasing the chances of success to analyze 
these archives. In addition, laser-capture micro-dissection (LCM) technologies showed to be a 
successful approach to separate and enrich for tissue parts (Isenberg et al., 1976; Emmert-
Buck et al., 1996; Coudry et al., 2007), allowing the isolation of RNA species from 
designated areas from any biopsy section, such as kidney glomeruli. Therefore, in this chapter 
we will assess the RNA sequencing of isolated total-RNA from LCMD glomeruli of FFPE 
biopsies. 
Many studies (n=961) have been reported using FFPE biopsies and microarrays for gene 
expression analysis. However, a lower number of studies (n=182) were also performed with 
LCM in their methodology or by RNA-sequencing (n=153). Only one4 study was found that 
1 PubMed query accessed in 13-01-2017: (FFPE OR ("formalin-fixed" AND "paraffin-embedded")) AND "gene 
expression" AND (biopsy OR biopsies) AND microarray) 
2 PubMed query accessed in 13-01-2017: (FFPE OR ("formalin-fixed" AND "paraffin-embedded")) AND "gene 
expression" AND (biopsy or biopsies) AND (LCM or "laser-capture") 
3 PubMed query accessed in 13-01-2017: (FFPE OR ("formalin-fixed" AND "paraffin-embedded")) AND "gene 
expression" AND (biopsy OR biopsies) AND (RNA-seq OR "RNA sequencing") 
4 PubMed query accessed in 13-01-2017: (FFPE OR ("formalin-fixed" AND "paraffin-embedded")) AND "gene 
expression" AND (biopsy OR biopsies) AND (LCM OR "laser-capture") AND (RNA-seq OR "RNA sequencing") 
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used an RNA-seq approach for dissected tissue using LCM techniques to profile lung cancer 
progression (Morton et al., 2014). Because of the low number of related publications, there is 
a relevant need to develop or improve RNA-seq methodologies for analyzing FFPE kidney 
biopsies, as well as isolated glomeruli obtained by LCM. Here, we show the validation results 
of standard RNA sequencing using libraries obtained from FFPE tissue. In addition, we tested 
this approach for RNA isolated from glomerular LCM and FFPE samples. 
4.2. Methods 
4.2.1. Validation of library preparation and sequencing protocols for FFPE material 
The performance of standard library preparation methods, such as NEBNext Ultra, for 
Illumina sequencing was evaluated for FFPE-tissue RNA. Total RNA was isolated at 
GenomeScan B.V. from 10 melanoma biopsies using Qiagen Allprep FFPE kit, and a mixture 
of RNA was prepared by equimolarly pooling. Dilution series from 200 ng to 1 ng were 
prepared to evaluate sequencing sensitivity. After rRNA depletion, cDNA libraries (NEBNext 
Ultra RNA-Seq kit) with dual indexing strategy were obtained. To compensate for the low 
input of lower dilution series, the number of PCR cycles was increased (Table 1). Library 
quality controls were performed to corroborate the expected library size (Fragment Analyzer) 
(Figure 1; Table 2). Sequencing was performed using a paired-end protocol on the Illumina 
Hiseq 2500 platform with SBS v4 reagents.  
 
 
Figure 1: Fragment Analyzer output of NEB RNA val rRNA dep FFPE 200. Due to already degraded RNA 
from FFPE and additional fragmentation this size differs from intact RNA. 
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Table 1: Concentration series phage Lambda using NebNext Ultra 
Input 200 ng 100 ng 50 ng 25 ng 10 ng 5 ng 2.5 ng 1 ng 
PCR cycles 8 9 10 11 12 13 14 15 
Size selection Y Y Y N N N N N 
 
Table 2: Quality control of library preparation metrics from Fragment Analyzer. 
Obtained reads in Fast-Q format were trimmed and filtered to remove sequencing adapters. 
Filtered reads were aligned to the reference genome sequence GRCh37.65 using Tophat 
v1.4.1 with the “--stranded-reverse” option, and with Bowtie v0.12.7. Alignments in standard 
alignment map format (S/BAM) were analysed using the RNA-SeQC v1.1.8 toolkit to retrieve 
RNA sequencing quality control measures (Table 3). In addition, specificity of the RNA 
sequencing library was determined by measuring read counts of features such as introns, 
exons and intergenic regions with Qualimap v2.0.1. Then, sensitivity of the dilution series 
was assessed by gene counts correlation using R software for statistical computing. Gene 
counts were calculated with HTSeq-count v0.5.4p5 and loaded to DESeq v1.10.1 R package 
for library size normalization. Finally, correlation matrix of r² values were calculated by 
fitting a linear model of log2 transformed normalized counts. 
Table 3: Number of rRNA reads, percentage rRNA reads, and number of detected genes in data set (FPKM > 1). 
4.2.2. Proof of principle of sequencing RNA from laser-capture micro-dissected 
glomeruli from kidney FFPE tissue 
Assessment of RNA sequencing for LCM glomeruli from FFPE tissue was performed using 4 
available nephrectomies (2 patients) or renal tumorectomies (2 patients) were provided by 
associated partner Fundación Jiménez Díaz (FJD) (Table 4). Uninvolved tissue parts from the 
Sample Input RNA (ng) ng/µl nmol/l Avg. size (bp) 
NEB RNA val rRNA dep FFPE 200 200 10.2 58.3 289 
NEB RNA val rRNA dep FFPE 100 100 3.3 17.3 310 
NEB RNA val rRNA dep FFPE 50 50 2.0 9.9 329 
NEB RNA val rRNA dep FFPE 10 10 1.6 8.0 329 
NEB RNA val rRNA dep FFPE 5 5 2.6 12.3 352 
NEB RNA val rRNA dep FFPE 1 1 2.0 11.1 302 
Sample Mapped reads rRNA reads % rRNA Genes found 
NEB RNA val rRNA dep FFPE 200 28,328,248 543,250 1.9 20,041 
NEB RNA val rRNA dep FFPE 100 18,629,113 201,774 1.1 20,000 
NEB RNA val rRNA dep FFPE 50 22,031,412 117,542 0.5 21,134 
NEB RNA val rRNA dep FFPE 10 19,872,319 206,189 1.0 17,317 
NEB RNA val rRNA dep FFPE 5 18,123,532 152,570 0.8 16,444 
NEB RNA val rRNA dep FFPE 1 15,215,216 622,437 4.1 9,111 
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tumorectomies can be considered as unaffected and were used to represent normal glomeruli 
(Hodgin, et al., 2010). Therefore, these samples contain fibrotic glomeruli and normal 
glomeruli, isolated from nephrectomies. To mimic the nature of kidney biopsies, only a piece 
of 2-3mm thick and 10-20 mm long was separated.  
 
Table 4: Selection of samples from kidney nephrectomies. 
Samples were processed for sectioning and LCM at the FJD. Sections of 5-6 µm were 
mounted on normal glass slides to be processed for LCM following adapted protocols for 
deparaffinization and staining for FFPE tissue (Table 4) (Hodgin et al., 2010; Grover et al., 
2012; Jackson et al., 2013). Deparaffinization was performed using xylene as it showed good 
results (Jackson, et al., 2013), and is recommended by Qiagen for their RNA isolation kits 
(Table 5). Cresyl violet staining was used to identify cellular types as it was shown to be less 
aggressive with RNA species for further RNA isolation (Grover et al., 2012). Then a Cresyl 
Violet Acetate staining procedure was adapted from Grover et al., (2012) (Table 5). 
Dissection of fibrotic and normal glomeruli was performed at the FJD using the inverted 
microscope (Zeiss) with UV-A laser and PALM capture system. Then, the isolation of RNA 
was performed using a commercially available kit from Qiagen (RNeasy FFPE) following the 
manufacturer’s protocol. Finally, the sequencing library to be sequenced on an Illumina 
HiSeq 2500 platform, was prepared using the same NEBNext Ultra protocol used for the 
validation of the library preparation and sequencing protocols for FFPE material. 
Read sequences in FastQ format for each of the 4 samples were trimmed to remove 
sequencing adapter using Trimmomatic v.0.30. Then, reads were aligned to the human 
reference sequence version GRCh38.p2 using TopHat v.2.0.14 with default parameters except 
for “--library-type fr-firststrand”, and with Bowtie aligner v.2.1.0. The alignment outputs in 
S/BAM format were sorted and indexed using Samtools v.1.2. Alignment quality metrics 
were collected using Qualimap v.2.0.1, and RNA-SeQC v.1.1.8. RNA feature counting was 
performed using HTSeq-counts v.0.6.1p1 for stranded libraries against the annotated features 
of the human genome in GTF format for the reference version GRCh38.p2.  
Sample ID 
Age 
(years) 
Gender 
Serum creatinine 
(mg/dl) 
eGFR 
(ml/min/1.73 m2) 
Obstruction Type Fibrosis 
7045-01-01 58 Woman 0.6 >60 No Nephrectomy Non-Fibrotic 
7045-01-02 67 Woman 0.9 >60 No Nephrectomy Non-Fibrotic 
7045-01-03 72 Woman 6.7 Dialysis No Nephrectomy Fibrotic 
7045-01-04 74 Woman 1.32 41.8 No Nephrectomy Fibrotic 
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Table 5: LCM slide preparation protocols 
4.3. Results 
4.3.1. Validation of library preparation and sequencing protocols for FFPE material 
RNA sequencing libraries obtained from FFPE tissue showed an average insert size was a bit 
lower than usually expected for RNA sequencing (400 bp), but within the acceptable value 
ranges (200 - 700 bp) (Table 2). Overall, the total number of reads sequenced, on average 
38.7M, were reduced by 17%, on average during the filtering and trimming steps. On average 
20M reads (63%) were uniquely mapped to the human reference genome sequence 
GRCh37.65 (Table 6). Samples with input material ≥ 50 ng showed the higher percentages of 
mapped reads, whereas samples with 1 ng as input material showed the lowest (Table 6). 
Presence of ribosomal RNA carry over in the libraries was below 2% in most of the samples 
and 4% for the lowest input material of 1 ng (Table 3). All samples however, show a similar 
Step Deparaffinization. 
1 Mount sections onto the membrane slides. 
2 
Dry the slides at 56˚C. (overnight recommended if tissue sections are mounted by floating in warm DEPC-
treated water) 
3 Bake at 60˚C for 1-10 minutes to finish melting paraffin (1-2 minute recommended after overnight drying) 
4 
Deparaffinize with xylene (minimum 2 minutes and twice; maximum 15 minutes in total if Membrane 
Slides 1.0 PEN are used) 
5 Wash with 100% ethanol, 1-2 minutes, twice, to remove excess of xylene. 
7 
Dry the slides shortly, 1-2 minutes, by leaning them against an RNase-free support on a lint-free absorbent 
paper. 
6 
Storage point. After drying, slides can be stored at -80˚C in an appropriate sealed RNase-free slide box with 
silica gel. 
 Staining solution* 
1 Dissolve 4% w/v Crystal Violet Acetate in 70% ethanol. 
2 Agitate the staining solution for several hours to overnight at room temperature. 
3 Filter to remove unsolubilized dye powder. 
 Slide staining* 
1 Without thawing the slides, transfer them to 100% ethanol for 30 seconds. 
2 95% ethanol for 30 seconds. 
3 75% ethanol for 30 seconds. 
4 70% ethanol for 30 seconds. (slightly agitate the slides to dissolve possible polar soluble used compounds) 
5 Stain with a dilution of 4% cristal violet in 70% ethanol for 30 seconds. 
6 70% ethanol for 30 seconds. (slightly agitate to help remove excess of staining dilution) 
7 75% ethanol for 30 seconds. 
8 95% ethanol for 30 seconds. 
9 100% ethanol for 30 seconds. 
10 Repeat the 100% ethanol for 30 seconds. 
11 
Dry the slides shortly, 1-2 minutes, by leaning them against an RNase-free support on a lint-free absorbent 
paper. 
12 Storage point. Slides can be stored at -80˚C in an appropriate sealed RNase-free slide box with silica gel. 
*Staining protocols adapted from (Grover, et al., 2012) 
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distribution of reads among exonic, intronic and intergenic regions, being 23%, 61% and 16% 
on average, respectively (Table 7).  
Table 6: Amount of raw, filtered and mapped reads and percentage of reads mapping of filtered reads. 
 
Table 7: Distribution of reads within genome annotation features. 
 
The number of genes detected, was over 20,000 for samples above 50 ng of input material 
(Table 3). However, decreasing input material detected lower number of genes until 1 ng 
which showed the lowest with only 9,111 genes detected (Table 3). The number of genes 
detected for each dilution of input material showed a correlation of over 0.93 r² for input 
higher than 50 ng (Table 8). However, lower amounts of input material show increasingly 
lower sensitivity up to 0.55 - 0.59 r² of the 1 ng dilution. 
Table 8: FFPE sample correlation r² for each level of input concentration 
4.3.2. Proof of principle of sequencing RNA from laser-capture micro-dissected 
glomeruli from kidney FFPE tissue 
Using LCM on kidney tissue sections for all 4 samples, we obtained an average of more than 
45 (n=9 to 66) glomeruli cross-sections (Table 9). RNA quality obtained from the isolated 
RNA of glomeruli cross-sections was <2.1 RIN score, which produced an RNA sequencing 
Sample Raw reads Filtered (%) Mapped (%) 
NEB RNA val rRNA dep FFPE 200 51,885,558 44,541,316 86 28,328,248 64 
NEB RNA val rRNA dep FFPE 100 31,670,180 27,210,978 86 18,629,113 69 
NEB RNA val rRNA dep FFPE 50 37,199,686 31,820,052 86 22,031,412 69 
NEB RNA val rRNA dep FFPE 10 37,128,894 30,554,342 82 19,872,319 65 
NEB RNA val rRNA dep FFPE 5 33,817,000 27,422,216 81 18,123,532 66 
NEB RNA val rRNA dep FFPE 1 40,463,678 32,287,048 80 15,215,216 47 
Average 38,694,166 32,305,992 83 20,366,640 63 
Sample exonic  (%) Intronic  (%) intergenic  (%) 
NEB RNA val rRNA dep FFPE 200 3,136,835 23% 7,722,838 56% 2,885,282 21% 
NEB RNA val rRNA dep FFPE 100 2,975,700 23% 7,859,929 62% 1,882,487 15% 
NEB RNA val rRNA dep FFPE 50 4,337,096 24% 11,957,265 65% 2,096,065 11% 
NEB RNA val rRNA dep FFPE 10 3,479,145 23% 9,744,110 65% 1,832,929 12% 
NEB RNA val rRNA dep FFPE 5 3,282,375 23% 9,181,771 65% 1,738,987 12% 
NEB RNA val rRNA dep FFPE 1 859,298 22% 2,107,400 54% 971,243 25% 
Average 3,011,742 23% 8,095,552 61% 1,901,166 16% 
Dilution of correlated samples: 200 100 50 10 5 1 
NEB RNA val rRNA dep FFPE 200 1      
NEB RNA val rRNA dep FFPE 100 0.95 1     
NEB RNA val rRNA dep FFPE 50 0.93 0.93 1    
NEB RNA val rRNA dep FFPE 10 0.86 0.86 0.85 1   
NEB RNA val rRNA dep FFPE 5 0.84 0.83 0.82 0.78 1  
NEB RNA val rRNA dep FFPE 1 0.59 0.58 0.57 0.56 0.55 1 
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library with an expected average size of ~300 bp (287-343 bp) (Table 9). However, the 
overall signal was very low (Figure 2) when compared to the overall signal obtained from the 
validation of FFPE sequencing (Figure 1). In addition, samples 2, 3 and 4 showed an 
unknown/unexpected signal with three peaks around 212 bp (Figure 2). 
 
Table 9: LCM stats, and QC for the RNA isolation and library preparation. 
Sample ID # cross-sections pg / µl / # µm2 N cells*  pg/µl RIN  ng/µl nM/l Avg. Size 
7045-01-01 66 35.12 1,309,391 10,054  2,318 2.1  0.7458 3.576 343 
7045-01-02 42 15.48 429,324 3,424  650 1  3.414 17.716 317 
7045-01-03 9 69.78 209,932 1,771  628 1  1.0624 6.863 255 
7045-01-04 65 2.431 1,537,360 11,771  158 1  0.5177 2.965 287 
 LCM  RNA QC  Library QC 
 
*Number of cells was estimated using cell diameter 13 µm. 
 
 
 
To evaluate the biological information retrieved from this RNA library preparation, we 
sequenced the libraries at low depth on a HiSeq2500 sequencer. We processed the reads as 
described above and extracted the gene/exon information by alignment against the human 
reference sequence. Overall, we obtained between 250,552 and 502,687 reads (Table 10). The 
maximum alignment percentage was 25% for sample 1, and lower for other samples (3-8%) 
(Table 10). Feature counting of mapped reads also shows low percentage of exonic reads, 
from ~1% to ~4% with sample 1 showing the highest percentage and sample 3 the lowest 
exonic percentage. 
 
 
Figure 2: Fragment analyzer signal for RNA isolated from glomeruli cross-sections. 
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Table 10: Feature contribution of aligned low-depth sequenced reads. 
4.4. Discussion 
A common procedure applied to renal biopsies is to be FFPE after the extraction to facilitate 
the storage, and sectioning for the diagnosis of the glomerular damage type. This also 
contributes in increasing the FFPE archives that could be used for research purposes in 
detriment of the scarce availability of fresh-frozen tissue (Coudry et al., 2007; Hodgin et al., 
2010; Eikrem et al., 2016). In this chapter, we evaluated the requirements for RNA 
sequencing of isolated material from FFPE tissue, to assess future possibilities of 
characterizing large patient cohorts with many years of follow-up data such as the cohorts 
potentially available from FFPE archives. It was known that the RNA isolated from FFPE 
material was the remnant of significant fragmentation and chemical alterations and a 
challenge for sequencing (Masuda et al., 1999). However, despite the limited quality of the 
RNA, we successfully quantified gene expression profiles from FFPE samples, clean of the 
interference of ribosomal RNA (<4%) (Table 3). These results show an increased sensitivity, 
when compared to similar work performed using microarray approaches (Hodgin et al., 2010; 
Mittempergher et al., 2011). We could observe the most probable effects from the degradation 
and chemical alterations of the FFPE procedures in the form of a reduction of the overall 
mapping observed (63% on average) (Table 6). In addition, the proportion of exonic mapped 
reads (23%) in conjunction with the proportions of intronic (61%) and intergenic (16%) 
mapped reads (Table 7), suggests a high proportion of carryover DNA material, most likely 
originating from the cross-linking in formalin between RNA and DNA molecules. The 
possibility of identifying interferences caused by degradation-associated FFPE effects may 
provide more accurate gene expression profiles than with other hybridization-based methods 
such as QPCR or microarrays. In addition, with the exposed methodology setup, we can 
suggest 50ng as the minimum input material required for an accurate quantification of 
expressed genes (>0.93 r2) (Table 3; Table 8). 
In renal diseases, the evaluation of glomerular lesions can be very informative to determine 
disease stages and progression rates (Haider et al., 2014; Wouters et al., 2015). The 
Sample ID # reads # aligned # exonic # no feature No feature % intronic % intergenic 
7045-01-01 250,552 64,731 (25.8%) 1,044 (4.17%) 63,687 25.42% 13.04% 12.38% 
7045-01-02 481,723 24,897 (5.2%) 403 (0.84%) 24,494 5.09% 2.78% 2.30% 
7045-01-03 334,883 11,779 (3.5%) 234 (0.70%) 11,545 3.45% 1.83% 1.61% 
7045-01-04 502,687 40,945 (8.1%) 798 (1.59%) 40,147 7.99% 4.57% 3.42% 
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enrichment and analysis of glomerular RNA showed to be a promising source of information 
to facilitate the diagnosis of glomerular lesions (Hodgin et al., 2010). By applying a similar 
approach as in the validation of RNA sequencing from FFPE material, we evaluated the 
possibility of profiling glomeruli’s RNA expression using LCM to assess expression 
differences between fibrotic and normal glomeruli. The number of glomeruli cross-sections in 
the majority of samples was sufficient to obtain a good representation and confident gene 
expression profiles, while minimizing possible biases and tissue heterogeneity (>20 cross-
sections; Table 4) (Hodgin & Cohen, 2010). Nevertheless, the sequencing information that 
could be extracted from these samples was almost null in terms of overall alignments and 
proportion of mapped exonic reads (Table 10). This might be due to the combination of low 
quantity and poor quality of the RNA that was isolated from the FFPE material (Table 9). 
Even sample one that showed the highest RNA integrity score (RIN 2.1) and concentration 
(2.3ng/µl) could not provide results comparable to previous work performed by Hodgin et al, 
2010 using a similar approach with microarray technology. The low proportion of overall 
mapping (<25.8%) and exonic mapping (<4%) (Table 10), when compared to the results 
obtained for the validation of FFPE sequencing (63% and 23%, respectively), suggests that 
further work may be needed for accurately profiling the RNA expressed from LCM 
glomeruli, including extra tuning of the LCM and RNA isolation protocols. 
In conclusion, we showed that gene expression profiling from FFPE samples is possible using 
RNA sequencing. However, additional work will be required to obtain reliable expression 
profiles from the low-quantity and low-quality RNA that is typically obtained when LCM is 
performed on glomeruli from FFPE kidney biopsies. 
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Chapter 5 
5. General Discussion 
Parts of this chapter were adapted from Daniel M. Borràs1 and Bart Janssen1 - “The use of 
transcriptomics in clinical applications.” (under revision). 
1GenomeScan B.V., Pleasmanlaan 1d, Leiden 
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5.1. Future trends of sequencing technologies in diagnostics 
In recent years, the number of research projects that included NGS as part of their approach 
has exponentially increased (Figure 1). The advancements in sequencing technologies and 
new approaches, as well as their increased accuracy and quality of data obtained facilitated 
this trend. A similar trend is also observed for those clinical publications that use NGS, 
however, with an expected delay in time (Figure 1). Finally, despite the very low numbers of 
publications reported that were using NGS in the field of kidney research, a significant 
proportion of them (76/178 in 2015) were oriented towards clinical research and diagnostics 
(Figure 1). Because of the continuous decrease of the sequencing costs observed in recent 
years, we hypothesize that the use of NGS for molecular testing will most likely keep 
increasing in the incoming years. Hence, the work presented in this thesis can aid in setting 
up the path towards a near future of NGS in clinical research. 
 
Figure 1: Number of yearly publications from 2000 to 2016 obtained using PubMed (16/03/2017) queries for:  
NGS “(NGS OR (next generation sequencing)) NOT (microarray OR micro-array)”; NGS and diagnostics 
“(NGS OR (next generation sequencing)) NOT (microarray OR micro-array) AND diagnostic”; Kidney and 
NGS “(NGS OR (next generation sequencing)) NOT (microarray OR micro-array) AND (renal OR kidney OR 
nephrology)”; and Kidney and NGS and diagnostics “(NGS OR (next generation sequencing)) NOT 
(microarray OR micro-array) AND diagnostic AND (renal OR kidney OR nephrology)”. In 2015, the total 
number of publications reported in the field of kidney diagnostics was 19,843, only 178 used NGS in kidney 
research, and 76 used NGS in kidney research oriented to diagnostics. 
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5.2. Long-read sequencing approaches for improved resolution and 
characterization of complex regions for diagnostics 
The advances of sequencing technologies, particularly in the direction of longer and more 
accurate reads, manifested the existing technical limitations of short-read sequencing, 
showing that for the resolution of complex regions in the reference human genome the 
required read length was estimated to be over 2000 bps (Lee and Schatz, 2012). In the case of 
PKD1, showcased in this thesis, current sequencing technologies used for the molecular 
testing in this complex gene include Sanger sequencing or newly developed short-read NGS 
approaches. Unfortunately, neither Sanger nor short-read NGS fulfil this >2000bps read 
length criterium. Hence, their power of resolution to resolve complex regions - which is the 
case for PKD1 gene - is insufficient as discussed in Chapter 2. The use of long-read 
approaches showed to be of value in many research studies when applied to resolve complex 
genetic situations, either previously known, or unknown, such as (1.) the reconstruction, 
resolution, and re-assembly of complex regions of the reference human genome including the 
closure of gaps (Chaisson et al., 2014; Huddleston et al., 2014; Steinberg et al., 2014); (2.) 
the characterization of entire gene families of complex genes for non-model or 
uncharacterized genomes (Larsen et al., 2014); (3.) the development of functional 
microsatellite markers (Grohme et al., 2013; Wei et al., 2014); (4.) the resolution of the 
highly repetitive, and complex central exon of MUC5AC, previously reported as an unknown 
region, or gap (Guo et al., 2014); (5.) the characterization and full resolution of the 100% 
GC-rich repeat region, and the mutation ranges of fragile X causing mutations in FMR1 gene 
(Loomis et al., 2013). All these, are clear examples of the need for long-read sequencing data, 
which show minimal or very low reference bias, as well as low or no bias for high GC/AT 
regions and repetitive sequences. 
Table 1: Medically relevant genes with inaccessible coding regions (problematic for short-read sequencing)*. 
 
 
Target region # individuals 
Known genes 
(RefSeq, 22364 genes) 
Medically relevant genes 
(ClearSeq IDP**, 3317 genes) 
Not properly 
covered 
(Depth* ≤8) 
Genome wide 
100% 1,404 (6.3 %) 63 (1.9 %) 
≥22% 5,375 (24 %) 362 (11 %) 
Exonic 
100% 412 (1.8 %) 52 (1.6 %) 
≥22% 2,069 (9.3 %) 307 (9.3 %) 
*Genome wide number of genes with poorly covered regions obtained from a published nine individual dataset by 
Sun et al., Human Mutation 2015. 
**ClearSeq Inherited Disease gene panel (Agilent Catalog, SureSelect DNA, design ID S0684402). 
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The accessibility and resolvability of genomic regions, particularly for medically relevant 
genes, are of importance for the accurate development of diagnostic applications. Coding 
regions (exons) in the human genome that are not well represented (covered) when using 
short-read NGS data can be defined as inaccessible regions (Table 1) (Sun et al., 2015). Many 
inaccessible regions are inaccessible because of high GC content. Inaccessible regions tend to 
overlap with the so-called unresolvable regions. These, usually include repetitive regions and 
low complexity sequences of the reference genome such as segmental duplications (SD), 
simple repeats (SR) or other repetitive elements, as well as high GC/AT content regions and 
also gaps (Table 2) (Figure 2). The gaps in the human reference sequence are usually 
complex regions that have simply not been resolved and therefore remain unknown (Chaisson 
et al., 2014; Huddleston et al., 2014; Steinberg et al., 2014) (Guo et al., 2014). The 
combination of segmental duplications, high GC-content, and/or repetitive elements impedes 
unique alignments against the reference sequence. Therefore, affecting the sequencing depth 
of short-reads in these regions because of the low mapping quality (Figure 2). Within all 
these inaccessible and unresolvable coding regions, we find some disease-associated genes 
that are routinely screened in diagnostic procedures (Figure 3). If the gene of interest lies 
within an inaccessible or unresolvable region, the use of short-read sequencing approaches 
would reduce the chances of resolving genetic variants that may be potentially pathogenic. 
Table 2: Medically relevant genes with repetitive elements potentially unresolvable by short-read 
sequencing. 
  
Known genes 
(RefSeq, 22364 genes) 
Medically relevant genes 
(ClearSeq IDP**, 3317 genes) 
Segmental Duplications ≥ 1 kbps 2,532 (11.3%) 699 (21%) 
Simple Repeats 
≥ 0.1 kbps 1,428 (6.4%) 462 (14%) 
≥ 1 kbps 360 (1.6%) 218 (6.60%) 
Repeats* 
≥ 0.1 kbps 2,290 (10.2%) 667 (20%) 
≥ 1 kbps 344 (1.5%) 270 (8.10%) 
*Repetitive element RepeatMasker track. 
**ClearSeq Inherited Disease gene panel (Agilent Catalog, SureSelect DNA, design ID S0684402). 
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Recently developed NGS-based (short-reads) diagnostic approaches for ADPKD showed 
95% - 100% sensitivity and specificity when compared to standard diagnostics using Sanger 
combined with multiplex ligation-dependent probe amplification (MLPA) (Eisenberger et al., 
2015; Trujillano et al., 2014; Tan et al., 2014). However, the comparison between two 
diagnostic approaches that both could suffer from lower resolution because of the use of 
short-reads does not demonstrate the true diagnostic performance of either of these 
approaches. When taking into consideration all patients included from a cohort, including the 
ones that could not be accurately genotyped, the diagnostic performance reported by newly 
developed short-read NGS methods could only provide a clear diagnosis for 115 out of 183 
(Rossetti et al., 2012), 16 out of 25 (Tan et al., 2014), 10 out of 12 (Trujillano et al., 2014), 35 
out of 55 (Eisenberger et al., 2015), and 24 out of 28 (Mallawaarachchi et al., 2016) screened 
ADPKD patients. The methodological sensitivity and specificity reported was >97% (97% - 
100%) when comparing the NGS-based results with the results of the standard Sanger-based 
diagnostics (Rossetti et al., 2012; Tan et al., 2014; Trujillano et al., 2014; Eisenberger et al., 
2015; Mallawaarachchi et al., 2016). This high sensitivity and specificity suggests that short-
read NGS-based ADPKD diagnostics approaches are strongly comparable to Sanger-based 
ADPKD diagnostics. However, it also shows that both approaches have the same technical 
limitations, namely short reads, and were not fully able to overcome the high complexities of 
the PKD1 gene loci. 
An enhanced resolution of complex regions of the reference human genome allowed the 
closure of gaps, and the reconstruction of low complexity sequences that was only possible 
using long-read sequencing (Chaisson et al., 2014; Huddleston et al., 2014; Steinberg et al., 
2014). Reduced mappability of NGS short-reads interfere with the variant calling algorithms, 
producing undesired false positives and negative calls (Lee and Schatz, 2012). The results 
shown in Chapter 2 about PKD1 diagnostics led to our proposal of a long-range PCR (LR-
PCR) targeted approach to sequence long-read amplicons for PKD1 and PKD2 genes using 
SMRT sequencing approach with the PacBio RSII platform. The proposed pipeline is still at 
early stages of development and will require to be further validated with a larger cohort of 
ADPKD patients. However, we showcased that a reliable diagnostics approach that can 
resolve complex genetic setups is required, indispensable, and possible for clinical 
applications. We believe that this is the very beginning of a new era of long-read diagnostics 
for complex genetic regions. In addition, long-read approaches may probably also replace  
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some other established diagnostic approaches simply because of the increased value for 
haplotyping, identifying large insertion/deletion breakpoints, as well as the low or no 
reference-biased variant calls that the majority of short-read approaches cannot currently 
offer. Some examples of the benefits of long-read sequencing for medically-relevant complex 
genes include: (1.) human leucocyte antigen (HLA) genotyping (Mayor et al., 2015); (2.) 
FMR1 expanded CGG-repeat haplotyping (Loomis et al., 2013); (3.) genotyping of MUC5AC 
central exonic gap, including SNVs, SNPs, CNVs, and SDs (Guo et al., 2013). 
5.3. RNA sequencing and system approaches for the identification and 
screening of disease biomarkers in complex diseases 
 Omics approaches when applied into clinical research and diagnostics, despite being quite 
costly, may be used to replace multiple tests of individual biomarkers. These individual 
biomarker tests would be required in increased numbers if these global approaches would not 
be available. Wide or global approaches such as RNA-Seq can screen for multiple disease 
determinants in a single run and obtain information on the cause of the disease as well as on 
the potential response to treatments among other factors. However, these wider screening 
approaches are still not commonly preferred over single gene PCR tests. The use of PCR for 
monitoring one or several genes is definitely cheaper than a complete expression profiling in 
the terms of price per sample. However, when considering the price per gene screened and 
the quality and quantity of information obtained, RNA-Seq offers a significant advantage. For 
instance, a 1 tier Fluidigm (multiple reaction RT-qPCR based platform) assessing 90 
transcripts would cost 22 Euro (25$) per sample or 0.24 Euro (0.27$) per gene (adapted from 
Chaussabel 2015), while an mRNA-Seq would cost under 400 Euro per sample but less than 
0.04 Euro per gene, considering that RNA-Seq potentially yields thousands of genes (Chapter 
1, Table 8). In addition, RT-qPCR-based measurements will provide only the signal referent 
to one single exon or region while RNA-seq would provide signal for the entire gene 
structure including splicing isoforms and presence of exon variants. Reducing the complexity 
of disease diagnostics towards a few key genes may reduce the immediate costs of the 
clinical assay. However, the cost of NGS is and will keep decreasing with the advances and 
developments of new sequencing chemistries and platforms, making NGS approaches even 
more affordable and accessible in the future, e.g. the latest high-throughput sequencer 
NovaSeq 6000 announced by Illumina. 
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RNA-Seq approaches have the potential to be widely applied in clinical research and 
molecular testing since they are reliable and reproducible (Chaussabel, 2015). Given the mass 
of available knowledge about the human genome and disease biomarkers, sequencing 
approaches should be considered as a potential option for the future development of clinical 
research and diagnostic assays. Some examples of the evolution of clinical research based on 
NGS approaches show their potential towards the development of personalized medicine. 
Renkema et al., (2014) reviewed several applications for chronic kidney disease (CKD) 
highlighting that NGS-based DNA genetic testing can reduce the costs and turnaround time 
in diagnostics of steroid resistant nephritic syndrome and autosomal dominant polycystic 
kidney disease (Renkema et al., 2014). The authors emphasize on the need of WGS 
approaches to identify nephronophthisis causative genetic variants due to oligogenic 
inheritance for genes such as NPHP2, NPHP3, and AHI1. In addition, NGS approaches 
allowed researchers to achieve a greater understanding of diseases and the pathogenesis of 
genetic disorders. Systems biology approaches that integrate data from various sources could 
also be used to screen for potential drug targets, for instance ADPKD animal models were 
used as an example to determine efficacy of vasopressin receptor V2 antagonist (Renkema et 
al., 2014). Using also a system wide unbiased RNA-seq approach, we showcased in Chapter 
3 that the analysis of expression profiles of AKI mice kidneys could be very informative to 
characterize one of the three most common causes of AKI observed in humans, which 
include ischemia, toxic exposure and obstruction (Yang et al., 2010). Overall, given the latest 
tendency of clinical research towards the advancement of personalized medicine approaches, 
we may predict an increase of research projects to develop system-wide and omics-based 
clinical applications. Several studies were recently reviewed by Chaussabel., (2015) to 
provide a detailed vision of the perspectives of some omics approaches, in particular for 
blood transcriptomics, in clinical research and diagnostics. Applications reviewed included 
neurological disorders (Autism and Alzheimer), organ transplant rejection and risks signature 
genes (liver, heart, kidney and bone marrow), and a wide variety of different affections such 
as exposure of environmental factors, respiratory diseases, allergy, stroke, infections, and 
diabetes among others. The use of system-wide and omics approaches such as blood 
transcriptomics showed to be beneficial in clinical research in terms of types of diseases that 
can be characterized, diagnostic tests developed, and potential therapeutic targets identified. 
In Chapter 3 we discussed the example of an unbiased RNA-seq approach to characterize 
renal diseases such as AKI. The results obtained using this approach could identify gene 
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trends and pathways activated independently for each different condition (Chapter 3, Table 
5). The transcription factor signature identified could be considered for further research as a 
potential AKI driver, and become key to the identification of AKI therapeutic targets 
(Chapter 3, Table 3; Chapter 3, Table 4). 
Other global approaches such as the current versions of genome wide gene expression 
microarrays, despite an improved and reasonably accurate probe design, still rely on the 
hybridization of fluorescent DNA to “quantify” expression. DNA hybridization methods are 
known to produce some background noise that can interfere with the true signal. There have 
been several studies and reviews that address this topic while comparing different 
technologies in terms of throughput, accuracy, cost and efficiency. For instance, Marioni et 
al., (2008) assessed the technical differences between micro-array technology and RNA-Seq. 
Despite the decent high throughput set-up that micro-arrays offer, the authors highlight the 
implicit high background noise of micro-arrays due to cross-hybridization. The methodology 
for controlling this noise in addition to the differences in the design of the hybridization 
probes makes micro-array results almost impossible to combine with other types of 
experiments (Marioni et al., 2008). This effect is mitigated in NGS approaches which showed 
much higher resolution, fewer artifacts, greater coverage, and a wider dynamic range than 
micro-arrays (Park, 2009). These factors as well as many other characteristics of microarray 
technology and RNA-Seq have been extensively compared and reviewed since the release of 
RNA-Seq in 2009 (Marioni et al., 2008; Mimura et al., 2014; Wang et al., 2009). It must be 
emphasized that the detection of low abundance transcripts could only be accurately 
performed by using RNA-Seq technology (Brennan et al., 2012). This, as well as the ability 
to sequence unknown regions makes sequencing approaches more sensitive and complete 
than micro-arrays, detecting many more differentially expressed genes (>25% more) in the 
case of RNA-seq (Sultan et al., 2008). Since RNA-seq gene quantification is based on the 
sequence alignments and not on hybridization fluorescence signal, the analysis of gene 
construct models with RNA-seq, such as Gdf15-KO mice analyzed in Chapter 3, can provide 
much increased precision and validation of the functionality of the Gdf15-KO construct 
(Chapter 3, Figure 1; Chapter 3, Supp. Figure 1). Our results show that the expression of 
aberrant transcripts, such as in the Gdf15-KO, would have passed completely unnoticed with 
a hybridization-based expression profile, such as microarrays, most likely leading to 
undesired false results or conclusions. Microarrays are still widely used in clinical research 
and diagnostics, and will most likely still have a complementary role in wider systems- or 
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omics-based applications (Schumacher et al., 2015). We showed that the use of global omics 
approaches such as RNA-seq showed increased potential to characterize complex diseases 
such as AKI. In particular, if the transcripts analyzed express different isoforms and 
haplotypes, and even more if the sequences of these transcripts are not well annotated or 
simply unknown. The development of future clinical research and diagnostic tests will 
certainly benefit from the quantity and quality of the information obtained using RNA-seq 
approaches in a single run. The molecular testing of AML can be considered a clear example 
of the future of RNA-seq in clinical diagnostics (Griffioen et al., 2016). 
Global omics-based NGS procedures have sufficient throughput and sensitivity to identify 
system-wide DNA modifications, even those ones that were not intended to be screened for. 
These unsolicited findings opened some discussions about the ethical and practical aspects of 
reporting these analysis results. If system-wide approaches are to be developed and 
implemented in the diagnostic field, the information obtained, and provided to the patient 
would require some previous filtering. However, the distinction between what are relevant 
intended findings and relevant but unsolicited findings should be drawn by the patient with an 
educated consent. We believe that information and transparency is crucial to provide the 
necessary environment for decision making. In the end, adequately informed patient that 
knows about the analysis test performed and the results that could be obtained will consent to 
receive the level of information requested (Bijlsma et al., 2016). 
5.4. Sample and data archives for improved clinical research 
Sample availability, is usually limited in the case of human tissue, and much more for fresh-
frozen tissue samples. This makes the process of sample selection a key step for the correct 
understanding of tissue associated biological processes. Blood samples, among other 
biofluids such as saliva, are one of the easiest tissue samples to obtain (Devonshire et al., 
2013). Many studies have been performed with blood samples to detect biomarkers and 
molecular determinants. However, the differentially expressed transcripts detected in tissue 
may be underrepresented in blood or only detectable in later disease stages (Chen and 
Snyder, 2013). Despite these drawbacks, there are successful studies that characterized blood 
samples using transcriptomics, for instance in immunological diseases (Chaussabel, 2015). 
Other types of biofluids may also be easily obtainable making them an interesting target 
source for many researchers that want to develop new diagnostics tools using these non-
invasive tissue sources such as saliva or urine (Devonshire et al., 2013; Suthanthiran et al., 
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2013). Most tissue sample types are either not that easily accessible such as heart, liver and 
other internal organ samples, or completely unavailable such as brain tissue. If sample 
availability is scarce, it makes the switch towards global analysis or omics approaches even 
more necessary since all information, such as genes, variants or proteins, expressed in such 
samples would be measured at once. If this approach were to be applied as routine diagnostic 
tests, it would serve two purposes: (1.) to perform the required diagnostics for the patient at 
the moment of the test; (2.) provide a wider overview of the patient status that could be stored 
in a database and used for future research, if the patient provided explicit consent. It is 
common practice for tissue biopsies to be formalin-fixed and paraffin-embedded (FFPE) to 
maintain tissue structure for sectioning, and for long term storage. This provides large 
amounts of samples in FFPE archives that could be used for research purposes and 
compensate for the scarce availability of fresh-frozen tissue. The possibility of analyzing 
these large FFPE sample archives, with many years of follow up data, would facilitate larger 
clinical studies with improved statistical power (Chen and Snyder, 2013). The use of omics 
approaches to analyze large FFPE archives would make a difference for those complex 
diseases where sample numbers are limited, as well as providing the time required for the 
collection of rare disease samples. However, as discussed in Chapter 4, the sequencing of 
FFPE samples is still challenging. 
When the total RNA is extracted from a biological sample we must take into consideration 
that its cell composition is an important source of variability. Tissue samples, for instance, 
contain different cell types that will express their own gene repertoire. For RNA-seq, the 
sample mRNA composition may also be influenced by internal, and external factors (i.e. 
nutrition, circadian stage, cellular cycle, stress, exercise or disease state). Sasagawa et al., 
showed that single cell transcriptome analysis using RNA-Seq was able to identify and 
quantify non-genetic cellular heterogeneity, and even differentiate cell types and cell cycle 
phases of a single cell type (Sasagawa et al., 2013). Therefore, it is important to use 
appropriate methods for targeted cell type enrichment, if possible, such as laser capture micro 
dissection (LCM) for selecting tissue areas from tissue slides, cell sorting for enriching the 
cell fraction of interest, or centrifugation for separating the desired cell population (Todd and 
Kuo, 2002; Taussig et al., 2010; Devonshire et al., 2013; Sasagawa et al., 2013; Gutierrez-
Arcelus et al., 2015). the results presented in Chapter 4, showed that human kidney biopsies 
may have too few glomeruli. Nevertheless, these results showed that it is possible to obtain 
glomeruli specific expression profiles using RNA-seq from LCM glomeruli of FFPE tissue 
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sections. Further advances in the development of a standardized protocol are still required to 
make the transcriptome profiles of the FFPE tissue archives fully available for clinical 
research. 
Other global approaches, such as hybridization-based methods including microarrays and 
PCR, are bound to existing (and potentially limited or biased) knowledge about the 
transcriptome, genome, and known variant annotations, and their association to possible 
disease phenotypes. Advances in the understanding of the human genome, function of genes 
and their link with disease phenotypes will lead to improvements in the design of PCR tests 
and micro-array experiments. However, currently only a few organisms such as Homo 
sapiens have a well-studied transcriptome and our understanding of its complexity is still far 
from being complete (Marioni et al., 2008). Therefore, tests performed to analyze more 
complex and heterogenic diseases are more challenging to implement. The use of whole 
genome, transcriptome or proteome approaches, including RNA-Seq, would facilitate the 
retrieval of relevant data of complex or rare diseases if these approaches were used in a larger 
scale, for instance with FFPE sample archives. This, coupled with the increasing number of 
databases for storage and easy access to data, would provide the basis for larger and more 
complete studies with data that maintain scientific relevance for many years. The switch to 
global approaches such as whole transcriptome analysis will enable better prediction of 
disease onset, outcome, severity, treatment response and in general easier patient 
management (Chaussabel, 2015). However, despite the numerous advantages that system-
wide approaches may offer to clinical research, many of these approaches are yet to be 
widely implemented in a diagnostic setting. This may be because of the general 
understanding that sequencing-based approaches such as RNA-seq has a cost-benefit risk 
when considered majorly from a monetary but not a medical point of view. If everything that 
needs to be measured is indeed measured by a transcriptome assay, there would be no market 
for dedicated assays, kits, and instruments for different tests and diagnostics (Chaussabel, 
2015). Moreover, the benefits of the shift to RNA-sequencing would potentially improve 
clinical research and disease diagnostics, and reduce health care burden especially for 
complex diseases. In this hypothetic situation, diagnostics for autoimmunity, cancer, 
cardiovascular diseases, infectious diseases, neurological diseases, nutrition deficiencies, 
pregnancy tests, as well as disease severity, onset, outcome and response to treatments could 
be monitored from a single centralized laboratory (Berry et al., 2010; Fehlbaum-Beurdeley et 
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al., 2012; Chao et al., 2013; Sarwal and Sigdel, 2013; Chaussabel, 2015). Hence, approaching 
the health care system to the so called personalized medicine. 
The significant progresses in high throughput technologies such as genomics, 
transcriptomics, proteomics and peptidomics among others, leads to the personalized high-
throughput precision medicine. The traditional symptom-oriented diagnosis and treatments 
would be complemented with individual molecular profiles of the patients, allowing a much 
better and efficient treatment (Chen and Snyder, 2013). In this situation, sequencing as a 
continuously improving high throughput precision omics technology would greatly facilitate 
this process. The detailed information of a transcriptome profile or exome profile would 
reflect potential physiological changes at the sample collection time. Additionally, the 
integration with other omics would enhance the scientific research process. Eventually, this 
would translate into improved health care by monitoring the patient health status and by 
applying personalized and preventive treatments. At first, one may think that this would 
increase the costs of the health care system since some of these omics assays are currently 
quite expensive. However, we argue that this would especially help the characterization and 
understanding of complex diseases (Huang and Mucke, 2012; Shah et al., 2012; Codina-Solà 
et al., 2015) and, in the long term, globally reduce the health care burden (Chen and Snyder, 
2013). 
If global screening approaches were to be routinely implemented in clinical applications the 
quantity of available data would increase the need of data handling measures. High 
throughput applications can produce a tremendous amount of data, which is challenging to 
process, handle and properly annotate with the purpose of further clinical interpretation. This 
calls for data integration in centralized databases to facilitate the analysis and interpretation 
of the collected results. This would stimulate advances in computer technologies and 
databases as well as bioinformatics that would improve and continuously increase the 
available knowledge. In the end, the objective of storing all these data and clinical results is 
to make it easier for researchers and clinicians to mine these databases with the appropriate 
algorithms to make more accurate and elaborated medical decisions. For this, comprehensive 
databases are required which would store health records, variant calls, expression profiles and 
all other patient related molecular information (Chen and Snyder, 2013). There are currently 
many databases that can provide comprehensive functional annotations such as The 
Catalogue of Somatic Mutations in Cancer (COSMIC) (Forbes et al., 2015) which is a 
comprehensive collection of somatic mutations for human cancer, or the Leiden Open 
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(source) Variation Database (LOVD) (Fokkema et al., 2011) which provides a tool to collect 
and display DNA variants. These databases may potentially facilitate the complex process of 
annotation of high throughput sequencing data. It is through the small effort of global sharing 
of particular findings that these databases are greatly improving over the years in quantity and 
quality of annotations. Other currently ongoing efforts are thrown into database collections of 
gene expression datasets such as the Expression Atlas (Petryszak et al., 2014). In this case 
gene expression profiles are publicly available and accessible and provides information about 
different organisms, expression patterns and biological conditions among others. The 
Expression Atlas includes RNA-Seq experiment data as well as microarray experiment data 
which can be re-analyzed through a web portal (www.ebi.ac.uk/gxa). There are other similar 
initiatives focusing on kidney research such as Nephroseq and the Renal Gene Expression 
Database (Zhang et al., 2014). Please refer to the available online resources for additional 
information (www.nephroseq.org; rged.wall-eva.net). Additionally, there is also the 
possibility of using publicly available RNA-Seq and microarray datasets in combination with 
clinical data. This is the case of the Gene Expression Omnibus (GEO) from NCBI (Barrett et 
al., 2013), or the European Genome-Phenome Archive (EGA) (Lappalainen et al., 2015), 
which offer international repositories of microarray and NGS datasets submitted by the 
research community. With these initiatives, the research community would certainly benefit 
from the work of any other researcher and would increase the statistical power of the studies, 
and the accuracy of diagnostics applications. 
5.5. Summary 
The increasing number of sequencing approaches and methodologies being developed and 
currently available will facilitate future clinical research of new diagnostic applications. The 
identification of strengths and limitations of new approaches, as well as the research question 
to answer is crucial to find the appropriate method in a case by case basis. In this thesis, we 
presented a selection of three renal diseases that could benefit from the use of new 
sequencing technology approaches. 
In Chapter 2, we have shown that the diagnosis of ADPKD, particularly for the complex 
PKD1 gene, can certainly benefit from the use of single-molecule long-read sequencing. In 
addition, we discussed in Chapter 5.2 the challenges of resolving complex genomic regions 
such as PKD1, and the extent of these regions into other medically relevant genes that would 
also benefit from a similar long-read based approach. 
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In Chapter 3, using RNA-seq we could characterize the expression profiles associated with 
AKI, as well as the expression profiles of AKI with Gdf15 deficiency. We showed that an 
unbiased RNA-seq approach can identify response-associated AKI drivers such as 
transcription factors. Furthermore, we discussed in Chapter 5.3 the strengths of RNA-seq and 
systems-based approaches over other and “cheaper” methodologies, and its increased value in 
the future of clinical research and diagnostics. 
In Chapter 4, we provided proof of principle that the sequencing of RNA from LCM isolated 
glomeruli for FFPE archived samples is plausible. In addition, we elaborated in Chapter 5 the 
impact of the accessibility of the expression profiles of FFPE sample archives in the future of 
clinical research.  
Overall, we showed that sequencing approaches offer new possibilities in the research field of 
renal diseases, and discussed their increased value in the future of clinical research and 
diagnostics. 
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Abstract 
Renal diseases have a high impact on the economy of any health care system worldwide. In 
addition, patient numbers are steadily increasing over the past decades with a prevalence of 
over 500.000 new end stage renal disease (ESRD) worldwide cases every year. ESRD is the 
final stage of chronic kidney disease (CKD) that has as the leading causes diabetes and 
hypertension, as well as glomerulonephritis, urolithiasis, autosomal dominant polycystic 
kidney disease (ADPKD), and progression of acute kidney injury (AKI), among others. 
However, in many cases, the mechanisms of these diseases affecting kidney and its function 
are poorly understood, or difficult to diagnose. Within this study, we used newer 
technologies, methodologies, and data analysis approaches to throw some light into the 
pathomechanisms of CKD and AKI. Moreover, potentially improving the diagnostic value 
for already existing diagnostic assays (e.g. ADPKD). 
In the past years, advances in DNA sequencing technologies have revolutionized the field of 
clinical research and diagnostics. High throughput sequencing such as next-generation 
sequencing (NGs) is being used because of its high quality and accuracy when analysing 
DNA samples. Other sequencing technologies have also shown their value such as long-read 
sequencing which is used because of its longer sequencing reads and accuracy resolving low-
complexity sequences, such as repetitive regions or high GC-percent regions. Within the 
scope of this thesis we used several cutting-edge sequencing approaches applied to renal 
disease’s clinical research to: 
1. Improve the diagnostic value of already existing diagnostic assays for ADPKD. 
ADPKD is an inherited disease that accounts for 5% to 10% of ESRD. However, the 
screening of the main ADPKD gene PKD1 is challenging because of its multi-exon 
structure, allelic heterogeneity, and high homology with six PKD1 pseudogenes, as 
well as extremely high GC content. Using direct long-read sequencing we showed 
that ADPKD diagnostics without interference of PKD1 homologous sequences is 
possible. 
2. Characterize the expression profile of AKI and the underlying mechanisms using 
RNA sequencing. Patients undergoing major surgery may develop AKI which has 
been associated with higher mortality risk and reduced renal functionality, and high 
risk of progression of CKD. Some evidences pointed out to the tubular system being 
at the middle of this pathophysiology and further recovery. However, the factors 
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involved in this recovery are still poorly understood. In this context, we characterized 
renal messenger RNA expression profiles of AKI in wild type and Gdf15 knock out 
constructs. Gdf15 was identified to be associated with lower tubular damage 
suggesting a protective role of the kidney. We identified 89 transcription factors that 
are potentially driving the response mechanisms in AKI, as well as other 13 
transcription factors possibly linked with the protective mechanisms of Gdf15. 
3. Evaluate the practical boundaries of RNA sequencing to characterize glomerular 
diseases for CKD. The analysis of renal biopsies is very informative to determine 
patient’s glomerular disease stage and progression rates. However, fresh frozen 
biopsies are limited or non-existent compared to the more abundant formalin-fixed, 
paraffin-embedded (FFPE) renal biopsies. FFPE tissue can be easily stored for long 
periods of time, allowing large sample archives with many years of clinical data 
collection and follow-up. We showed that characterizing glomerular disease 
expression profiles by RNA sequencing from FFPE samples is possible. However, our 
data suggests that the required number of glomeruli in cross sections may be higher 
than the number glomeruli present in a usual renal biopsy. 
Finally, we elaborated about the future impact of the results obtained in the context of clinical 
research, and their value for the understanding or diagnostics of renal diseases. 
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Résumé 
Les maladies rénales ont un impact important sur l'économie de tout système de santé dans le 
monde. En outre, le nombre de patients augmente régulièrement au cours des dernières 
décennies avec une prévalence de plus de 500 000 nouveaux cas de maladie rénale en phase 
terminale (ESRD) dans le monde entier chaque année. L'ESRD est l'étape finale de la maladie 
rénale chronique (CKD) qui a comme principales causes le diabète et l'hypertension, ainsi 
que la glomérulonéphrite, urolithiasis, la polykystose rénale autosomique dominante 
(ADPKD) et la progression de la lésion rénale aiguë (LRA), entre autres. Cependant, dans de 
nombreux cas, les mécanismes de ces maladies affectant le rein et sa fonction sont mal 
connus ou difficiles à diagnostiquer. Dans le cadre de cette étude, nous avons utilisé des 
technologies plus récentes, des méthodologies et des approches d'analyse de données pour 
jeter un peu de lumière dans les pathomécanismes de la CKD et de l'AKI. En outre, 
l'amélioration potentielle de la valeur diagnostique des tests diagnostiques déjà existants (par 
exemple ADPKD). 
Au cours des dernières années, les progrès dans les technologies de séquençage de l'ADN ont 
révolutionné le domaine de la recherche clinique et du diagnostic. Le séquençage à haut débit 
tel que le séquençage de prochaine génération (NG) est utilisé en raison de sa haute qualité et 
de précision lors que l'analyse des échantillons d'ADN. D'autres technologies de séquençage 
ont également montré leur valeur, comme le séquençage à longue lecture qui est utilisé en 
raison de ses longues lectures de séquençage et de la précision de résolution de séquençages 
de faible complexité, telles que les régions répétitives ou des régions de GC-pourcentage 
élevé. Dans le cadre de cette thèse, nous avons utilisé plusieurs méthodes de pointe de 
séquençage appliquées à la recherche clinique sur la maladie rénale afin de: 
1. Améliorer la valeur diagnostique des tests diagnostiques déjà existants pour 
l'ADPKD. ADPKD est une maladie héréditaire qui représente de 5% à 10% de 
l'ESRD. Cependant, le criblage du principal gène ADPKD PKD1 est difficile en 
raison de sa structure multi-exon, de son hétérogénéité allélique et de son homologie 
élevée avec six pseudogènes PKD1, ainsi que d'une teneur en GC extrêmement 
élevée. En utilisant le séquençage direct à longue lecture, nous avons montré que le 
diagnostic ADPKD sans interférence des séquences homologues PKD1 est possible. 
2. Caractériser le profil d'expression de l'IRA et des mécanismes sous-jacents en utilisant 
le séquençage de l'ARN. Les patients qui subissent une chirurgie majeure peuvent 
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développer une IRA qui a été associée à un risque de mortalité plus élevé et une 
fonctionnalité rénale réduite, et un risque élevé de progression de la CKD. Certaines 
preuves indiquent que le système tubulaire est au milieu de cette pathophysiologie et 
de la récupération ultérieure. Cependant, les facteurs impliqués dans cette reprise sont 
encore mal compris. Dans ce contexte, nous avons caractérisé les profils d'expression 
de l'ARN messager rénal d'AKI dans des constructions de type sauvage et knock-out 
Gdf15. Gdf15 a été identifié comme étant associé à des lésions tubulaires inférieures 
suggérant un rôle protecteur du rein. Nous avons identifié 89 facteurs de transcription 
qui sont potentiellement moteurs des mécanismes de réponse dans l'IRA, ainsi que 
d'autres facteurs de transcription 13 éventuellement liés avec les mécanismes de 
protection de Gdf15. 
3. Évaluer les limites pratiques du séquençage de l'ARN pour caractériser les maladies 
glomérulaires pour la CKD. L'analyse des biopsies rénales est très informative pour 
déterminer le stade de la maladie glomérulaire du patient et les taux de progression. 
Cependant, les biopsies congelées fraîches sont limitées ou inexistantes par rapport 
aux biopsies rénales fixées au formol et à la paraffine (FFPE) plus abondantes. Les 
tissus FFPE peuvent être facilement stockés pendant de longues périodes, ce qui 
permet de disposer d'importantes archives d'échantillons avec de nombreuses années 
de collecte de données cliniques et de suivi. Nous avons montré que la caractérisation 
des profils d'expression de la maladie glomérulaire par séquençage d'ARN à partir 
d'échantillons de FFPE est possible. Cependant, nos données suggèrent que le nombre 
requis de glomérules dans les coupes transversales peut être supérieur au nombre de 
glomérules présents dans une biopsie rénale habituelle. 
Enfin, nous avons développé l'impact futur des résultats obtenus dans le cadre de la recherche 
clinique et leur valeur pour la compréhension ou le diagnostic des maladies rénales.
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